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Abstract
RGD and heparan sulfate (HS) modified poly(2-hydroxyethyl methacrylate)-
(PHEMA) was synthesised as a porous 3D sponge hydrogel. The synthetic
pathway for the modification of PHEMA began with copolymerising HEMA with
glycidyl methacrylate followed by the reaction of the glycol with hexamethyle-
nediamine. This introduced a free amine onto the hydrogel which was used
to covalently immobilise two different biomolecules using the same chemistry.
The RGD peptide is well known as a biomolecule that can improve the adhe-
sion of a variety of cells to a surface and HS provides the binding activity of all
adherent cells to a wide variety of proteins. The binding activity of HS is known
to mediate important cell behaviours such as cell adhesion, proliferation, dif-
ferentiation and assist in wound repair. Therefore RGD and HS were used to
improve cell adhesion and proliferation on PHEMA and to create a scaffold that
had potential for tissue engineering applications.
The hydrogels were characterised with a variety of chemical and physical tech-
niques. The immobilisation of RGD and HS was confirmed and quantified
both individually on the hydrogels and also with the immobilisation of both bio-
molecules on the same hydrogel. The pores were interconnected and suffi-
ciently large to enable cell migration into the material with diameters between
10-30 µm. The high swelling content of the hydrogels mimicked the in vivo
environment of native tissue. Rheology measurements were performed to ex-
amine the elasticity and stability of the hydrogels under physiological condi-
tions. The hydrogels were found to have elasticity similar to that measured for
fibroblasts. These results indicated that the hydrogels had great potential as a
scaffold for deep tissue regeneration.
The bioactivity of immobilised RGD and HS was accessed with cell culture
work. Two mouse cells lines were used, 3T3 fibroblasts and C2C12 myo-
blasts. All modification steps were observed to improve the biocompatibility
of the hydrogel in comparison to PHEMA. HS was shown to retain bioactiv-
ity after immobilisation resulting in improved cell adhesion, proliferation and
differentiation. Incorporation of the RGD peptide showed a more moderate
iii
improvement in cell behaviour when compared to the results from HS. The im-
mobilisation of both RGD and HS on the same hydrogel resulted in the best
cell behaviour. Most important was the finding that the presence of HS on
the hydrogel was required for the successful differentiation of C2C12 cells into
myotubes.
Additional characterisation of the bioactivity of the synthesised hydrogels in-
volved immunofluorescence and an enzyme linked immunosorbant assay (ELI-
SA). The immunofluorescence detected the fibronectin that had been produced
by the cells while they were cultured on the hydrogels. The cells expressed
more fibronectin on the modifed hydrogels, especially the end modifications.
The differences in 3T3 cell adhesion and proliferation correlated well with the
amounts of fibronectin produced by the cells, the differences with the C2C12
cells were more subtle. More importantly, the expressed fibronectin was more
organised and mature on the HS hydrogels. The ELISA was designed to
further confirm the activity of the immobilised HS. It used the known affin-
ity between basic fibroblast growth factor (bFGF) and HS. The results clearly
showed that the immobilised HS had retained its bioactivity and was readily
able to bind bFGF. These results showed that the immobilised HS was able
to bind and sequester molecules to control cell signalling, these signals en-
hanced cell behaviour and promoted cell differentiation. This mimicked the
in vivo interaction between HS on the cell surface and soluble proteins in the
extracellular matrix.
The project has shown that PHEMA can be effectively modified to create a
bioactive hydrogel scaffold. The improved bioactivity of the hydrogel could be
used for tissue regeneration applications. The hydrogel demonstrated import-
ant results such as: 1) the immobilised HS was able to bind a growth factor that
is important for wound healing, 2) fibroblasts and myoblasts adhered and prolif-
erated well on the modified hydrogels and 3) myoblast differentiation was only
observed on the hydrogels with immobilised HS. These results showed that
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1.1 Introduction to Tissue Engineering
Tissue engineering is described by the National Institute of Health (NIH) as
a topic of research that evolved from the field of biomaterial development
and refers to the practice of combining scaffolds, cells and biologically ac-
tive molecules into functional tissues. The NIH describes the goal of tissue
engineering as: to assemble functional constructs that restore, maintain or im-
prove damaged tissues or whole organs. Tissue engineering has also been
described as ‘the creation (or formation) of new tissue for the therapeutic re-
construction of the human body, by the deliberate and controlled stimulation of
selected target cells through a systematic combination of molecular and me-
chanical signals’1. In a more simple form; tissue engineering involves the use
of living cells, and seeding a biomaterial with cells before implantation, to aid in
tissue formation or regeneration, thereby producing a therapeutic or diagnostic
benefit2–5.
A biomaterial is defined as any material, natural or synthetic, that is suitable to
be placed in contact with living tissue. Biomaterials were traditionally designed
to be relatively biologically inert to avoid unwanted inflammation responses.
These biomaterials were designed as inert coatings for medical prostheses
such as pacemakers and joint replacements, as well as with applications such
as contact lenses. Such surfaces need to avoid the adhesion of cells and
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biomolecules to maintain their functionality.
Now the focus has changed and biomaterials are designed to actively interact
with the body to assist in the repair or replacement of tissue that has been
damaged or lost. Biomaterials are required when the body is unable to com-
pletely or successfully repair its own tissues. The role of the biomaterial is to
provide structural support to the affected area while initiating the body’s own re-
generative processes. Biomaterials can be designed as permanent implants,
or as slowly degrading materials that are eventually completely replaced by
native tissue. Biomaterials are applicable for any situation where the patient
has suffered damage to tissue. The cause of the tissue damage could be due
to disease, surgery, injury or birth defects or a combination of all four. The
scarcity of replacement organs and tissues is one of the main drivers for the
abundance of research in the biomaterial area6. The outcome of tissue en-
gineering and biomaterial research is that a much greater number of patients
could be treated for ailments caused by loss of tissue or organ function6.
Engineering complex tissues is perhaps the most ambitious goal of all tissue
engineers5. Engineering of functional vascular networks, interfaces, structural
hierarchy and complex functional features is emerging as an unparalleled sci-
entific and technical challenge for the next generation of tissue engineers5.
As the field of tissue engineering expands and the complexity of biomaterials
increases the definition of a biomaterial has broadened. Biomaterials can be
made from synthetic or natural components, or the combination of both. These
include tissue, and components of tissue, that are extracted from the body and
are purified or modified. The functions of biomaterials have expanded to in-
clude applications that: completely replace native tissue, assist with the repair
of native tissue, or provide therapeutic drugs. A current definition for a bioma-
terial is ‘a substance that has been engineered to take a form which, alone
or as part of a complex system, is used to direct, by control of interactions
with components of living systems, the course of any therapeutic or diagnostic
procedure, in human or veterinary medicine’1.
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1.2 The Extracellular Matrix
Native tissue is not made up solely of cells7. A substantial part of a tissue’s
volume is the extracellular area which is largely filled by an intricate network of
macromolecules that constitute the extracellular matrix (ECM)7. The ECM is
the body’s natural tissue regeneration scaffold and consists of highly orches-
trated supramolecular assemblies of hydrated and crosslinked fibrous proteins,
proteoglycans, growth factors and other soluble molecules8,9. The ECM is an
important component of every tissue and it often determines the physical prop-
erties of the tissue. However the ECM is not merely a physical support for na-
tive tissue, it is a dynamic and bioactive scaffold that regulates cell behaviour.
The ECM has the ability to communicate spatially and temporally with cells
thereby directing cell behaviour via matrix interactions with cell-surface recep-
tors10. It is dynamic due to cell-matrix communication occurring in both di-
rections resulting in a matrix that is able to respond to cell signals and affect
changes in its local microenvironment10,11. The ECM determines cell survival,
development, migration, proliferation, shape and function as well as directing
and organising tissue morphogenesis, homeostasis and regeneration in patho-
physiological situations7,8,10,11. This influence is due to the highly specialised
and complex molecular composition of the ECM and the adaptability of the
ECM to the functional requirements of a particular tissue7,9,10,12.
The main components of the ECM are fibrous proteins: collagens, elastin,
laminins and fibronectin. Collagens are a family of fibrous proteins which col-
lectively are the most abundant proteins in mammals7. Collagens are secreted
by connective tissue cells (as well as other cell types) and are a major com-
ponent of skin and bone7. Cells are known to interact with the collagen that
they have secreted, aligning and compacting the collagen to create long-range
order in the ECM7. For example fibroblasts (connective tissue cells) influence
the alignment of collagen to create dense layers of connective tissue that bind
cells within most organs in the body7. In contrast, elastin forms elastic fibers
in the ECM which provide resilience and allows the matrix to stretch7. Elastin
is the dominant ECM protein in arteries7.
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The laminins are a tri-glycoprotein complex that are important for the develop-
ment and maintenance of cell organisation. For example, laminins have been
demonstrated to stimulate cell growth and differentiation, promote neurite out-
growth and mediate cell communication13. Fibronectin is also a large glycopro-
tein that contributes to the organisation of the ECM and provides attachment
sites for cells7. The tripeptide sequence RGD (arginine, glycine, aspartic acid)
is a central feature of one cell binding domain of fibronectin7. This peptide
sequence has often been used to increase cell binding to a surface.
Another important macromolecular component of the ECM are proteoglycans.
Proteoglycans consist of a core protein that has covalently bound pendant
chains of polysaccharides known as glycosaminoglycans (GAGs)14,15. Pro-
teoglycans are diverse due to their different core proteins and different GAG
chains. They are classified by the predominant GAG chain15. Proteoglycans
are thought to play a major role in the chemical signaling between cells7. They
bind various signaling molecules such as growth factors, proteases and pro-
tease inhibitors and have the ability to enhance or inhibit the activity of these
proteins7.
The binding of a protein to proteoglycans may lead to: restriction of the pro-
tein’s action by steric hindrance of it’s activity, sequestration of the protein and
delayed release, protection of the protein from enzyme degradation or locally
concentrate the protein to improve it’s effective presentation to cell-surface re-
ceptors7. In particular the specific binding of growth factors to proteoglycans
can effectively modulate cellular growth, cell development, angiogenesis and
tissue regeneration16,17. Maintenance of the appropriate structure and con-
centration of proteoglycans is critical for a healthy tissue. Proteoglycans are
strongly anionic polymers that absorb large amounts of water, this provides
compressive strength to the ECM18. This is particularly important for tissues
such as cartilage which are required to resist compressive loads19,20.
Glycosaminoglycans are unbranched polysaccharide chains that are composed
of repeating disaccharide units of D-glucuronic or L-iduronic acid and either N-
acetylglucosamine or N-acetylgalactosamine7,21. They are highly negatively
charged due to the abundance of sulfate and carboxyl groups on their chains7.
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The polysaccharide chains in GAGs are not able to fold into compact structures
in the same way that polypeptide chains can. This allows them to form gels,
even at low concentrations, which incorporate large amounts of water and cre-
ates a swelling pressure that can withstand compressive stress. These gels
are also highly porous permitting the rapid diffusion of nutrients, metabolites
and hormones7.
There are 6 different types of GAGs; hyaluronan (also known as hyaluronic
acid), dermatan sulfate, keratan sulfate, chondroitin sulfate, heparin and hep-
aran sulfate (HS)21,22. It is the GAG chains which provide proteoglycans with
an ability to function as: physiological barriers, reservoirs for signaling proteins
and binding partners for structural macromolecules21. Indeed, GAG chains
provide most of the bioactivity attributed to proteoglycans and play a pivotal role
in biological processes like morphogenesis, angiogenesis and wound heal-
ing23,24.
Another important component of the ECM are the soluble molecules that act
as signaling molecules. These include chemokines, cytokines, hormones, vi-
tamins and biological factors. There are three major classes of factors that
act as extracellular signaling molecules; mitogens, growth factors and survival
factors. These are usually soluble cell secreted proteins, proteins bound to the
surface of cells or components of the ECM7,25. Mitogens are proteins that stim-
ulate cell division, growth factors stimulate cell growth (increase in cell mass)
and survival factors promote cell survival by suppressing apoptosis. Some ex-
tracellular signal proteins can act as both a growth factor and a mitogen to
stimulate cell growth and cell division7. They can also direct cell migration, ac-
tivate various cell types and initiate new gene expression26. These properties
are recognised as playing important roles for wound healing processes and
the direct application of growth factors to wounds has been shown to accel-
erate the normal healing process26. Platelet-derivated growth factor (PDGF),
epidermal growth factor (EGF), transforming growth factor alpha (TGF-a), ba-
sic fibroblast growth factor (bFGF) and transforming growth factor-b1 (TGF-b1)
are polypeptide growth factors that have significant activity in tissue repair pro-
cesses27.
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Individual ECM components have many positive effects on cell behaviour. How-
ever, as native ECM is a matrix that is composed of multiple bioactive molecules,
it is not surprising to find that these molecules also act synergistically in vivo.
One example is the importance of the complex that is formed by heparan sul-
fate proteoglycans (HSPGs), growth factors and their receptors. This complex
is required for optimal growth factor signaling, of members of the fibroblast
growth factor (FGF) family28,29.
In native ECM, some growth factors are stored in a latent form through their
binding to the sulfated regions on the HS chains of HSPGs16. This can concen-
trate the growth factors close to cells. In addition, the binding of some growth
factors to HS chains may protect the growth factor from normal proteolytic
degradation. It may also enhance and stabilise interactions on the cell sur-
face leading to the cross-linking of receptors and receptor activation28,29. The
FGF family and their receptors (FGFR) interact with the HS chains of HSPGs
and so coordinate cell-fate decisions such as cell growth, development, angio-
genesis and tissue regeneration16,28. Hence, the ECM has enormous potential
for regulating various signaling events that influence cell behaviour and effect
tissue regeneration.
The influence of the ECM on cell behaviour extends to cell shape, attachment,
proliferation, migration, differentiation and survival. The ECM affects cell shape
through influencing the organisation of the cell’s cytoskeleton7. For example
a lack of fibronectin results in poorly adhered cells whilst abundant filbronectin
commonly gives rise to well adhered cells, identified by their flattened shape
and organised actin filaments7. Most cells require attachment to the ECM to
proliferate and survive. Strong attachment of cells to the ECM and a spread
morphology has been demonstrated to increase cell growth. This effect has
been presumed to assist in the repair of tissues after injury7. The migration of
cells through the ECM commonly occurs via the localised enzymatic degrada-
tion of the matrix. Cells secrete proteases that locally and specifically degrade
the matrix allowing their migration while the structural integrity of the ECM is
maintained7. The most common enzymes involved in this process are matrix
metalloproteases which degrade matrix proteins such as collagen, laminin and
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fibronectin7.
Cell proliferation is affected by the strength of cell attachment to a substrate.
This is due to the intracellular signals that are created when a cell attaches to
a surface and forms focal adhesions. Focal adhesions are formed when ECM
proteins such as laminin and fibronectin interact with cell-surface receptors
known as integrins. This interaction leads to the activation of protein kinases
which then activates intracellular signaling pathways that can promote cell di-
vision and survival7. Focal adhesions are composed of actin filaments that link
the cytoskeleton to the ECM through integrins on the cell surface. Actin is a
prevalent protein in the cell that polymerises to form filaments known as F-actin
(or filamentous actin). These actin filaments form an assortment of networks
and bundles that are interconnected to form the actin cytoskeleton30. Within a
cell stress fibers are composed of actin and myosin bundles and are important
for cell adhesion to ECM substrates and in cellular mechanotransduction (the
cell converts mechanical signals from the arrangement/orientation of the actin
fibers into a biochemical response)7,31.
Cell fate decisions in vivo are largely controlled by exogenous signals pre-
sented on the ECM32 and the ECM is essential for guiding cells through distinct
development paths33. It contains extrinsic cell signals that creates a highly
defined and specialised cell microenvironment, which is essential for correct
tissue development and continued function33. The ECM has a variety of forms
in different tissues and at different development stages in the same tissue10,34.
The structural diversity observed in different ECMs is due to the combinations
of specific molecular interactions involving different isoforms, ratios and geo-
metrical arrangements of collagen, elastin, proteoglycans and adhesion pro-
teins33. One example of how the ECM can be specialised is the stem cell
niche. This is now assumed to exist in all adult tissues9. The stem cell niche is
a specialised microenvironment where the ECM and growth-modulating factors
stored within it help sustain a stem cell pool9.
While there is much information about the ECM and it’s effects on cells and tis-
sues, there is still a lot of information that is lacking. The complex and dynamic
nature of the ECM complicates results and makes it difficult to nail down which
7
component has exactly what effect. Moreover, the number of possible syner-
gistic effects between individual components is overwhelming. It is most likely
these collaborative molecular interactions within the ECM are what enables the
ECM to provide such a successful template to communicate with cells and to
guide tissue repair and maintenance.
1.3 Designing New Biomaterials
The need for better designed or more complex biomaterials is apparent from
the limited applications of the currently available commercial products. The re-
liance on native tissue to create functional commercial biomaterials limits their
widespread availability. Ultimately, it is hoped that these engineered tissues
will alleviate the extreme shortage of tissues and organs for transplantation35.
The underlying concept of tissue engineering is that cells have an inherent ca-
pability to organise into tissues and organs if given the proper environment of
mechanical and chemical signals6. The basic assumption of this technology is
that cells cultured in an environment that closely mimics the native, will develop
into tissues that resemble natural tissues6.
1.3.1 Physical Properties
Selecting the correct physical properties for a biomaterial is vital. The bioma-
terial needs to be able to provide the same physical support to surrounding
tissue and cells as the native tissue. Without this physical support the bioma-
terial can fail in its application. This is especially true when the biomaterial is
designed to be a permanent replacement for native tissue. Such instances nor-
mally involve joint or bone damage that can’t be repaired by other means such
as tissue grafts. In this application the biomaterial needs to be able to handle
the same compressive and tensile stress as native bone. Additionally replace-
ment joints need to have sufficient lubrication to allow for continual repetitive
stress.
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Physical support is equally important for biomaterials in soft tissue applications.
In these applications the support is for the cells that will attach and grow on
the biomaterial. The attachment site for a mammalian cell is typically another
similar cell or the ECM and the elastic modulus of cells or ECM ranges from
10 to 10,000 Pa36. As the stiffness of the biomaterial has been shown to have
an effect on how cells adhere to the material37, it is important that materials
for soft tissue applications are designed with the elastic modulus of the natural
tissue in mind.
Cells possess their own contractile force that senses the substrate stiffness12.
Hence, changing the substrate stiffness can affect cell secretion of ECM com-
ponents and this may change the immediate microenvironment12. This in turn
may induce or enhance cell differentiation, proliferation or apoptosis38. There-
fore altering the stiffness of the biomaterial can have major effects on cell be-
haviour. The lack of stiffness in a biomaterial is referred to as the elasticity. The
elasticity of the biomaterial should be matched to the native tissue ECM and a
mismatch of elasticity can result in the failure of the biomaterial in vivo12. Cells
placed on a biomaterial with an elastic modulus significantly less than that of
the native tissue ECM are generally more rounded and less spread. This mor-
phological difference is due to poor cell adhesion which often leads to low cell
proliferation and enhanced apoptosis39.
Other physical properties that are known to affect cell behaviour are: wetta-
bility, surface molecular mobility, surface free energy, porosity and topography.
These physical properties of biomaterials tend to affect cell behaviour via af-
fects on protein adhesion to the biomaterial surface. The wettability or hy-
drophilicity of a biomaterial is determined by the charge and polarity of the sur-
face40. Wettability will affect the type and orientation of adsorbed proteins40.
Hydrophobic surfaces irreversibly adsorb large quantities of albumin, a protein
which does not support cell attachment whereas, hydrophilic surfaces tend to
adsorb proteins that support cell adhesion such as fibronectin40. As a result
cells on hydrophobic surfaces will generally retain a round morphology and
weak attachment while those on hydrophilic surfaces will be more elongated
and show better attachment.
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Altering the molecular mobility and surface free energy of a biomaterial changes
the morphology of adherent cells37. Generally an increase in either, or both,
properties results in better cell attachment and spreading37,41. Highly dynamic
polymer surfaces with high molecular mobility results in adherent cells with
an elongated morphology while less mobile surfaces have adhered cells with a
rounded morphology37. For example, the aspect ratio of fibroblasts was shown
to increase (elongation of adhered cells) as the molecular mobility of the ma-
terial was increased37.
The surface free energy of a material determines the extent of protein adsorp-
tion to a surface and adsorption density of proteins affects the density of cell
adhesion, the number of cells adhering, cell proliferation rate and projected cell
area37. Interestingly a direct correlation was found between increasing the to-
tal surface free energy of a material and the density of adsorbed fibronectin37.
Protein adsorption onto the biomaterial surface is the most important factor
in determining cell behaviour. Most research with cells is done in media con-
taining serum and the first proteins to interact with the biomaterial will be from
the serum. Protein adsorption is a process that takes minutes compared to
cell adhesion which can take hours41–44. Hence, modification of the physical
properties of a biomaterial is primarily about optimising protein adsorption.
Manipulating the surface free energy of a biomaterial can also force the cell to
follow a pattern designed on the surface41, possibly because this determines
the pattern of protein adsorption. As the surface free energy of a biomate-
rial is equal to the surface tension multiplied by the surface area45, when the
topography changes so too does the surface energy. This means surface to-
pography can be considered as a component of surface free energy. It is well
established that cells react to micrometer range topographic features such as
grooves, ridges and wells46. Micro and nano-patterning of the surface can
be used to manipulate cell shape, adhesion, migration, differentiation, pro-
tein synthesis and gene expression47. Recently the focus has been towards
nanoscale changes in topography to cause changes in: cell adhesion, motil-
ity, cytoskeletal condensation, activation of tyrosine kinases, and modulation of
intracellular signaling pathways that regulate transcriptional activity and gene
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expression46,48–51.
Multiple factors of the topography modulate cell behaviour, these include: the
scale (micro down to nano), shape, type (grooves, steps, pillars), spacing and
symmetry of the topographic features46,48–51. Generally the presence of fea-
tures such as ridges, steps and grooves increases cell attachment and pro-
liferation. Cells are also observed to align with ridges, steps and grooves.
This alignment is due to the cells ability to sense the tension or stress in the
surface which results in reorganisation of the cells cytoskeleton47. Ridges as
thin as 70 nm are observed to guide cytoskeletal assembly and align the cells
to the direction of the ridges48,52. Upon introduction of nano-topography to a
biomaterial, an early cell response is to increase filopodia and microspikes33.
Nano-features possibly modulate the interfacial forces that guide cytoskeletal
formation and membrane receptor organisation33. Increasing the nanoscale
roughness of the walls of pores in a biomaterial can increase cell attachment,
proliferation and ECM component expression42,53,54.
Several studies have established that similar nanoscale topography may elicit
similar biological effects regardless of the chemistry of the biomaterial. One
example is the similarity of smooth muscle cell behaviour on nanopatterned
poly(methyl methacrylate) (PMMA) and poly(dimethylsiloxane) (PDMS). The
differing surface chemistry of the two polymers is unlikely to result in the same
adsorption of proteins49 as PMMA is hydrophillic while PDMS is strongly hy-
drophobic. Yet the smooth muscle cells were very similar in their adhesion and
morphology on the two surfaces.
In contrast different cell types prefer different surface morphologies. Work by
Kubinova et al., showed that mesenchymal stem cells preferentially attached
on the flat surface of the scaffold, outside of the pores55. The few that attached
inside the pores were long and thin as they adapted their morphology to the
pore surface. In contrast neural stem cells were observed to attach preferen-
tially to the rhombus shaped pores of the scaffold. Thus, as the response to
substrate topography is cell type specific it is important that the topography of
the biomaterial is appropriate for the intended application.
11
1.3.2 2D versus 3D
The natural environment for cells is the three dimensional (3D) ECM. While
many characteristics and behaviours of cells can be observed when cultured
on the two dimensional (2D) surface of tissue culture plastic, to mimic native
cell behaviours cells should be observed in a 3D environment. One of the
first to demonstrate differences in cell behaviour from 2D to 3D culture was
Peterson et al., with breast epithelial cells. Cell morphology and behaviour only
mirrored that seen in vivo when the cells were grown within a 3D reconstituted
basement membrane matrix56.
Many researchers have demonstrated the substantial difference in the proper-
ties of cells in 2D culture compared to the native 3D environment9,57–59. 3D
cell culture techniques aim to recapitulate the in vivo biology and has signifi-
cantly impacted our understanding of ECM architecture and its role in tissue
remodeling9. Therefore the new focus in biomaterials and tissue engineer-
ing research is on 3D biomaterials that are better at mimicking the native 3D
environment. It has been established that cell attachment and morphology is
distinctively different in a 3D biomaterial compared to a 2D surface59. Cells
tend to be more spread on surfaces and have a more stellate spindle-shaped
morphology within 3D scaffolds. This difference in morphology is due to the
traction forces provided by contractile cell-matrix interactions at both the lead-
ing and trailing edge of the cells59. This difference in cell morphology also
affects the cells motility and the process used by the cells to migrate through
the biomaterial59,60. The benefit of 3D cell culture is that it allows for the inves-
tigation of cell signaling61 and cell matrix interactions62 in a more in vivo like
environment60.
Differences in cell proliferation can be observed when cells are grown in 3D
as opposed to 2D culture. Rat bone marrow cells show significantly higher
proliferation when cultured on a 3D alginate matrix compared to 2D alginate
discs63. Mahoney et al., suggest that 3D matrices provide a more suitable
environment for the expansion of neural precursor cells as their survival is sig-
nificantly greater in 3D than 2D culture64. The importance of a 3D environment
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for epithelial cells is recognised as it promotes normal epithelial polarity and dif-
ferentiation58. Fibroblasts have an artificially induced polarity when cultured in
2D whereas fibroblasts are normally nonpolar cells. Fibroblasts adhere more
effectively, have differing morphology and show enhanced proliferation and mi-
gration rates in 3D culture57,59,65. Fibroblasts in 3D culture show triple colo-
calisation of a5integrin, paxillin and fibronectin similar to the colocalisation that
defines 3D-matrix adhesions in vivo57. 3D matrix adhesions enhanced cellu-
lar functional activities compared to 2D adhesions57 therefore to investigate or
replicate in vivo cell behaviour, it is vital to use a 3D culture system.
1.3.3 Chemical and Biological Properties
Chemical and biological modifications are often made to biomaterials in or-
der to mimic the ECM. These modifications involve physical and chemical at-
tachment of ECM components, their derivatives, synthetic versions of ECM
components or other natural components. Researchers commonly incorporate
full-length ECM proteins in biomaterials to take advantage of the innate bioac-
tivity and functionality of these proteins. However there are limitations to using
full-length proteins as they are susceptible to denaturation and degradation, re-
quire mild reaction conditions, have batch-to-batch variation and scale-up diffi-
culties35,66–68. This results in the unavailability of binding domains, the devel-
opment of antigenicity and loss of specificity66. As full-length proteins contain
several binding regions their random folding makes it difficult to deduce which
motif will be presented and therefore cell responses are unpredictable68,69.
Additionally as these proteins are not human in origin, they may elicit unde-
sirable immune responses and increase infection risks68. As a consequence
much of the current research focuses on using shorter peptide sequences that
mimic the binding domains of native ECM proteins.
There are many advantages associated with using short peptide sequences.
These include: relatively easy synthesis, easier purification and characteri-
sation, cost effectiveness, less antigenicity, greater specificity, higher stability
against conformational change and more control is possible over the density
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and orientation of the binding domains67,68,70,71. Due to their synthetic na-
ture and smaller size, peptides are more easily incorporated into biomateri-
als, than the full-length protein from which they are derived67,68. The most
commonly used peptide sequences are: RGD, KQAGDV, REDV, PHSRN, IK-
LLI, LRE, LRGDN, PDGSR, IKVAV, LGTIPG, YIGSR, DGEA, GFOGER and
VAPG69. Short peptide sequences can be immobilised on biomaterials by a
variety of methods. Immobilisation via covalent bonding can be achieved by
plasma treatment, copolymerisation and by the direct reaction of biomolecules
with the functionalised materials ith amine or thiol groups69.
The RGD peptide is most commonly studied as it stimulates cell adhesion
by cells that express the appropriate integrins68,71. RGD has been used to
modify biomaterials for various applications including: fibroblast adhesion and
spreading, neuronal regeneration, endothelial cell attachment and the culturing
of human embryonic stem cells69. Massi et al., immobilised RGD onto poly(2-
hydroxyethyl methacrylate) (PHEMA) and poly(ethyleneterephthalate) (PET)
surfaces. The aim of the work was to produce bioadhesive biomaterials that
were independent of adsorbed adhesion molecules from the culture medium.
The addition of RGD to the PHEMA or PET surface resulted in a ~400-fold or
~4-fold increase, respectively, in the number of spread fibroblasts. Attachment
and spreading of aortic endothelial cells on the RGD modified surfaces was
serum independent and a complete monolayer formed by 24 hours72. Cook et
al., used a copolymer of poly(lactic acid) (PLA) and lysine (PLAL) to introduce
functional amino groups into degradable PLA. These amino groups were used
to immobilise RGD containing peptides. This resulted in a 4-fold increase in
the spreading of endothelial cells. This work, in the 1990’s was the first demon-
stration of a synthetic, resorbable biomaterial that facilitated cell adhesion and
spreading6.
As research on peptide modified biomaterials continued, various techniques
were explored to optimise the bioactivity of the immobilised RGD and other
peptide sequences. Factors that affect the bioactivity of the peptide include:
peptide concentration, peptide clustering or orientation, the method of immobil-
isation and the inclusion of synergistic molecules71,73. It is now common for a
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spacer or linker to be used for the immobilisation of short peptides. The spacer
prevents steric hindrance of adjacent peptides and helps to maximise recep-
tor binding. This improves the biological activity of the peptide and enhances
cell adhesion69. These RGD based peptides, can be completely synthetically
produced or they can be obtained by recombinant gene technology. Synthesis
of recombinant peptides can be controlled to increase batch consistency, this
results in molecules that maintain native orientation with controllable structural
and functional characteristics. As recombinant molecules are extracted from
organisms they may trigger innate and acquired immune responses unlike pep-
tides that are completely synthetic69.
Kubinova et al., modified Poly(2-hydroxyethyl methacrylate-co-2-aminoethyl methacry-
late) (P(HEMA-AEMA)) with a laminin derived peptide sequence55. The effect
of the addition of the Ac-CGGASIKVAVS-OH peptide to the scaffold was exam-
ined by monitoring the behaviour of the mesenchymal stem cells. On unmodi-
fied scaffolds the cells were less spread and didn’t show many branched struc-
tures. With the peptide present the cells formed numerous branched lamelipo-
dia and membrane protrusions. Development of actin filaments were observed
after 4 hours of culture with vinculin staining showing evidence of focal adhe-
sions at the ends of the actin filaments after 3 days55.
Recombinant peptides have been used with synergistic sequences to improve
receptor specificity such as PHSRN with RGD. A spacing of 4nm between RGD
and the synergy site PHSRN in the recombinant peptide mimicked the native
spacing in fibronectin. Inclusion of the synergistic site lead to an increase in
osteoblast adhesion, spreading, focal adhesion contact, actin organisation and
cell function indicators but a decrease in ECM production71. These results mir-
ror those by other researchers who found synergistic adhesion and spreading
of hamster kidney cells and macrophages when using the two peptides to-
gether74,75. The synergistic effects are interesting and promising for improved
cell adhesion and spreading on biomaterials however the down regulation of
ECM production may be problematic for tissue engineering purposes.
ECM components other than proteins or their peptides have been used to
modify biomaterials to improve their cell adhesion properties. Commonly used
15
molecules are proteoglycans and glycosaminoglycans (GAGs). These molecules
play a critical role in regulating cellular adhesion, migration and proliferation
and impart important physiochemical properties to tissues76. Whole proteo-
glycans have not been widely used to modify biomaterials. This is most likely
due to their large size and limitations like those already described for whole
proteins. Ingavle et al., incorporated a proteoglycan complexed with hyaluro-
nan, aggrecan, into a scaffold77. Aggrecan was incorporated physically into
the scaffold by creation of an interpenetrating polymer network (IPN). The ef-
fect of aggrecan on chondrocyte adhesion was shown to be comparable with
that of RGD. The authors note that considering the comparable results from the
two biomolecules immobilised the use of RGD is preferable as it is significantly
more cost effective77. It is more common to use small sections of proteogly-
cans that replicate individual binding domains, or the relevant GAG chain to
introduce bioactivity to a biomaterial.
In the early 2000’s researchers began to chemically modify GAG molecules to
create new biomaterials14. By modifying the GAGs, their physicochemical and
mechanical properties could be tailored while maintaining their natural biocom-
patibility, biodegradability and lack of immunogenicity14. These biomaterials
have been explored for the following tissue engineering applications: materi-
als for localised drug delivery, barriers to prevent post-surgical adhesions and
dressings and matrices for wound healing and bone repair14,24.
Hyaluronic acid (HA), the only GAG that is not synthesised as a proteogly-
can, has been chemically modified to form biocompatible, macroporous hydro-
gel biomaterials that provide new ways to store and release combinations of
growth factors24. HA is the only non-sulfated GAG and is a strong inducer
of angiogenesis, although this effect is dependent on its molecular weight as
only low molecular weight HA stimulates endothelial cell proliferation and mi-
gration24. The use of HA as a drug delivery scaffold for growth factors com-
bines an interactive biomaterial that can participate in tissue responses with
the growth factor24.
The possible synergistic effect of immobilising heparin (a sulfated GAG) within
a HA biomaterial along with 2 growth factors was investigated by Riley et al.78.
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Vascular endothelial growth factor (VEGF) and angiopoietin 1 were the growth
factors selected. They respectively, initiated an angiogenic response and pro-
moted late-stage maturation of newly formed vessels78. The results showed
that the delivery of multiple growth factors can significantly improve vascular
growth.
Much of the biological activity of HSPGs has been ascribed to the HS chain28.
It was shown that mutations in HS biosynthesis results in significant develop-
mental defects that are not observed when mutations are introduced into the
core protein28. Since this discovery HS has been increasingly implicated in
cell-cell adhesion, cell-matrix adhesion, cell migration and proliferation, blood
coagulation, inflammation and tissue regeneration28. HS is a variably sulfated,
linear polysaccharide composed of repeating disaccharide units of gluronic
acid and glucosamine79. HS sulfation tends to be irregular, therefore each
tissue has a unique, characteristic HS profile that also varies according to the
stage of tissue development28,29,79. The variation in sulfation results in dif-
ferent growth factor binding to HS from different cell types. As a consequence
different tissues have different HS-growth factor complexes28,79,80. There is ev-
idence that HS is expressed in tissue and developmental stage-specific forms
that are required for embryonic organ formation28. HS has been shown to
avidly bind to a variety of growth factors that are involved in controlling cell
phenotype, these are the: FGFs, VEGFs, hepatocyte growth factor (HGF) and
members of the TGF-b superfamily including the BMPs79. FGF signaling can
be carefully and deliberately regulated by the application of appropriate HS
chains. For example, Chipperfield et al., has shown that HS derived from
adult neural tissue can be used to induce a neuronal phenotype in primary
osteoblasts28,81.
HS binds many species, not only growth factors but also chemokines, mor-
phogens, most of the large glycoproteins in the ECM and a suite of proteases
and synthetic enzymes80. A role of HS may be to allow extremely precise and
specific interactions to occur at the correct time and place during the matura-
tion and regeneration of tissue80. The fact that HS and HS-like molecules have
been demonstrated to be important regulators of bone repair and regeneration
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after injury through their growth factor modulation supports this view29. In ad-
dition HS in basement membranes assists the attachment of endothelial and
epithelial cells and regulates vascular permeability76. In vivo administration of
a synthetic polymer that mimics HS was shown to accelerate the regeneration
and re-innervation of skeletal muscle82. All of these factors highlight the ad-
vantages of incorporating HS into biomaterials to increase their bioactivity and
enhance their potential to assist in tissue regeneration.
1.4 Tissue Regeneration Scaffolds
Tissue regeneration scaffolds are biomaterials that are specifically designed
to assist in the healing, growth and repair of damaged, lost or diseased tis-
sues. Despite many early successes, there are few engineered tissue products
available for clinical use, and significant challenges remain for long-term repair
of biomechanically functional tissues2. The reasons for graft failure in animal
studies and preclinical trials are not fully understood, but include a combination
of biological and mechanical factors that can lead to the breakdown of repair
tissues under physiologic loading conditions2. The challenge is not as sim-
ple as matching a single mechanical parameter, rather, most tissues possess
complex viscoelastic, nonlinear and anisotropic mechanical and physicochem-
ical properties that may vary between patients (eg. age, site)2.
One area that has a range of commercially available products is the promo-
tion of wound healing. These products consist of wound dressings or topical
treatments that are often designed for the healing of ulcers. Xelma is an extra-
cellular matrix protein treatment that has been shown to increase the healing of
ulcers by approximately 22% when used weekly with appropriate bandaging83.
Dermagraft is a human dermal fibroblast derived acellular matrix designed for
the treatment of diabetic foot ulcers84. Both products require multiple appli-
cations over 2-3 months for complete healing of full thickness wounds. These
products are limited in their application to skin wounds were no exposure of
tendons, muscles, ligaments or bone occurs.
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The other commercial products that are available are scaffolds designed to pro-
vide enhanced cell growth for experimental research. These include Extracel
which is a 3D hydrogel matrix made of semi-synthetic components. Thiol mod-
ified hyaluronan (created by bacterial-fermentation), thiol modified gelatin and
thiol reactive polyethylene glycol diacrylate, when mixed can form a hydrogel,
sponge or film. This product is limited to experimental research applications
and does not extend to in vivo tissue regeneration.
Another commercial product that is widely used for cell culture is Matrigel, a re-
constituted basement membrane extract from Engelbreth-Holm-Swarm (EHS)
mouse sarcoma. The main components are laminin, collagen IV, enactin and
a variety of growth factors. Matrigel can be used as a 2D coating or a 3D
matrix. Matrigel has demonstrated better performance as a substrate to sup-
port the adhesion and proliferation of many cell types. It has also been shown
to promote better differentiation of muscle derived cells85 and to maintain the
differentiated state of zona glomerulosa cells86.
The PuraMatrix Peptide hydrogel is composed of molecules with a repeat-
ing RADA peptide sequence (arginine-alanine-aspartic acid-alanine). It self-
assembles into a 3D nanofiber scaffold and has been tested as a transplanta-
tion scaffold for Schwann cells in spinal cord regeneration applications87. The
QGel matrix is a PEG based hydrogel that can be modified to contain different
peptides. It has been used to develop a lab-on-a-chip system to isolate and
culture cancer cells for potential applications as an early cancer diagnostic de-
vice88.
There is an apparent lack of commercial products that are able to be used for
wounds other than skin wounds. This is possibly due to the need for a 3D
biomaterial that enables 3D healing. Such a material needs to be sufficiently
porous to allow for cell migration into the material and diffusion of waste out of
the material. The material is also required to produce structural support and
provide the same elasticity and strength as the native tissue. The interaction
between biomaterials and cells is not completely understood as the interac-
tions are complex. This results in the current trial and error methodology that
is used for most biomaterials research.
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1.5 Introduction to Hydrogels
Hydrogels are polymers that are able to imbibe large amounts of water within
their structure without dissolving. Hydrogels have a unique set of properties
that resemble those of native tissue ECM: high water content, tissue-like elas-
ticity, low interfacial tension as well as providing facile transport of nutrients and
waste89,90. As hydrophilicity is one of the most important factors for bioma-
terials in medical use91, their hydrophilicity along with other properties makes
hydrogels ideal candidates for ECM mimetics90. Easy alteration of the physical
form of hydrogels allows for precise control over molecular weight, degradation
time and hydrophobicity, as well as other attributes, allowing hydrogels to be
tailored for specific biomaterial applications35,89. Their unique set of proper-
ties makes them a highly attractive class of biomaterial and recently they have
been used as in vitro cell culture platforms90. Biomaterials that are intended
for clinical or commercial use need to be reproduced identically. Synthetic hy-
drogels are ideal candidates as their chemical and physical properties can be
reproduced easily and they are inherently more homogeneous.
1.5.1 PHEMA
Poly(2-hydroxyethyl methacrylate) (PHEMA) is a hydrophillic polymer that has
been extensively studied for biomedical applications92. PHEMA gels are highly
biocompatible and are well tolerated as implanted prostheses due to their sim-
ilarities in physical properties with that of native tissue92,93. The physical prop-
erties of PHEMA that resemble native tissue are its high water content, its
elasticity and its low interfacial tension91. PHEMA gels are also optically clear
and resilient and have been used in soft contact lenses93.
PHEMA gels are easy to prepare, they can be fashioned into any shape and a
wide variety of molecules that are difficult to immobilise can be stably incorpo-
rated into the gel94. PHEMA is chemically inert and stable in varying conditions
of pH and temperature95. PHEMA is highly resistant to enzymatic digestion,
as well as acid and alkaline hydrolysis, with the exception that alkaline hydrol-
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ysis can occur at high pH and high temperature89,91. When alone PHEMA’s
inertness is reflected in the unwillingness of cells to attach to its surface91,96,
but PHEMA is easily copolymerised with other monomers to alter the chemical
or mechanical properties of this hydrogel89.
PHEMA has been used for a variety of applications that include: chemical gas
sensors95, in vitro toxin removal from plasma97,98, red blood cell isolation99, or-
thopaedic and dental implants100, drug delivery101–105, anti-coagulation treat-
ment106,107, immobilisation of enzymes and other biomolecules for improved
bioactivity and bioreactor applications92,108–110, contact lenses and artificial
corneas111,112, orbital implants113, plastic surgery114,115, advanced burn/wound
dressings/artificial skin116–119, nerve conduits120–125, chromatography of pro-
teins, as a substrate for a tumor model126 and as an in vitro cell culture sub-
strate127. PHEMA hydrogels are among the synthetic polymers that have
been approved by federal agencies for biomedical and pharmaceutical applica-
tions109. This is an important factor that can assist in the approval of a PHEMA
biomaterial, which is an essential step towards commercial use.
Most applications of PHEMA use the gel form of the hydrogel. Pore size in the
gel form is limited to the nano- and low micrometer range127. When the water
content of the hydrogel is kept low, generally less than 50 wt%, the gel formed
is optically transparent, homogeneous and nanoporous. Alternatively when the
initial water content is raised above 50 wt% a phase separation occurs during
polymerisation. This is due to the limited solubility of PHEMA in water and the
resultant polymer is an heterogeneous opaque white sponge with micro-sized
pores89. Another form of PHEMA that has been widely studied is the brush
morphology on the surface of a substrate. A review of PHEMA brushes on
different surfaces revealed the ability of PHEMA brushes to be used to alter
the cell adhesion properties of the surface. In general dense PHEMA brushes
limit cell and protein adhesion while less dense brushes allow for the adhesion
of both. This trend can be used to create tune-able surfaces by varying the
density of the PHEMA brush128.
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1.5.1.1 PHEMA for Tissue Regeneration
The brush form of PHEMA has been demonstrated to be able to adsorb var-
ious ECM proteins. Brush PHEMA on a glass surface has been shown to
improve the adsorption of fibronectin to the surface resulting in good adhesion
of 3T3 fibroblasts37. PHEMA has also been modified with GRGD peptide to
improve cell adhesion of 3T3 fibroblasts. The addition of GRGD increased
the spreading behaviour of the cells by 3 orders of magnitude72. PHEMA
has also been used to improve cell adhesion to the surface of other materi-
als. Poly(dimethyl siloxane) (PDMS) films were modified with PHEMA via an
interpenetrating polymer network (IPN) method and collagen I was covalently
linked to the film. The films were tested with L929 fibroblasts. The cells main-
tained a spherical morphology with little spreading on plain PDMS films. Better
cell adhesion and spreading was observed on the P(DMS-HEMA) IPN, but the
most cells were observed on the collagen coated P(DMS-HEMA) surface129.
PHEMA brushes on glass and silicone substrates have been modified with
RGD and PHSRN peptides. The surface with only the PHSRN peptide did
not perform well with fibroblasts. Surfaces with RGD alone or RGD mixed
with PHSRN worked better, a ratio of 50:50 and 20:80 (RGD:PHSRN) worked
best. These results demonstrate the specificity of peptides and the potential of
synergistic effects130.
Self-assembling rosette nanotubes have been formed within PHEMA. The rose-
tte nanotubes were based on DNA base pairs, cytosine and guanine, modified
with an aminobutyl group to point outwards while the DNA base pairs form
the inner part of the nanotube structure. These macromolecules were incor-
porated into the monomer mixture and were observed to form the nanotubes
during polymer synthesis. Human keratinocytes and skin fibroblasts showed
high cell adhesion and better proliferation compared to the plain PHEMA131.
Brush PHEMA on a glass slide has been modified with a peptide sequence
using click-chemistry. The YIGSR peptide was added to the polymer with a
controlled concentration gradient on the surface. Human vein endotheliocytes
(EC) and human vein smooth muscle cells (SMC) were separately placed on
22
the brush gradient surface. ECs were observed to orientate themselves with
the gradient and migrate preferentially in the direction of the concentration gra-
dient. SMCs were less affected by the gradient showing less orientation and
directed migration. The gradient was observed to assist in the preferential di-
rectional migration of the ECs over the SMCs, the ECs also had an increased
migration rate over the SMCs132. This targeted cell specificity has potential
in tissue regeneration applications as it could be used to ensure the migration
of cell types that are most beneficial for the current step in the regeneration
process and help to avoid the migration of cells that could hinder the process.
Another test was performed on the brush PHEMA using a confluent layer of
cells on the peptide gradient. In this test the cells needed to over-come cell-
cell interactions to migrate along the surface. Significant migration of the EC
cells was observed in the direction of the gradient. Therefore the PHEMA
brushes with peptide gradients were shown to be able to significantly affect
cell migration and preferentially assist in the migration of one cell type over
another132.
A PHEMA brush has been used to direct cell migration. The molecular weight
of the PHEMA was varied to adjust the brush height and create a gradient on
the surface from 3 nm to 30 nm thick. Various brush gradients were created
to adjust the slope between 0.8-3.2 nm/mm. Human vascular smooth muscle
cells reacted to the gradients with their adhesion and spreading observed to
decrease as the brush thickness increased. The cells were also observed to be
preferentially orientated and migrate down the gradient. The steeper surfaces
were observed to have higher cell migration down the slope with a maximum
value of 87% for the 1.6 nm/mm slope compared with 58% on the 0.8 nm/mm
slope. The orientation of the cells was affected by the PHEMA brush thickness
and to a smaller extent by the gradient on the surface with the 15 nm thick
brush showing the best cell orientation133.
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1.5.1.2 PHEMA for Stem Cell based Regeneration
PHEMA has been investigated as a culture material for embryonic stem cells.
Initial work showed that embryonic stem cells grown for 48 hours on a PHEMA
gel, that had been treated with gelatin, were comparable to those grown on
gelatin coated tissue culture plastic134. This demonstrated the non-toxicity of
PHEMA towards embryonic stem cells. The researchers extended this work
by incorporating porogens and different crosslinkers into PHEMA. Embryonic
stem cells were observed to proliferate best on PHEMA containing 40 wt%
ethylene glycol dimethacrylate and an increase in pore size increased cell pro-
liferation. Interestingly in this work no significant increase in cell proliferation
was observed after the PHEMA was treated with gelatin135. PHEMA has been
copolymerised with 2-dimethylaminoethyl methacrylate (DMAEMA) to increase
the positive charge on the scaffold. The scaffold supported the proliferation of
embryonic stem cells, but not the proliferation of fibroblasts136. This observa-
tion highlights the specificity of biomaterials in their support of only certain cell
types.
PHEMA has been copolymerised with cholesterol to introduced hydrophobic
areas into the scaffold, to increase protein adsorption to the material. The
PHEMA-cholesterol polymer demonstrated mesenchymal stem cell (MSC) at-
tachment, after the covalent attachment of laminin, via carbodiimide chemistry,
the cells were significantly more spread and more uniform in shape137. The
incorporation of cholesterol increased the protein adsorption to the surface
which assisted in cell attachment. Interestingly the immobilisation of laminin
improved cell adhesion to the non-porous polymer but no improvement was
seen on the porous version. The lack of improvement after laminin attachment
to the porous scaffold was thought to be due to the method of immobilisa-
tion, the laminin was immobilised via lysines which could have changed the
structure of the protein137. To overcome this problem a peptide from laminin,
Ac-CGGASIKVAVS-OH, was incorporated55. The peptide improved the num-
ber of adhered MSCs as well as increasing cell spreading. It also supported
the attachment, proliferation and differentiation of neural stem cells. When
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macro sized pores were introduced into the scaffold, the pores were prefer-
entially colonised by the neural cells while the MSCs attached more to the
flat surfaces (around the pores) of the scaffold55. These results highlight the
sensitivity of cells to the topography of the scaffold, and indicates the physi-
cal characteristics of biomaterials can be optimised for certain cell types and
therefore specific applications.
The effect of varying the surface chemistry on the performance of PHEMA has
been studied. PHEMA was copolymerised with glycidyl methacrylate (GMA)
as a film that could be easily modified with various functional groups by using
the reactivity of the epoxy group. Glutaraldehyde was used to attach various
single amino acids and amino acid analogues to the film. The surfaces mod-
ified with amino acids were observed to have the highest MSC number along
with the hydrolysed P(HEMA:GMA)-OH surface. Specifically the films with 4-
aminobenzoic acid and L-phenylalanine performed the best with cell numbers
~50% higher than the control138. This research demonstrates the importance
of the surface chemistry of biomaterials as small changes in the chemistry can
result in large changes in bioactivity and cell type specificity.
Gel PHEMA has also been soaked in collagen I in buffer solutions of different
pH values to obtain optimum adsorption conditions. The PHEMA was then
further soaked in laminin and fibronectin. PHEMA that had been soaked in
collagen demonstrated better MSC and astrocyte attachment and proliferation
than the plain PHEMA. Additional adsorption of laminin or fibronectin further
improved cell attachment and proliferation of both cell types139.
1.5.1.3 PHEMA for Nerve Regeneration
In the 1980’s Carbonetto et al., prepared PHEMA gels for studying nerve fibre
growth93,94. They permitted neuron attachment but did not support nerve fiber
growth. The incorporation of various biomolecules into the PHEMA gel gave
rise to degrees of improvement in nerve fiber growth. These biomolecules in-
clude: fibronectin, b nerve growth factor (bNGF) and several types of collagen.
The biomolecules were added to the monomer mixture and upon polymeri-
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sation the small pore size of the gel (~0.4 nm) caused them to remain per-
manently trapped within the gels. Best nerve fiber growth was observed with
PHEMA gels that contained fibronectin, collagen or bNGF, while the incorpora-
tion of heparin, poly-L-lysine, cytochrome and wheat germ agglutinin showed
no improvement on PHEMA alone93.
A few examples of how PHEMA has been applied for nerve regeneration in-
clude; a PHEMA film with multi-walled carbon nanotubes (CNTs) to create a
conductive film140, a porous PHEMA sponge seeded with Schwann cells to
improve integration with host tissue and enhance axon growth141, a porous
PHEMA cryogel with poly(lactic acid) to improve neuron cell adhesion and axon
growth142, and a copolymer of PHEMA with N-(2-hydroxypropyl methacry-
late) (HPMA) and RGD to improve in vivo performance124. The P(HE-MA-
co-HPMA) scaffold was successfully produced as a commercial product, Neu-
roGelTM, which is currently undergoing clinical trials by Aqua Gel Technolo-
gies125.
A unique PHEMA scaffold has been created by spinning the monomer solution
in a cylindrical mold during polymerisation. The resultant tubes were more
porous on the inside graduating into a non-porous gel on the outside143. These
tubes were later created as a copolymer of PHEMA with methyl methacrylate,
in vivo testing showed the tubes to be biocompatible for 8 weeks120 and able
to facilitate the re-connection of the spinal cord in a rat model122. The tubes
were additionally reinforced with a poly(caprolactine) (PCL) coil, these were
able to out-perform autographs in a rat model over 16 weeks121. These results
were astounding as they represent the ultimate goal for biomaterials which is
to be a viable replacement for autographs. To achieve this they need to be
able to perform equally to an autograph to produce new functional tissue that
is identical to the native tissue.
1.5.1.4 Other Applications for PHEMA
The incorporation of biological molecules within the PHEMA network is still be-
ing explored. One example is the use of a methacrylated RGD sequence to
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copolymerise the peptide into the PHEMA sponge. This improved the bioac-
tivity of the PHEMA, as human corneal epithelial cells were shown to spread
better on this surface than on a plain PHEMA sponge144. Sponge PHEMA has
also been applied for drug delivery applications, it has been attached to the
end of a catheter and shown to improve the delivery of insulin into surrounding
tissue102. A PHEMA hybrid has been used to enhance hypoxic differentiation
of MSCs into chondrocytes145.
PHEMA has been grafted onto polyethylene to assist in the attachment of
MC3T3-E1 osteoblasts146. A PHEMA cryogel was able to support the prolifer-
ation of MSCs, the cells expressed alkaline phosphatase (ALP) which is asso-
ciated with the post-proliferative stage of ECM maturation147. A foaming agent
has been used to create super porous PHEMA, the scaffold was modified with
gelatin and shown to support the proliferation of MC3T3-E1 cells. Interestingly
these scaffolds performed better than the hydroxyapatite (HA) material148, this
was a significant result as HA is a major component of bone and therefore
one of the most commonly used materials for bone regeneration applications.
These results suggest potential for PHEMA cryogels in bone regeneration ap-
plications.
1.6 Aim
The aim of this research is to investigate the synthetic methods to introduce
biomolecules onto the 3D porous PHEMA hydrogels, to further evaluate the
bioactivity of the modified PHEMA hydrogels by qualitatively and quantitatively
examining the adhesion, proliferation and differentiation of cells on the hydro-
gels. Additionally to explore how different biomolecules can be used to opti-
mise a scaffold for different tissue regeneration applications.
Various synthetic approaches will be studied to modify the porous PHEMA with
limited interference of the 3D structure. The biomolecules, HS and RGD, have
been selected for their ability to improve cell adhesion and cell development.
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The immobilisation of both HS and RGD on the same hydrogel are explored
for any synergistic effects. The potential of the modified hydrogels for use in
deep tissue wound healing applications are investigated.
28
Chapter 2
Synthesis and Characterisation of
Bioactive PHEMA
2.1 Introduction
The modification of PHEMA can be achieved in a variety of ways, it has been
copolymerised149, grafted146, laser treated150, soaked in biomolecule solu-
tions135, had macromolecules entrapped within it140 and had biomolecules at-
tached both physically108 and chemically144. Most reported work on PHEMA
has used the gel form. The sponge form of PHEMA was selected for this work
as it is a 3D porous material with interconnected pores and the pore size is eas-
ily controlled by varying the water content during polymerisation151. This work
built on knowledge gained from decades of research on PHEMA100,152, yet it
had the innovative twist of functionalising the sponge hydrogel with biomolecules
to create a scaffold more appropriate for tissue engineering applications.
This chapter is focused on the synthesis and characterisation of PHEMA hy-
drogels with various biomolecules. The biomolecules chosen for this research
were heparan sulfate (HS) and the RGD peptide. The RGD peptide was se-
lected because it facilitates the adhesion of many cell types to substrates that
carry this motif. The RGD peptide is a central feature of one of the cell bind-
ing domains of fibronectin7, and its integrin ligands are present on a variety
of different cell types. Importantly it can be produced synthetically which im-
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proves reproducibility, reduces production costs and is amenable to scale-up if
the scaffold is to be later manufactured on a commercial scale. While RGD has
been attached to many surfaces, only one report exists of its incorporation into
sponge PHEMA144. It was incorporated by methacrylating the peptide followed
by copolymerisation with HEMA, cell quantification was not performed but mi-
croscopy showed differences in cell morphology with the presence of RGD.
This work aims to produce an RGD immobilised PHEMA, with a different syn-
thetic approach to extend the investigation by quantifying any cell proliferation
improvement upon RGD immobilisation on PHEMA.
The other biomolecule, HS, was chosen because heparan sulfate proteogly-
cans (HSPGs) play pivotal roles in biological processes such as morphogen-
esis, angiogenesis and wound healing and much of this bioactivity can be
attributed to their HS GAG chains23,24. Importantly HS chains interact with
growth factors of the FGF family and their receptors (FGFR) and so coordinate
cell-fate decisions such as cell growth and cell differentiation, which are key
to tissue regeneration16,28. Interestingly HS immobilisation on PHEMA has
not been previously reported. Although HS has been crosslinked through a
collagen matrix153, and incorporated in electrospun polycaprolactone29 and
poly(lactic-co-glycolic acid)154. The electrospun scaffolds were tested with
stem cells, whereas the collagen scaffold was implanted into rats and it stimu-
lated considerable tissue regeneration in vivo. It was therefore anticipated that
the incorporation of HS into PHEMA would improve the bioactivity of PHEMA.
The co-immobilisation of HS and RGD on a substrate has not been reported,
however heparin and RGD have been immobilised on a PEG scaffold155. There-
fore both HS and RGD were investigated for their potential to improve PHEMA
bioactivity and create a hydrogel that could have tissue regeneration applica-
tions.
The hydrogels produced were then characterised chemically and physically
using a series of techniques that included: chemical characterisation using
Attenuated Total Reflectance-Fourier Transform Infra-Red spectrometry (ATR-
FTIR), titration, UV-Vis absorbance and elemental analysis, physical charac-
terisation using Thermogravimetric Analysis (TGA), rheometer, Brunauer, Em-
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mett and Teller (BET) analysis, Scanning Electron Microscopy (SEM) and equi-
librium water content (EWC%) determination. The rheology equipment also al-
lowed for all measurements to be performed while the hydrogels were swollen
and at 37ºC. This was ideal as the results were reflective of how the hydrogels
would react in vivo. These techniques were used to investigate the properties
of the hydrogels to determine the potential of the hydrogels for tissue engineer-
ing applications.
2.2 Materials
2-hydroxyethyl methacrylate (HEMA, Bimax), ethylene glycol dimethacrylate
(EDMA, Bimax), ammonium persulfate (APS, BDH chemicals), heparan sulfate
(HS, derived from procine intestinal mucosa with average Mw of 15,000 g/mol,
Celsus Laboratories, Ohio, USA) and RGD tri-peptide (95%, GL Biochem,
Shanghai, China) were used as received. Glycidyl methacrylate (GMA, 97%),
N,N,N’,N’-tetraethylmethylenediamine (TEMED, 99%), 1,9-dimethylmethylene
blue (80%), glycine, hexamethylenediamine (98%), N-(3-dimethylaminopropyl)-
N’-ethylcarb-odiimide hydrochloride (EDC, >98.0%), N-hydroxysuccinimide (NHS,
98%), sodium chloride (NaCl), hydrochloric acid (HCl), sodium hydroxide (NaOH),
ethanol (70 vol%) and dimethylsulfoxide (DMSO) were all purchased from Sigma
Aldrich. The purchased chemicals were used as supplied unless otherwise
stated below.
Silicone tubing with inner diameter 20 mm and outer diameter 26 mm (Geck-
oOptical), 6x200x200 mm clear float glass plates (Perth City Glass). Basic
ethanol was made by dissolving 20 g NaOH in 500 mL ethanol. Farndale
reagent156 consisted of 18 mg/L 1,9-dimethylmethylene blue, 3 g/L glycine and
2.4 g/L NaCl in deionised water with the pH adjusted to 3.0 with 2 M HCl.
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2.3 Chemical Synthesis
2.3.1 Synthesis of PHEMA and P(HEMA:GMA)
Poly(2-hydroxyethyl methacrylate), (PHEMA) and poly(2-hydroxyehtyl methacr-
ylate-co-glycidyl methacrylate), (P(HEMA:GMA)) hydrogels were synthesised
as a sheet using the mould schematically illustrated in Figure 2.1. The chem-
ical composition of the hydrogels is summarised in Table 2.1. The hydrogel
codes for PHEMA and P(HEMA:GMA) are P and PG respectively.
Figure 2.1: Diagram of the hydrogel mould.
The glass plates were soaked in basic ethanol for 16 h at room temperature
before use. The polymer mould (Figure 2.1) was made by placing the silicon
tubing (inner diameter 20 mm, outer diameter 26 mm) between 2 glass sheets.
The appropriate amounts of reagents, summarised inTable 2.1, were mixed in
the following order: HEMA dissolved in deionised water followed by addition
of GMA, EDMA and APS. TEMED was added last and the solution was trans-
ferred into the pre-assembled mould within 5 min of the addition of TEMED.
The mould was placed into an air-tight container with an open vessel of water
to provide a humid environment. The container was left at room temperature
for 3 h, followed by 50ºC for 12 h. The polymer was removed from the mould
and transferred into 500 mL of deionised water. The polymer was rinsed and
the water replaced daily for 2 weeks, to produce a hydrogel sheet that was
2-3 mm thick once swollen. The hydrogel sheet was cut into 9 mm diameter
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discs using a metal punch and stored in deionised water at room temperature.
PHEMA was synthesised with an identical procedure by omission of GMA.
Table 2.1: Chemical composition of hydrogel scaffolds.
Hydrogel
HEMA GMA Water EDMA APS* TEMED
(g) (g) (g) (mL) (mL) (mL)
PHEMA 8 0 32 34 136 68
P(HEMA:GMA) 7.4 0.6 32 34 136 68
*APS was used as a 10 wt% solution
2.3.2 Synthesis of P(HEMA:GMA)-NH 2
A modification of the procedure of Bayramoglu et al.138, was used to ami-
nate P(HEMA:GMA) discs to produce P(HEMA:GMA)-NH2. Briefly; 100 discs
(approximately 10 g) were added to a solution of hexamethylenediamine (2.3
g) in 40 mL deionised water. The solution was stirred at 170 rpm and 65ºC
for 4 h then left at room temperature for 16 h with continued stirring at 170
rpm. The discs were rinsed 10 times with 100 mL deionised water and stored
in deionised water at room temperature. Aminated discs were denoted by,
P(HEMA:GMA)-NH2 and the hydrogel code, PGN.
Back titration was used to determine the success of the amination and to quan-
tify the free amine content. In brief, 6 discs of PG and PGN, were separately
freeze dried and ground with a mortar and pestle, the final mass was 140 mg.
The powdered hydrogels were suspended in 10 mL of 0.01 M HCl and agitated
at 170 rpm for 4 h at room temperature. The solution was decanted from the
hydrogels and the powder was rinsed 3 times with 1 mL deionised water. The
rinses were added to the decanted solution and the solution was made up to
25 mL in a volumetric flask. The solution was back-titrated with 0.01 M NaOH
using 0.5% phenolphthalein in ethanol as an indicator. The average titre from
3 titrations was used to determine the difference in titre between PG and PGN.
The titre difference was used to calculate the n(NaOH) which had a ratio of 1:1
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to the n(HCl) that reacted with the free amines on the hydrogel as described in
equation 1 with units, mmol NH2/g hydrogel.
2.3.3 Synthesis of P(HEMA:GMA)-HS
A solution of 260 mg EDC, 80 mg NHS and 110mg HS in 30 mL deionised
water was placed in an ice bath for 20 min. The mole ratio of EDC:NHS was
2:1, and EDC was used in a 5-fold excess with respect to the number of -COOH
groups on HS (which was estimated to be 34/molecule). Approximately 5 g of
PGN (50 discs) were added to the EDC solution and remained in the ice bath
with shaking at 170 rpm for 3 h, then removed from the ice bath and agitated at
room temperature for 16 h. The reaction solution was decanted from the discs
and kept. The discs were rinsed 3 times with 10 mL deionised water for 10 min
at 170 rpm. These rinses were combined with the decanted reaction solution
and kept. The discs were further rinsed 10 times with 100 mL deionised water
and stored in deionised water at room temperature until use. Discs that were
functionalised with HS were denoted by, P(HEMA:GMA)-HS and the hydrogel
code PGH.
To quantify the HS content, 2 mL Farndale reagent (details of Farndale reagent
in section2.2) was mixed with 2 mL decanted reaction solution and the ab-
sorbance at 525 nm immediately measured in triplicate using a PerkinElmer
UV-Vis Lambda25 spectrometer156,157. HS standards were made in deionised
water at concentrations of 0.08, 0.16, 0.20, 0.25, 0.32, 0.39, 0.50, 0.63, 0.76,
1.01, 1.26, 1.57, 2.14, 2.57 and 3.14 mg/L. A standard curve was achieved
by similarly measuring the HS standards by mixing equivalent volumes with
Farndale reagent and reading absorbance at 525 nm as described.
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2.3.4 Synthesis of P(HEMA:GMA)-RGD
PGN was also used to immobilise the RGD peptide. Briefly, 85 mg EDC, 25 mg
NHS, 65 mg RGD were dissolved in 25 mL deionised water and placed in an
ice bath. The molar ratio of EDC:NHS was 2:1, and EDC was used in a 1.2-fold
excess with respect to the number of -COOH groups on RGD. Approximately
5 g P(HEMA:GMA)-NH2 (50 discs) were added to the solution and agitated at
170 rpm at 4ºC for 3 h. The reaction and purification was carried out in the
same fashion as described in 2.3.3. The rinses were added to the reaction
solution and kept for further analysis. The discs were stored in deionised water
at room temperature until use. Discs that were functionalised with RGD were
denoted by, P(HEMA:GMA)-RGD and the hydrogel code PGR.
To quantify the immobilisation of RGD, the reaction solution was titrated against
0.01 M NaOH using 2-3 drops of 0.5% phenolphthalein indicator in ethanol. A
calibration curve was created by titrating known amounts of RGD (0, 13, 26,
39, 52 and 65 mg) in a solution of 0.5 mM EDC and 0.2 mM NHS in deionised
water.
2.3.5 Synthesis of P(HEMA:GMA)-HS&RGD
Following quantification of RGD immobilisation, P(HEMA:GMA)-RGD was fur-
ther modified with HS as described in 2.3.3. A solution of 260 mg EDC, 80 mg
NHS and 110mg HS in 30 mL deionised water was placed in an ice bath for
20 min. The molar ratio of EDC:NHS was 2:1, and EDC was used in a 5-fold
excess with respect to the number of -COOH groups on HS (which was esti-
mated to be 34). Approximately 5 g of P(HEMA:GMA)-RGD (50 discs) were
added to the EDC solution and remained in the ice bath with shaking at 170
rpm for 3 h, then removed from the ice bath and agitated at room temperature
for 16 h. The reaction solution was decanted from the discs and kept. The
discs were rinsed 3 times with deionised water for 10 min at 170 rpm. These
rinses were combined with the decanted reaction solution and kept. The discs
were stored in deionised water at room temperature until use. Discs that were
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functionalised with HS and RGD were denoted by, P(HEMA:GMA)-HS&RGD
and the hydrogel code PGHR. Numbers have been used in the hydrogel codes
to distinguish between hydrogel batches.
Table 2.2: Names and codes used for the synthesised hydrogels.









For ATR-FTIR, elemental spectroscopy, thermogravimetric analysis, surface
area determination and SEM imaging, the samples were frozen at -80ºC for
16 h followed by freeze drying at -54ºC for 2 h (ScanVac CoolSafe, LaboGene,
Denmark). The freeze dried samples were ground to a fine powder for anal-
ysis unless otherwise specified. For other measurements the samples were
dehydrated on Teflon sheets at 80ºC for 24 h.
2.4.2 Equipment and Operation Conditions
A Perkin Elmer Attenuated Total Reflectance Fourier Transform Infrared (ATR-
FTIR) spectroscope was used to analyse samples. A scan range of 3600 - 600
cm−1 and resolution of 1.0 cm−1 was averaged over 250 scans.
A Perkin Elmer Series II CHNS/O Analyser 2400 was used in CHNS mode.
The column was flushed by running 3 blanks and the calibration checked using
cystine (29.99% C, 5.03% H, 11.67% N, 26.69% S) and acetanilide (71.09% C,
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6.71% H, 10.36% N) as the analytical standards. 1-2 mg of the hydrogel was
weighed and a minimum of 5 replicates run for each sample. For low sulfur
detection the analyser was calibrated with acetanilide as a blank.
For TGA, about 11 mg of each hydrogel was weighed into 150 mL alumina
crucibles. The samples were analysed with a flow rate of 20 mL/min of argon
and 25 mL/min of oxygen. The samples were held at 25ºC for 10 min then
heated at 5ºC/min up to 900ºC.
For SEM, a high resolution field emission electron gun Zeiss NEON 40EsB
FIBSEM was used at an accelerating voltage of 3.00 keV, an aperture size of
30 µm and working distance between 2-3 mm. All samples were mounted on
SEM stubs with carbon tape and coated with 3 nm of platinum prior to imaging.
A Micromeritics TriStar II BET was used to determine the surface area of the
hydrogel discs via Brunauer-Emmett-Teller (BET) analysis. Three 9 mm diam-
eter discs of each sample were analysed. Multipoint BET analysis was per-
formed with the relative pressure range of 0.20 - 0.55, the de-gas time before
BET analysis was set to 2 h. Outliers were removed to ensure a correlation co-
efficient of 0.93 or above. TriStar 3020 analysis program was used to calculate
the surface area. All samples were de-gassed for 16 h prior to analysis.
2.4.3 Equilibrium Water Content
The equilibrium water content (EWC%) was determined by measuring the dif-
ference in hydrogel weight when hydrated and dry. The hydrogel was first
weighed hydrated then placed in an 80ºC oven for 24 hours. The hydrogel was
then weighed again and the EWC% calculated using equation 2 below. The
average of 5 samples was calculated.
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2.4.4 Viscoelastic Properties
A Haake MARS II modular advanced rheometer system was used to perform
shear testing of the hydrogel discs. 5mm thick discs were kept hydrated during
analysis via oscillation stress sweep, oscillation frequency sweep and creep-
recovery test measurements. A flat plate (PP35Ti) was used for all measure-
ments, 240 grit sandpaper was attached to the top and base plate to reduce
slipping of the hydrated scaffold discs. Measurements were taken at room
temperature and at 37ºC.
The gap height for all measurements was determined by keeping the normal
force between 0.2-0.4 N. The oscillation strain sweep was performed at a fre-
quency of 1 Hz and the strain was swept from 0.05-3%. The oscillation fre-
quency sweep was performed at a constant strain of 0.35% with a frequency
range of 0.02-1 Hz. The creep/recovery test was performed with a stress of 10
Pa which was ramped up for 120 s. The stress was removed and the recovery
monitored for a further 400 s. HAAKE RheoWin Data Manager software was
used to extract the raw data. For repeated creep/recovery tests a stress of 10
Pa was applied over 30 s followed by a recovery of 240 s.
2.5 Results and Discussion
2.5.1 Synthesis of Hydrogels
The synthetic pathway used is summarised in the scheme in Figure 2.2. The
first step involved copolymerising HEMA with glycidyl methacrylate (GMA),
which has been widely used to react with primary amines to functionalise hy-
drogels158. The reasoning behind first synthesising the hydrogel and then
modifying the GMA was to maximise the retention of control of the intercon-
nected porous structure of sponge PHEMA. After the sponge was formed the
glycidyl group of GMA was reacted with hexamethylenediamine. The incorpo-
ration of a free amine into the hydrogel enables a wide range of biologically
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active molecules to be immobilised using the same, simple chemistry which
does not require prior chemical modification of the biomolecule. In addition,
because both HS and RGD could be immobilised via the same chemistry, syn-
thesis of scaffolds containing either HS or RGD or both was possible.
The chemistry for the biomolecule immobilisation was a water soluble carbodi-
imide system. This involved the activation of carboxylic acid groups on the
biomolecules with N-hydroxysuccinimide (NHS) with the simultaneous reac-
tion of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) to form a pep-
tide bond with the free amine on the hydrogel. This chemistry is widely used
and others have used this approach to covalently bind collagen to PHEMA126
and to crosslink collagen and star-PEG with heparin32,159. The star-PEG-
heparin scaffold was additionally post-modified with RGD using the EDC/NHS
system32.
2.5.2 Amination Determination
The success of the amination reaction was determined by measuring the amount
of free amine present on the hydrogels by back titration. The results showed
that 20-77 mmol of free amine was present per gram of hydrogel after the re-
action of P(HEMA:GMA) with hexamethylenediamine. The assumption was
made that all of the GMA added to the monomer mixture polymerised dur-
ing synthesis of the hydrogels, the chemical conversion was in the range of
14-53%. Low conversion of GMA with free amines has been observed by
others with 0.1% conversion realised when polyethylenimine was immobilised
using identical chemistry160. Others have observed 36% conversion of GMA
with hexamethylenediamine138 but conversions as low as 0.01% have been
reported158. The relatively low yields in the present study were likely due to
the 3D nature of the hydrogels, where it was assumed that most of the conver-
sion of the glycidyl groups happened on the surface of the discs. Additionally
it was possible that some of the glycidyl groups were hydrolysed during poly-
merisation, this has been investigated during emulsion polymerisation of GMA
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Figure 2.2: Scheme of hydrogel synthesis and modifications to immobilise
biomolecules.
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with up to 30% hydrolysis measured when polymerisation occurred at 60°C 161.
The high standard deviation of the current results was likely due to the nature
of the technique. The back titration relied on the protonation of all free amine
groups on the hydrogel to consume the HCl, the reduction in HCl was then de-
termined by titration with NaOH. The variability in the results could also have
been due to the presence of unreacted glycidyl groups which may have been
hydrolysed with HCl. The difference in titre from the titration of PGN and PG
was used in an effort to reduce the effect of the unreacted GMA on the results.
Table 2.3: Quantified free amine present on the hydrogels.
Hydrogel code
GMA content Free amine content¹ GMA conversion²
(mmol/g hydrogel) ( mmol/g hydrogel) (%)
PGN8 150 66 ± 25 44
PGN12 142 40 ± 25 28
PGN21 147 48 ± 0* 33
PGN22 145 77 ± 14 53
PGN23 144 29 ± 15 20
PGN27 146 20 ± 13 14
PGN28 144 45 ± 12 31
PGN29 152 62 ± 14 41
PGN30 156 66 ± 18 42
PGN31 157 61 ± 16 39
PGN33 157 55 ± 38 35
¹values determined by back titration, results were mean ± standard deviation, n = 3
²conversion was determined as the percentage of free amines that were reacted
*data for PGN21 had no standard deviation because the results were identical
2.5.3 HS Quantification
The amount of immobilised HS was quantified using a colourmetric dye and
UV-Vis spectroscopy. The meta-chromatic dye, 1,9-dimethylmethylene blue in
the Farndale reagent is electrostatically attracted to the highly negative charge
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Figure 2.3: Change in absorbance of 1,9-dimethylmethylene blue (from Farn-
dale reagent) with HS concentration. Not all concentrations of HS used in the
calibration curve are shown for clarity of the figure.
of the sulfate groups on HS156,157. The coordination of 1,9-dimethylmethylene
blue to HS results in a colour change from blue to purple (or pink) when the
concentration of HS is sufficiently high. The colour change was monitored via
UV-Vis spectroscopy as shown in Figure 2.3. As the concentration of HS in-
creased the signal at 590 nm decreased and a new signal at 535 nm appeared.
A calibration curve was created for HS by measuring the absorbance at 525
nm (Figure 2.4). The amount of HS left in solution after reaction with the scaf-
fold was measured with UV-Vis and the value of unreacted HS calculated. This
value was then subtracted from the initial amount of HS and the amount of HS
immobilised on the scaffold was calculated.
Several batches of P(HEMA:GMA)-HS were synthesised. The summary ta-
ble (Table 2.4) shows the reproducibility of the immobilisation technique. The
amount of immobilised HS was consistently between 1.0 - 3.09 mg HS/g hydro-
gel. The 3 batches with lower amounts of immobilised HS were due to those
batches having RGD immobilised on them first. Therefore the lower amount of
HS was expected as there were fewer sites available for HS attachment. The
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Figure 2.4: Calibration curve for 1,9-dimethylmethylene blue (from Farndale
reagent). Linear relationship with increasing concentration of HS.
Table 2.4: Quantified amount of HS immobilised on hydrogels..
Hydrogel code
Free amine content Amount of HS on hydrogel¹
(mmol/g hydrogel) ( mmol/g hydrogel)
PGH8 66 ± 25 3.09 ± 0.05
PGH12 40 ± 25 1.0 ± 0.4
PGH23 29 ± 15 1.8 ± 0.3
PGH27 20 ± 13 2.4 ± 0.2
PGH33 55 ± 38 2.2 ± 0.1
PGHR21 48 ± 0 1.4 ± 0.3
PGHR30 66 ± 18 1.5 ± 0.2
PGHR31 61 ± 16 2.0 ± 0.5
¹values determined by UV-Vis measurement with Farndale reagent as mean ±
standard deviation, n = 3
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amount of immobilised HS, 15-46 mg/g hydrogel, was similar to that achieved
by others, for example, 60 ± 5 mg HS/g scaffold by crosslinking the HS through
a collagen scaffold using EDC and NHS23. The HS used in the published re-
port was of higher molecular weight, approximately 25 kDa, compared to the
approximate 15 kDa form used in this work, which could have accounted for
the higher mass immobilised on the collagen scaffold. Additionally it should be
noted that the HS could have been tethered at multiple points on the hydrogel.
The number of COOH groups per HS molecule was estimated at 34, therefore
it was highly probable that the HS was anchored to the hydrogel by reaction
with multiple amine groups.
2.5.4 RGD Quantification
Quantification of the amount of RGD peptide immobilised on the hydrogel discs
was achieved via titration of the reaction solution against standardised NaOH.
The deprotonation of RGD is shown in Figure 2.5 and the reaction resulted in
a molar ratio of 2:1. As EDC and NHS interfered in the titration, a lower ratio
of EDC:COOH was used for the RGD immobilisation, 1.2:1. To additionally
reduce the interference of EDC and NHS, their amounts were held constant for
all immobilisation reactions and calibration solutions. The calibration solutions
were used to create a curve from which the amount of RGD left in solution after
immobilisation could be determined.
Figure 2.5: Chemical equation showing the reaction of RGD with NaOH.
The calculated amount of RGD immobilised on the hydrogel is summarised in
Table 2.5. Some variability in the immobilisation amounts was measured, the
immobilised RGD was between 22-87 mmol/g hydrogel. These results were for
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the hydrogels with HS and RGD attached as well as RGD alone. The vari-
ability in the results was likely due to the reduced sensitivity of the titration as
EDC and NHS were both present and also reacting with the NaOH. The con-
version rates that were above 100% were likely due to a 2-fold effect, firstly the
free amine content could have been under-estimated (as previously discussed
in 2.5.2) and secondly the reduced sensitivity of the RGD titration may have
contributed to an over-estimation of the immobilised RGD.
Table 2.5: Immobilised RGD on the hydrogels.
Hydrogel code Free amine content Amount of RGD¹ Conversion²
(mmol/g hydrogel) ( mmol/g hydrogel) (%)
PGR22 77 ± 14 74 96
PGR28 45 ± 12 98 217
PGR29 62 ± 14 68 110
PGHR21 48 ± 0* 79 164
PGHR30 66 ± 18 85 129
Free amine content is mean ± standard deviation, n = 3
¹values determined by titration with NaOH
²conversion determined as the percentage of free amine that reacted with RGD
*result for PGHR21 had no standard deviation because the results were identical
2.5.5 Elemental Analysis
Elemental analysis results are summarised in Table 2.6. The measured results
fit the theoretical values well for carbon and hydrogen, being within 9%. From
the difference between the measured and theoretical values, it can be con-
cluded that the water content was approximately 5 wt% which was consistent
with the TGA analysis results. The amination of P(HEMA:GMA) was confirmed
by the increase in signal for nitrogen from 0% to 0.16% for P(HEMA:GMA)-
NH2. A further increase in the nitrogen signal to 0.19% for P(HEMA:GMA)-HS
confirmed the immobilisation of HS.
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Table 2.6: Elemental analysis results (wt%).
Hydrogel
Theoretical Measured¹
Carbon Hydrogen Nitrogen Sulfur Carbon Hydrogen Nitrogen Su lfur #
P1 55.37 7.75 0 0 52.21 7.45 0 -
PG1 55.39 7.74 0 0 52.38 7.68 0 1.0*
PGN1 55.40 7.75 0.05 0 52.54 7.74 0.16$ 1.2
PGH1 54.72 7.68 0.09 0.15 50.19 7.92 0.19$ 1.6*
¹values are the mean of 5 samples
$values determined to have increasing trend with respect to P1 & PG1 by
Jonckheere-Terpstra test
#values determined after the equipment was calibrated for low sulfur samples on
hydrogels: PG23, PGN23 and PGH23, average of 3 samples
*statistical significance determined by 2 tailed t-test with equal variances (p<0.05)
The theoretical calculations showed that the concentration for sulfur was just
above the limit of detection of the analytical detector, which was 0.1 wt%.
Despite this there was no significant difference observed in the sulfur sig-
nal. Therefore separate analysis was performed to determine the sulfur con-
tent of the hydrogels and this involved the column being specifically calibrated
for low sulfur samples. The sulfur signal increased from P(HEMA:GMA) to
P(HEMA:GMA)-HS, 1.0 - 1.6 wt% (Sulfur# in Table 2.6). The difference in signal
for sulfur between P(HEMA:GMA)-HS and, P(HEMA:GMA) and P(HEMA:GMA)-
NH2, indicated that the amount of HS was between 3.6 and 5.9 mmol/g polymer.
This result was higher than the UV-Vis results which measured 1.8 mmol HS/g
polymer (Table 2.4). As these samples were bordering on the limit of detection
for elemental analysis the UV-Vis results were used for further discussion.
Due to the over-estimation of the sulfur signal the remaining hydrogels were
analysed with a CHN column. The measured results for carbon and hydrogen
showed good agreement with the theoretical values with most results within
±10%. A better fit was realised with the addition of 5 wt% water in the sam-
ples, which was measured by TGA, and these results were consistent with
the results on P(HEMA:GMA)-HS. The incorporation of amine, HS and RGD
all resulted in increased nitrogen signals for PG31. The nitrogen signal also
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Table 2.7: Elemental composition (wt%) of the hydrogels.
Hydrogel
Theoretical Measured¹
Carbon Hydrogen Nitrogen Carbon Hydrogen Nitrogen
P2 55.37 7.75 0 52.72 7.26 0
P4 55.37 7.75 0 52.47 7.11 0
PG28 55.45 7.73 0 49.63 6.95 0.16*
PGN28 55.48 7.76 0.13 49.87 6.99 0.14*
PGR28 55.43 7.76 0.21 49.72 7.39 0.18*
PG31 55.45 7.73 0 52.45 7.23 0.16*
PGN31 55.50 7.77 0.17 52.27 8.46 0.21*
PGHR31 54.43 7.66 0.37 52.01 8.96 0.40*
¹values were the average of 5 samples
*statistical significance was tested with a 2 tailed T-test with equal variances (p<0.05)
increased from P(HEMA:GMA)-NH2 to P(HEMA:GMA)-RGD, 0.14-0.18 wt%,
due to the immobilisation of RGD. These results were statistically significant
and further confirmed the modifications that were quantified by titration.
2.5.6 ATR-FTIR
The ATR-FTIR spectrum for PHEMA is shown in Figure 2.6. The signals as-
cribed to PHEMA were; a strong and broad signal observed at 3400 cm−1 due
to the O-H stretch162. Medium absorption bands at 2950 cm−1 and 2885 cm−1
were ascribed to the antisymmetric stretching vibration of C-H in the methyl
and -CH2 groups163. Another strong signal was observed at 1720 cm−1 due to
the carbonyl C=O stretch162. Medium to strong signals in the range 1250-1070
cm−1 (maybe also 1030 peak) were ascribed to the C-O and the antisymmetric
stretching of C-O-C163. The signal at 1450 cm−1 corresponded to CH3and CH2
bending deformations and the signals 970-900 cm−1 were due to C-O-C defor-
mation92. The signal at 750 cm−1 was associated with the bending vibration
mode of CH2 and CH2 rocking that is characteristic of methacrylic polymers.
A change in the relative intensity of the signals at 1020 cm−1 and 1075 cm−1
was observed as the hydrogels were modified. The copolymerisation of HEMA
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Figure 2.6: ATR-FTIR spectra of PHEMA (a), P(HEMA:GMA) (b),
P(HEMA:GMA)-NH2 (c) and P(HEMA:GMA)-HS (d).
with GMA increased the 1020 cm−1 signal due to the introduction of more C-
O-C groups. The signal further increased after the immobilisation of HS due to
the multiple C-O-C groups contained in the biomolecule. No further character-
istic signals were observed from the modifications performed on PHEMA due
to the overlap with the strong signals from PHEMA. For example, the charac-
teristic amine signals from hexamethylenediamine were obscured by the broad
O-H stretch and strong carbonyl stretch of PHEMA. The strongest character-
istic signals for HS were due to the carboxylic acid groups which also produce
signals within the range of the PHEMA O-H and carbonyl stretches.
An indirect approach was used to confirm the reaction of HS to the free amine
groups on the hydrogels. Briefly, 94 mg HS was reacted with 24 mg hexam-
ethylenediamine, 206 mg EDC and 64 mg NHS in deionised water at room
temperature for 24 h. The product was dried with a rotor evaporator and the IR
spectra taken. The spectra of the product had 2 signals at 2940 cm−1 and 2860
cm−1 which corresponded to the hexamethylenediamine signals (Figure 2.7).
Additionally the reaction was confirmed by the retention of the primary amine
signal at 1630 cm−1 and a new signal at 1550 cm−1 which indicated the pres-
ence of a secondary amine. This showed that the HS was attached to one end
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Figure 2.7: ATR-FTIR spectra demonstrated the reaction of HS with hexam-
ethylenediamine. Hexamethylenediamine (a), HS (b) and aminated HS (c).
of the hexamethylenediamine. These results were further strengthened by the
UV-Vis results which were able to quantify the amount of HS that had been
immobilised on the hydrogels.
2.5.7 TGA
The TGA results showed a gradual weight loss between 25-210ºC followed
by the primary weight loss which occured between 210-440ºC (Figure 2.8).
The initial weight loss between 25-100ºC was due to the evaporation of water
from the hydrogels, and this was between 4.6 - 5.7%. The water was prob-
ably absorbed from the atmosphere before analysis. This result was used in
the elemental analysis which showed a great fit with theoretical results with
5 wt% water in the hydrogels. The primary weight loss was due to the de-
composition of the hydrogels, this began at 210ºC for PHEMA, while decom-
position of P(HEMA:GMA) was delayed until 276ºC. The copolymer displayed
increased thermal stability due to the incorporation of GMA. Examination of
multiple batches of the hydrogel showed low variability between the batches,
as seen in Figure 2.9. The thermal stability of PHEMA was consistent with
49
Figure 2.8: TGA curves for PHEMA and P(HEMA:GMA).
TGA results obtained by others105,164 and the copolymerisation of PHEMA
with methylmethacrylate similarly delayed thermal decomposition165. The de-
composition of the hydrogels after the further modification with hexamethylene-
diamine and HS was unchanged from that of P(HEMA:GMA). These results
demonstrated that the modified hydrogels had improved thermal stability over
PHEMA and were stable at physiological temperature.
Figure 2.9: TGA curves for 3 batches of hydrogel showing low batch-to-batch
variability. PG10 (red), PG12 (blue) and PG23 (green).
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2.5.8 Pore Structure, Surface Area and EWC%
The SEM images showed the porous structure of the hydrogel scaffolds and
the spherical structure of the polymer. The pore structure of the hydrogels
was maintained after the chemical modifications as seen in Figure 2.10. The
PHEMA hydrogel had some areas with thin string-like structures, these were
likely an artefact and have been observed by others in PHEMA sponges166.
Interestingly the pores for PG10 were the most distinct and large with the
spherical structure of the polymer appearing smaller than all other hydrogels.
Smaller spherical structure of the hydrogel has been attributed to the early on-
set of phase separation which reduces the droplet size166. The solubility of
GMA in water is 2.3 wt%, therefore it was possible that the early onset of the
polymerisation was enhanced by the higher solubility of GMA in PHEMA than
in water. Another possible cause was the increased temperature used for the
synthesis of PG10, 60ºC for 20 h followed by 70ºC for 3 h. All other hydrogels
were synthesised at 50ºC for 12 h, the difference in synthesis temperature may
have caused an earlier onset of the phase separation resulting in the formation
of smaller polymer spheres and pronounced pore size.
The pores in the copolymer appeared to have contracted after modification with
hexamethylenediamine. There were no observable differences in pore size
or polymer morphology between P(HEMA:GMA)-NH2, P(HEMA:GMA)-HS and
P(HEMA:GMA)-RGD. All hydrogels were seen to contain pores with the same
spherical structure. P(HEMA:GMA)-HS&RGD appeared more dense than the
other hydrogels, this could have been due to variations during sample prepara-
tion (freezing and freeze drying) or due to the angle at which the hydrogel was
imaged (imaging pores at an angle can make them appear narrower). All hy-
drogels showed the effect of freezing as striations that were created across the
samples, these were most obvious on PG10, PGN10 (diagonally) and PG30
(vertically).
All of the average EWC% results were similar which indicated that all hydrogels
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Figure 2.10: SEM images of the cross-sectional area of hydrogels. All images
were taken at 3keV with a working distance of 5.0 mm giving 500x magnifica-
tion, the scale bar was 20 mm.
Table 2.8: EWC% values for the hydrogels.
Hydrogel EWC%¹
number PG PGN End modification
6 80.3 ± 0.4 79.9 ± 0.5 PGR 79.4 ± 0.2
8 82.3 ± 0.4 - PGH -
9 79.0 ± 0.5 80.4 ± 0.5 PGR 79.5 ± 0.5
10 81.4 ± 0.7 - PGH -
15 81.5 ± 0.2 80.0 ± 0.1 PGHR 79.7 ± 0.6
16 81.8 ± 0.5 80.1 ± 0.4 PGHR 79.5 ± 0.3
¹values were the average of 5 samples ± standard deviation
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maintained their hydrated nature after modification (Table 2.8). The EWC% for
PHEMA was: 76 ± 4, 76 ± 1 and 76.5 ± 0.6 for P2, P3 and P4 respectively. The
modified hydrogels had higher EWC% values between 79-82% indicating an
increase in swellability over PHEMA. The amount of GMA in the hydrogels was
kept low to avoid the large reduction in equilibrium water content which was
observed by Santander-Borrego when they used greater than 6 mol% incor-
poration of GMA in HEMA167. These results contrasted with the SEM images
which showed an apparent decrease in pore size, therefore the contraction in
the pores did not affect the EWC%. These results demonstrated that the hydro-
gels maintained a constant degree of swelling in water after all modifications.
The surface area of the hydrogels was measured using BET analysis. PHEMA
had a surface area of 24 ± 5 m2/g and the modified hydrogels: 21 ± 3 m2/g,
39 ± 2 m2/g, 36 ± 5 m2/g for PG10, PGN10 and PGH10, 36 ± 2 m2/g, 17
± 3 m2/g, 28 ± 7 m2/g for PG28, PGN28 and PGR28, 36 ± 10 m2/g, 22 ±
11 m2/g, 39 ± 4 m2/g for PG30, PGN30 and PGHR30 respectively. None of
the differences between the various hydrogels were statistically significant.
These results indicated that the apparent pore contraction observed in the
SEM images did not result in a significant decrease in the surface area. The
EWC% and surface area values were similar to those obtained by others when
PHEMA was crosslinked with EDMA, others have observed an EWC% of 65%
and surface area of 25.61 m2/g127. When PHEMA was crosslinked with N,O-
dimethacryloylhydroxylamine, EWC% values of 68 and 67% and surface areas
of 43.83 m2/g and 54.31 m2/g were obtained135. Therefore taking the SEM,
EWC% and surface area results together, all of these results demonstrated
that the modifications on PHEMA maintained the hydrated nature, surface area
and porosity of PHEMA.
2.5.9 Viscoelastic Properties
The viscoelastic properties of the hydrogels were measured with a rheometer
as this equipment measured the hydrogels response to shear stress. The rhe-
ology equipment also allowed for all measurements to be performed while the
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hydrogels were swollen and at 37ºC. The water content of PHEMA has been
demonstrated to affect the viscoelastic properties as it has a plasticising effect
(increases the elasticity/stretch-ability)168. This was ideal as the results were
reflective of how the hydrogels would react in vivo. The values determined for
the hydrogels were the: elastic modulus, viscous modulus and elastic recov-
ery. The elastic modulus is also known as the storage modulus and it described
the solid behaviour of the hydrogels, the greater the elastic modulus the more
the material reacts as an ideal elastic solid (resists deformation and returns
to its original shape). The viscous modulus, also known as the loss modu-
lus, described the flow or liquid characteristic of the hydrogels. The larger the
viscous modulus the more the material is able to dissipate energy, usually as
heat. Most materials exhibit both characteristics to varying degrees and are
therefore known as viscoelastic.
Table 2.9: Elastic and viscous moduli of the hydrogels at room temperature
and 37ºC.
Hydrogel code G’ (kPa)¹ G” (kPa)¹ G’ (kPa)² G” (kPa)²
P3 2.9 ± 0.4 0.48 ± 0.06 2.48 ± 0.04 0.34 ± 0.03
PG17 2.7 ± 0.2 0.37 ± 0.02 - -
PGN17 2.6 ± 0.1 0.40 ± 0.02 - -
PGH17 3.4 ± 0.3 0.40 ± 0.03 2.52 ± 0.09 0.31 ± 0.06
PG24 2.7 ± 0.4 0.32 ± 0.08 - -
PGN24 2.5 ± 0.1 0.32 ± 0.06 - -
PGR24 3.0 ± 0.4 0.36 ± 0.03 3.0 ± 0.1 0.19 ± 0.02
PG25 2.7 ± 0.1 0.37 ± 0.02 - -
PGN25 2.4 ± 0.2 0.33 ± 0.06 - -
PGHR25 2.7 ± 0.2 0.46 ± 0.05 3.0 ± 0.2 0.36 ± 0.02
G’ = Elastic modulus, G” = Viscous modulus
¹values were the average of 20 measurements from 5 samples ± standard deviation
at room temperature
²values were the average of 20 measurements from 3 samples ± standard deviation
at 37ºC
The oscillation stress sweep was used to determine the linear viscoelastic re-
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gion of the hydrogels, which is the region where the elastic and viscous mod-
uli are independent of the strain in the material. An oscillation strain sweep
within the linear viscoelastic region was then used to measure the moduli,
these are summarised in Table 2.9. The elastic modulus of PHEMA was 2.9
± 0.4 kPa. In order to determine whether any of the modifications on PHEMA
had a significant effect on the viscoelasticity of the hydrogels, all intermediates
(P(HEMA:GMA) and P(HEMA:GMA)-NH2) corresponding to the 3 end mod-
ifications were tested. The 3 batches of P(HEMA:GMA) had similar elastic
moduli to each other and PHEMA. P(HEMA:GMA)-HS had the highest elastic
modulus of 3.4 ± 0.3 kPa, followed by P(HEMA:GMA)-RGD which had 3.0 ± 0.4
kPa. The slight increase in the elastic modulus was due to the immobilisation
of HS and RGD on the hydrogel. Interestingly P(HEMA:GMA)-HS&RGD had
elastic modulus of 2.7 ± 0.2 kPa which was not markedly different to PHEMA.
The viscous modulus was highest for PHEMA and P(HEMA:GMA)-HS&RGD
at 0.48 ± 0.06 kPa and 0.46 ± 0.05 kPa respectively. The viscous modulus
was constant for 2 of the P(HEMA:GMA) batches, P(HEMA:GMA)-NH2 and
P(HEMA:GMA)-RGD. All of the hydrogels displayed solid-like behaviour as the
elastic moduli were greater than the viscous moduli.
Table 2.10: Elastic recovery of the hydrogels at room temperature.
Hydrogel code Recovery (%)¹
P3 73.0 ± 0.9
PG17 80.6 ± 0.4
PGN17 72.5 ± 0.9
PGH17 79.5 ± 0.4
PGR24 74.0 ± 1.1
PGHR25 68.5 ± 0.5
¹stress of 10 Pa was applied gradually over 120 s followed by a recovery of 400 s.
Results were the average of 5 samples ± standard deviation
PHEMA and the end modification hydrogels were tested at 37ºC to mimic
physiological conditions. All of the hydrogels demonstrated similar mechanical
properties when tested at physiological temperature. These results showed
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that the hydrogels would retain their mechanical properties for in vivo appli-
cations which is essential for successful tissue engineering applications. The
moduli values obtained for the hydrogels was within the range measured by
AFM for fibroblasts, 3-12 kPa169, as individual cells and a reconstituted tissue
model, 1-2.5 kPa170,171. The AFM results were a measure of Young’s modulus
which is typically a little larger than the shear modulus, which was measured
in this work. These data suggested that the hydrogels have an appropriate
elasticity to support fibroblast adhesion.
Figure 2.11: Elastic recovery of hydrogels after application of repeated stress
at 20°C. Stress of 10 Pa was applied over 60 s (30 s for P(HEMA:G MA)) fol-
lowed by a recovery of 240 s.
The creep/recovery analysis was used to determine the ability of the hydrogels
to recover after the application of stress. The elastic recovery of the hydrogels
was determined by the difference in the maximum and minimum strain mea-
sured with the physiologically relevant shear stress of 10 Pa. This stress is
indicative of the shear stress in skin associated with movement such as run-
ning172. The hydrogels were observed to recover well with values from 68.5-
80.6% (Table 2.10). The recovery was similar for PHEMA, P(HEMA:GMA)-NH2
and P(HEMA:GMA)-RGD, and higher for P(HEMA:GMA) and P(HEMA:GMA)-
HS. These results may have indicated some improvement in the elastic recov-
ery of the scaffolds due to the copolymer and modification steps. However the
results from P(HEMA:GMA)-NH2 and P(HEMA:GMA)-HS&RGD did not comply
with that hypothesis. Interestingly P(HEMA:GMA)-HS&RGD demonstrated the
lowest recovery which correlated with it also having the lowest elastic modulus
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of all the end modifications. As this hydrogel had the highest viscous modu-
lus it was possible that the immobilisation of both biomolecules enhanced the
fluid characteristics of the hydrogel while simultaneously impairing the elastic
properties.
Figure 2.12: Elastic recovery of hydrogels after repeated application of stress
at 37ºC. Stress of 10 Pa was applied over 30 s followed by a recovery of 240 s.
Additionally the amount of HS immobilised on PGH17 and PGHR25 varied,
0.84 ± 0.05 and 2.9 ± 0.1 mmol HS/g hydrogel respectively. As more HS was
attached to PGHR25, it was possible that greater crosslinking occurred on this
hydrogel. More immobilised HS, covalently bound to the hydrogel at multiple
points would restrict the movement of the hydrogel. This restriction in move-
ment would impair the hydrogels ability to recover elastically from an applied
stress, resulting in the reduction of the recovery by 11%.
The overall high recovery values for the hydrogels indicated good elastic prop-
erties which are essential for a permanent implant. A permanent implant
would undergo repetitive compression and tension moments as well as shear
stress. These results showed that the hydrogels have great potential to cope
with applied stress without permanent deformation as they have the ability to
spring back into shape once the stress is removed. To extend these results
P(HEMA:GMA) and P(HEMA:GMA)-HS hydrogels were tested for repeated
creep/recovery to determine their performance after multiple stress events, this
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was in effect, an attempt at a shear fatigue test. Fatigue testing is most often
performed on hard materials (moduli >100kPa) with tensile or compressive
systems, however the long term success of soft implants is also reliant on
maintained mechanical properties that match the surrounding tissue. Repe-
tition of the test showed that the recovery of P(HEMA:GMA)-HS approached
100% after 5 cycles and P(HEMA:GMA) demonstrated the same trend. These
results meant that the hydrogel underwent some rearrangement or small defor-
mation during the first 2 cycles and remained stable thereafter. These results
indicated that the hydrogels should be able to withstand the repeated stress
that would be encountered by a permanent implant.
The elastic recovery from repeated creep/recovery tests of the hydrogels was
also determined at 37ºC. The recovery of PHEMA approached 100% by cycle
14, P(HEMA:GMA)-HS by cycle 7 while P(HEMA:GMA)-RGD and P(HEMA:GMA)-
HS&RGD were seen to approach 100% recovery by cycle 4. These results
showed that the modified hydrogels were able to recover their shape more
rapidly after multiple applications of stress than PHEMA. These results con-
firmed that the hydrogels would be stable and provide consistent physical sup-
port under repeated stress conditions at physiological temperature under phys-
iological shear stress. This suggested that the hydrogels have potential to pro-
vide long term support to soft tissue when implanted.
2.6 Conclusions
Several modifications of PHEMA were achieved. PHEMA was copolymerised
and modified to enable immobilisation of HS and RGD. The amination of the
P(HEMA:GMA) was confirmed by titration and elemental analysis. Immobil-
isation of HS was confirmed indirectly with ATR-FTIR, directly by elemental
analysis and quantification of HS and RGD immobilisation was by UV-Vis and
titration respectively. The results showed consistent immobilisation of 1-3.09
mmol HS/g polymer and 22-87 mmol RGD/g polymer. Immobilisation of both
58
HS and RGD resulted in 1.4-2.0 mmol HS/g polymer and 22-87 mmol RGD/g
polymer.
The synthesised hydrogels were all porous with high EWC%, which indicated
high water content similar to that of native tissue. The results from TGA demon-
strated that P(HEMA:GMA) had increased thermal stability over PHEMA. The
surface area of the modified hydrogels as well as the other physical proper-
ties measured did not vary significantly from that obtained with PHEMA, which
indicated that the modifications did not adversely affect the biocompatible char-
acteristics of PHEMA.
Measurement of the viscoelastic properties of the hydrogels showed that the
hydrogels had elasticity similar to soft tissue and relaxed muscle. The highest
elastic modulus measured was for P(HEMA:GMA)-HS, 3.4 ± 0.3 kPa at room
temperature. Interestingly the highest elastic modulus measured at 37ºC was
for P(HEMA:GMA)-RGD and P(HEMA:GMA)-HS&RGD at 3.0 ± 0.1 kPa and
3.0 ± 0.2 kPa. The elastic recovery of the hydrogels was tested and found to be
high, 68.5 - 80.6% at room temperature with similar results at 37ºC. Repeated
creep/recovery tests showed the hydrogels ability to retain their shape after
multiple applications of stress. These results showed that the elastic recovery
of the hydrogels approached 100% after 4-7 cycles. This indicated that the
hydrogels had some small re-arrangement in their structure during the first
few applications of stress but were stable thereafter. Therefore the hydrogels
demonstrated stable physical properties that are compatible with an application
as a permanent implant.
In conclusion the synthesised hydrogels were characterised chemically and
physically. Chemically the hydrogels were successfully modified to incorporate
HS and RGD. The elasticity of the hydrogels was shown to be close to that of
soft tissue and relaxed muscle. Lastly the hydrogels showed the ability to with-
stand repeated stress at physiological temperature and shear stress. These
hydrogels have potential for use in soft tissue regeneration applications.
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Chapter 3




Heparan sulfate (HS) is a co-receptor acting in the formation of some cell-
cell adhesions and cell-matrix adhesions. In addition its interactions with cell
surface receptors contribute to cell proliferation, cell motility and differentia-
tion173. HS is known to bind fibronectin, laminin and collagens in the ECM, all
of these have been found to be important for cell adhesion. Additionally, cell
interactions with some matrix proteins can facilitate differentiation, for example
fibronectin has been found to enhance the differentiation of murine myoblast
cells, C2C12174. The contribution of HS to the normal physiological function
of a wide range of different cell types was recognised when HS was discov-
ered to bind members of the FGF family of growth factors. This binding was
required for sustained signaling through the various cell surface FGF recep-
tors80,173. More recently, HS has been recognised as a required biomolecule
for the binding of FGF family members to direct the change from cell prolifera-
tion to differentiation80.
Surprisingly, HS immobilisation on sponge PHEMA has not been previously re-
60
ported. Heparin, a GAG similar to HS but more sulfated, has been immobilised
on PHEMA for therapeutic drug delivery and antithrombogenic activity107,175,
but its effect on cell differentiation was not investigated. Interestingly, heparin
incorporated into a fibrin scaffold to allow for the binding of bFGF, resulting in
significant improvements in neurite behaviour, specifically the enhancement of
neurite extension formation176. Heparin, of a similar molecular weight to the
HS used in this study, was shown to improve fibroblast adhesion and prolif-
eration in a way that was superior to the results obtained with another GAG,
chondroitin sulfate177. In connective tissue, fibroblasts are the main cells that
are involved in the deposition, maintenance and remodeling of the ECM177
and as a result are important for tissue regeneration. Of particular interest
to the present study was the finding that the expression of HS proteoglycans
(HSPGs) were up-regulated during muscle regeneration178. They are essen-
tial for the transmission of mechanotransduction signals which are important
for cell spreading, assembly of the actin cytoskeleton and cell contractility179.
Collectively all of these data demonstrate the likely importance of HS in tissue
regeneration applications.
When developing a scaffold for tissue regeneration that contains HS it is not
enough to quantify the amount of HS immobilised on the hydrogel, it also needs
to be shown that the immobilised HS is active. Quantitative analysis in Chapter
2 showed that 1-3.09 mmol HS/g polymer was immobilised. To examine the
bioactivity of the immobilised HS, two approaches were taken in this chapter,
one was a binding assay to assess whether the HS that was immobilised could
bind a growth factor likely to be involved in tissue regeneration. The second
approach was to assess the effect of the immobilised HS on cell behaviour in
tissue culture.
A review of the literature suggested that basic fibroblast growth factor (bFGF)
could be a growth factor that both binds to HS and is involved in tissue regen-
eration. For example, bFGF is a major growth factor involved in skin wound re-
pair173, and the introduction of bFGF and HS into a scaffold has been demon-
strated to improve cellular invasion in vivo153. Also a PHEMA copolymer
soaked in HS solution then bFGF solution has been shown to improve neu-
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ral stem cell growth180. As there is a known strong affinity between HS and
bFGF, it was possible for an assay to be designed to assess the bioactivity of
the immobilised HS by how much bFGF was bound. Accordingly, an Enzyme
Linked ImmunoSorbant Assay (ELISA) was designed using bFGF as the HS
binding growth factor. The analysis of the hydrogels with a bFGF ELISA had
the dual approach of testing the bioactivity of the immobilised HS, and of in-
dicating whether the hydrogels are likely to sequester bFGF in vivo thereby
enhancing their tissue regeneration potential.
The second way the bioactivity of the synthesised hydrogels was examined
was through cell culture. It was argued that an increase in cell adhesion or
cell development would indicate that the HS is active. Having considered the
measured elasticity of the hydrogels, 2 cell types were chosen that are de-
rived from tissues of soft and intermediate stiffness. These were 3T3 mouse
fibroblasts and C2C12 mouse myoblasts. It has been reported that HS facili-
tates the bioactive processes of bFGF which are critical for fibroblasts and my-
oblasts181. Fibroblasts are one of the most abundant cells in connective tissue
and myoblasts are cells that have the potential to differentiate into myotubes
which is the first step towards developing muscle fibre. Accordingly these cell
types will provide evidence of whether the hydrogels may be suitable for use
in deep tissue wound healing applications. Cell behaviour was observed by
fluorescent microscopy and cell proliferation was measured by assay.
3.2 Experimental Procedure
3.2.1 Reagents and Buffers
Chloroform 99% pure (Merck, Melbourne, Australia), ultrapure water (Baxter
Healthcare, Sydney, Australia), Hank’s Buffered Saline Solution (HBSS, Hy-
Clone, Thermo Fischer Scientific, Waltham, USA), tissue culture phosphate
buffered saline (TC PBS, Hyclone, Thermo Fischer Scientific), 0.05% Trypsin-
EDTA (0.05% (w/v) trypsin in 5 mM ethylenediamine tetraacetic acid (EDTA),
Gibco, Thermo Fischer Scientific), CellTiter AQueous One (Promega, Sydney,
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Australia), alamarBlue (Invitrogen) and CellTiter Glo 3D Cell Viability Assay
(Promega), rhodamine phalloidin (200 units/mL, Molecular Probes, Invitrogen,
Thermo Fischer Scientific) were all used as supplied.
Carboxylic acid diacetate succinimidyl ester (CFSE, CellTrace Oregon Green®
488, Molecular Probes) was dissolved in dimethylsulfoxide (DMSO, Sigma
Aldrich) to give 2 mM solution and stored at -20◦C.
Phosphate buffered saline (PBS) was made as a 10x concentrate and con-
sisted of 150 mM NaCl (VWR, Prolab, Brisbane, Australia), 8.4 mM Na2HPO4
(Chem Supply, Adelaide, Australia) and 1.6 mM NaH2PO4.H2O (AnalaR BDH,
VWR) dissolved in MilliQ water, pH was adjusted to 7.4 using 1M HCl (Sigma
Aldrich) and filtered with 0.2 mm filter and stored at room temperature. PBS
was made by diluting 100 mL of concentrate in 900 mL MilliQ water.
HEPES buffered saline (HBS) consisted of 150 mM NaCl (VWR, Prolab), 10
mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) (HEPES, Life Tech-
nologies, Thermo Fischer Scientific), 1 mM MgCl2 and 1 mM CaCl2, stored at
4◦C.
4’, 6-diamino-2-phenylindole (DAPI, Sigma Aldrich) was diluted in HBSS to
give 2 mg / mL solution.
Tris buffer consisted of 5 mM tris(hydroxymethyl) aminomethane (VWR Prolab)
dissolved in ultrapure water, pH adjusted to 7.6 using 1M HCl, sterile filtered
with 0.2 mm filter, stored at room temperature.
0.05 M carbonate/bicarbonate buffer consisted of 0.016 M Na2CO3 (Sigma
Aldrich) and 0.034 M NaHCO3, (Selby Biolab, Thermo Fischer Scientific) dis-
solved in MilliQ water, the pH was adjusted to 9.6, filtered with 0.2 mm filter and
stored at 4◦C.
Tween 20 was prepared as a 0.05% (v/v) solution of polyoxyethylene sorbitan
monolaurate (Tween 20, Sigma Aldrich) dissolved in 1xPBS.
Bovine serum albumin in PBS (BSA, fraction V, culture grade, HyClone, Thermo
Fischer Scientific), was prepared as a 1% (v/v) solution in TC PBS .
Paraformaldehyde (Sigma Aldrich) was prepared as a 4% (w/v) solution dis-
solved in TC PBS, the pH was adjusted to 7.4, the solution was filtered with
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0.45 mm and 0.2 mm filters and stored at 4◦C in the dark.
Triton X-100 (TX-100, Amresco, Cleveland, USA) was prepared as a 0.1% (v/v)
solution dissolved in TC PBS and stored at 4◦C.
3.2.2 Cell Culture
3T3 murine fibroblasts (European Collection of Cell Cultures, Porton Down,
UK) were cultured in proliferation media: RPMI (Gibco, Thermo Fischer Sci-
entific) supplemented with 10% (v/v) fetal bovine serum (FBS, CSL Limited,
Melbourne, Australia), 2 mM of L-glutamine, 10 mM HEPES and 1 mM sodium
pyruvate were purchased from Gibco BRL. C2C12 murine myoblasts (Ameri-
can Type Culture Collection, Manassas, VA, USA) were cultured in proliferation
media: Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL) with 10%
(v/v) FBS and 2 mM L-glutamine, 10 mM HEPES and 1 mM sodium pyruvate.
For differentiation the C2C12s were cultured in differentiation media that con-
sisted of DMEM with 2% (v/v) horse serum (Gibco BRL) and 2 mM L-glutamine,
10 mM HEPES and 1 mM sodium pyruvate.
Cells were cultured under sterile conditions at 5% CO2 and 37◦C to approxi-
mately 70% confluency in 25 cm2 tissue culture flasks (Nunc, ThermoFisher
Scientific). Cells were harvested by rinsing with PBS and EDTA and incubat-
ing with 0.05% (w/v) trypsin in 0.5 mM EDTA (Gibco), for 3 min at 37◦C. The
3T3 cells were subcultured at 20x104 cells / flask and C2C12 cells at 5x104
cells / flask. Cell numbers were determined using a Coulter Multisizer (Coulter
Electronic, Sydney, Australia). Cells cultured on hydrogel scaffolds for experi-
ments that involved cell imaging used phenol red free RPMI (Sigma) or DMEM
(HyClone).
3.2.3 Cell Culture on Hydrogels
The hydrogel scaffolds were sterilised before being used in ELISA or cell cul-
ture. The discs were sterilised using chloroform182. Forty hydrogel discs were
placed inside dialysis tubing (SnakSkin, 3.5 K MWCO, Thermo Scientific) with
64
20 mL PBS. Up to 4 dialysis tubes filled with hydrogel discs were placed in 2 L
of 0.5% (v/v) chloroform in PBS and left stirring at 4◦C for 16 h. Dialysis tubes
were removed from the chloroform solution and placed into 2 L PBS with stir-
ring at 4◦C for an hour, this was repeated twice. The discs were removed from
the dialysis tubing under sterile conditions and stored in sterilised containers
in TC PBS at room temperature.
Hydrogel discs (9 mm in diameter) were pre-incubated in 0.5 mL phenol red
free proliferation medium in 24 well plates for 2 h at 37◦C before cell seeding.
The media was removed and the 3T3 and C2C12 cells were seeded onto the
discs at 1.0-1.2x104 cells/disc and 1.4-2.2x104 cells/disc respectively in 25 mL
of the appropriate cell culture medium. The cells were incubated at 37◦C for
30 min, then 1 mL phenol red free proliferation medium was added, the culture
media was changed every 48 h.
3.2.4 Cell Staining
Cells were stained with CFSE as follows: the hydrogels were rinsed 3 times
with 1 mL warm HBSS then 50 mL of 20 mM CFSE in HBSS was added and
incubated for 10 min at 37◦C followed by 3 rinses with 1 mL warm HBSS.
The cells on the hydrogels were covered with a glass cover-slip and visualised
using fluorescent microscopy (Zeiss Axioskop) with lexcitation = 494 nm and
lemission = 522nm and imaged using Spot Advanced software (SPOT™ Imag-
ing solutions).
For rhodamine phalloidin staining, the cells were fixed on the hydrogels by
incubation in 0.5 mL of warm 4% (w/v) paraformaldehyde at room temperature
for 30 min in the dark. The hydrogels were rinsed twice with 1 mL PBS and the
cells were permeabilised with 0.5 mL cold 0.1% (v/v) TX-100 and incubated at
4◦C for 4 min. The discs were rinsed twice with 1 mL PBS and then incubated
in 5% (v/v) rhodamine phalloidin in HBS for 2 h in the dark at room temperature.
The discs were rinsed 3 times with 1 mL HBS and counter-stained with DAPI by
incubation in 0.5 mL of 2 mg/mL DAPI at 37◦C for 5 min followed by 3 rinses with
1 mL warm HBS. The cells on the hydrogels were covered with a glass cover-
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slip and visualised using fluorescent microscopy (Zeiss Axioskop, Gottingen,
Germany) with lexcitation = 554 nm and lemission = 573 nm for rhodamine
phalloidin, lexcitation = 340 nm and lemission = 488 nm for DAPI and imaged
using Spot Advanced software (SPOT™ Imaging solutions, Sterling Heights,
Michigan, USA).
3.2.5 Immunofluorescence of Cell Expressed Fibronectin
Hydrogels were seeded with 3T3 or C2C12 cells and the cells were cultured
for 2-3 days. The hydrogels were rinsed 3x1 mL HBS at 37◦C for 2 min then
incubated in 1 mL 4% paraformaldehyde at room temperature for 10 min. The
hydrogels were rinsed 3x1 mL HBS with 300 rpm shaking for 5 min, then incu-
bated in block solution (10% FCS and 1% BSA in HBS) at 4◦C for 16 h before
incubation with 100 mL of 50 mg/mL rabbit polyclonal fibronectin antibody (Ab-
cam, ab2413) in block solution or 100 mL buffer solution at room temperature
for 3 h. The hydrogels were rinsed 3x with 1 mL HBS with shaking at 300 rpm
for 2 min, then incubated with 100 mL of 10 mg/mL secondary antibody (Alexa
Fluor® 488 F(ab’)2 goat anti-rabbit IgG, Molecular Probes, Invitrogen) in block
solution at room temperature for 2 h. The hydrogels were rinsed 3x with 1
mL HBS with 300 rpm shaking for 2 min followed by incubation in 0.5 mL of
2 mg/mL DAPI in HBS at room temperature for 10 min. The hydrogels were
rinsed 3 times with HBS and imaged with a glass coverslip on a Nikon A1+
confocal microscope (Nikon, Tokyo, Japan) using NIS-Elements AR analysis
version 4.1 software.
3.2.6 Enzyme Linked ImmunoSorbant Assay (ELISA)
An ELISA to detect basic fibroblast growth factor (bFGF, Peprotech, Rocky
Hills, USA) was as follows: 96 well plates (Maxisorp Immuno Plate, NUNC)
were coated with 50 mL of 2 mg/mL anti-bFGF mouse monoclonal antibody
(mAb, R&D systems, Minneapolis, USA, IgG2B clone: 10060) in 0.05 M car-
bonate/bicarbonate buffer (pH 9.6). The plate was incubated at 4◦C for 16 h
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and then rinsed 3 times with 200 mL 0.05% (v/v) Tween 20 in PBS.
Figure 3.1: Procedure for testing the bioactivity of the immobilised HS on the
hydrogels. (a) Hydrogel discs (blue) with immobilised HS (purple circles) were
incubated in bFGF (light green), the green triangles are bFGF molecules. The
arrows indicate the binding of bFGF to HS. (b) Hydrogels were rinsed with PBS
(light blue) to remove any non-specifically incorporated bFGF. (c) Bound bFGF
is eluted off the hydrogels in a solution of sodium chloride (orange) and (d) this
eluent was used in the ELISA.
The hydrogel scaffolds were incubated in 100 mL bFGF (25 mg/mL, Peprotech)
diluted in 5 mM Tris buffer (pH 7.6) at room temperature for 2 h with shaking
at 500 rpm. The discs were rinsed 3 times for 10 min in 0.5 mL of 5 mM Tris
buffer with shaking at 500 rpm. The bFGF bound to the HS in the discs was
eluted in 1 mL of 1.5 M NaCl in PBS for 30 min with shaking at 500 rpm at room
temperature. The eluted bFGF was diluted 1/10 in PBS and then added to the
immobilised anti-bFGF mAb in the wells of the ELISA plate and incubated for
2 h at room temperature (see Figure 3.1).
A calibration curve was created using 100 ng/mL bFGF in 1.5 M NaCl in PBS
and serially diluting across the plate, the solutions were then transferred to
the ELISA plate and incubated for 2 h at room temperature. 100 mL of 1
mg/mL biotinylated anti-bFGF mouse mAb (R&D systems, IgG2A clone: 10043)
in 1% (v/v) BSA was incubated at room temperature for 1 h. The plate was
rinsed 3 times with 200 mL 0.05% Tween 20 and then 100 mL of 1/1000 dilu-
tion streptavidin-biotinylated horseradish peroxidase complex (GE Healthcare,
Hatfield, UK) in 1% BSA in PBS was incubated at room temperature for 30 min.
The plate was rinsed 3 times with 200 mL 0.05% Tween 20 and once with 200
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mL PBS before addition of 100 mL of 3,3’,5,5’-tetramethylbenzidine (TMB, Mi-
crowell Peroxidase Substrate System, KPL, Maryland, USA) and incubation at
room temperature for 10 min. 100 mL of 1 M orthophosphoric acid (APS Chem-
icals) was added and the absorbance was measured at 450 nm using a Perkin
Elmer (Waltham, Massachusetts, USA) multimode plate reader, EnSpire 2300.
3.2.7 Cell Quantification with ImageJ
ImageJ (version 1.46r, National Institutes of Health, Bethesda, MD, USA) was
used to process images of CFSE stained cells on the hydrogel discs. A min-
imum of 9 images taken at 120x magnification were used, the objective field
area was randomly selected across the disc to obtain a representative sample.
The images were converted to binary images and processed to subtract back-
ground and reduce noise. Objects above 113 mm2 were counted, this area was
calculated from the minimum cell diameter used for cell number determination,
12 mm for C2C12 cells (therefore p x 6 mm2).
3.2.8 Cell Quantification with AQueous One
The assay used the CellTiter AQueous One Solution from the Cell Proliferation
Assay kit (Promega). The cells were cultured on the hydrogels for 5 days,
harvested with trypsin diluted 1/10 in EDTA and plated at 0.2x104 cells/well in
a 96 well plate for 3 days. On day 0, 1, 2 and 3 after subculture, 20 mL AQueous
One was added and incubated at 37◦C for 2 h, absorbance was measured at
490 nm using an Enspire 2300 plate reader.
3.2.9 Cell Quantification with alamarBlue
For cell adhesion the cells were seeded onto 4 mm diameter hydrogel discs at
a concentration of 3.6x104 cells/disc and incubated at 37◦C for 30 min. Pro-
liferation media (200 mL) was added to the wells and the plate incubated at
37◦C for an hour, 10 mL alamarBlue was added and incubated at 37◦C for 4
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h. Fluorescence was measured using an excitation wavelength of 560 nm and
an emission wavelength of 590 nm using an Enspire 2300 plate reader. The
cell number was determined by comparison with a calibration curve of cells
grown on tissue culture plastic. Cell concentrations were within the range that
showed a linear relationship between cell number and the fluorescent signal.
For cell proliferation the cells were seeded onto 4 mm diameter hydrogel discs
at a concentration of 0.4x104 cells/disc and incubated at 37◦C for 30 min. Pro-
liferation media (200 mL) was added to the wells and the plate incubated at
37◦C for an hour, 10 mL alamarBlue was added and incubated at 37◦C for 4
h. Fluorescence was measured as described in 3.2.9. This procedure was
repeated on day 1, 2 and 3 with the medium changed every day before and
after the addition of alamarBlue. The cell number was quantified by referring
to a calibration curve of cells grown on tissue culture plastic at concentrations
within the linear range of the assay (i.e. there was a linear relationship between
cell number and fluorescent signal).
3.2.10 Cell Proliferation with CellTiter-Glo
The assay used the CellTiter-Glo Luminescent Cell Viability Assay (Promega).
3T3 and C2C12 cells were seeded onto 8 hydrogel discs, 5 mm diameter, at
a concentration of 2x105 and 2.6x105 cells/mL respectively and incubated at
37◦C for 45 min. Proliferation media was added and the discs were further
incubated at 37◦C for 2 h. For the day 0 timepoint, 4 of the discs were used,
these were transferred to a white plate and 50 mL CellTiter-Glo reagent was
added. The plate was agitated at 500 rpm for 5 min and left at room tem-
perature for another 25 min before luminescence was measured with a Perkin
Elmer EnSpire 2300 multimode plate reader. The other 4 discs were incubated
for 2 days and the assay procedure was repeated, this procedure was repeated
with different time points.
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3.3 Results and Discussion
3.3.1 Method Development
Figure 3.2: Adhesion of 3T3 cells on the hydrogels. On day 3 the cells were
treated with trypsin as per standard cell harvesting protocol and the hydrogels
stained with CFSE, scale bars show 100 mm.
To assess if the immobilisation of HS improved the bioactivity of the hydro-
gels, experiments were designed to examine if there were differences in cell
behaviour. The cell behaviours examined were cell adhesion, cell proliferation
and cell differentiation. Quantification of cell numbers on the hydrogels was
difficult because of the nature of the hydrogels; as they were 3D, opaque and
white. This meant that direct observation and imaging of the cells on the hy-
drogels was not possible. The following subsections provide the details of the
trialled but unsuccessful methods for cell number quantification. These 3 tech-
niques have been used with hydrogels and other scaffold materials but were
ultimately unsuccessful due to the various difficulties created by the nature
of the 3D porous hydrogel created in this work. The details of the success-
ful method that was proven reliable and reproducible can be found in section
3.3.3.1.
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A commonly used alternative approach for cell quantification involves harvest-
ing the cells; this was attempted but it was not possible to remove all of the cells
from the P(HEMA:GMA)-HS hydrogels using trypsin as the harvesting reagent
(Figure 3.2). Another approach is to degrade or dissolve the scaffold to re-
lease the cells, but this was also not possible as PHEMA is not degradable.
This suggested cell quantification would require a colorimetric or fluorescent
stain followed by microscopic imaging. Images could then be analysed with
software, such as ImageJ, to quantify the cell number present on each hy-
drogel. Cell proliferation determination can also be done with image analysis,
however accurate quantification may be difficult at later time points due to cells
migrating into the hydrogel, aggregating or fusing together as was the case
with the C2C12 cells.
3.3.1.1 ImageJ
Figure 3.3: Scheme showing the image processing steps for cell counting us-
ing ImageJ.
The processing of images, of the CFSE stained cells grown on the hydrogels,
using ImageJ was straight-forward. Analysis of 3 cell culture experiments with
C2C12 cells was performed, the results showed the total cell number from
3 randomly selected fields on the hydrogels. The highest cell number was
found on P(HEMA:GMA)-HS, which indicated that more cells had adhered
to P(HEMA:GMA)-HS (Figure 3.4). Lower cell numbers were observed on
P(HEMA:GMA) and the lowest cell numbers were on PHEMA. These results
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demonstrated that the modifications on PHEMA improved the bioactivity of the
hydrogel resulting in higher adhesion of C2C12 cells.
Figure 3.4: Total number of C2C12 cells on the hydrogels on day 1, n = 3.
1.7x104 cells were seeded/disc for experiment 17 and 1.9x104 for experiments
18 and 20.
However, due to situations where the cells were not evenly distributed across
the hydrogel and where the cells aggregated or made contact with one another,
it was difficult to determine how many cells were contained in the group. This
affected the accuracy of the cell count and although it was observed to be an
issue on day 1, giving rise to assay to assay variability, this variability was even
more apparent from day 3 onwards. As the hydrogels were 3D, it was probable
that the cells were at different levels in the hydrogels, with some being directly
beneath or on-top of others. In this situation the signal from two cells was
assessed as being from one very bright cell by the software. Due to these
limitations, this method was not used further.
3.3.1.2 AQueous One Assay
The more recently developed AQueous One assay uses a tetrazolium salt that
is reduced by cells to form a soluble formazan product. However, in my ex-
periments not all of the formazan product remained in solution and variable
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Figure 3.5: Bioreduction of AQueous One. The tetrazolium compound in
AQueous One is bioreduced by cells to form the formazan product which can
be detected in solution by absorbance measurements.
amounts of this product were deposited on the hydrogel and could not be sol-
ubilised for measuring in the plate reader, therefore direct quantification of cell
number on the hydrogels was not possible. This assay was used to determine
whether cell viability and cell proliferation were affected by cell exposure to the
hydrogels. Accordingly cells grown on the hydrogels were harvested and re-
plated onto tissue culture plastic and cell numbers were determined using the
AQueous One assay at various times after plating. As seen in Figure 3.6 the
proliferation of 3T3 cells that were harvested from the hydrogels very closely
resembled the proliferation of the control cells (cells grown on tissue culture
plastic for the entire time). Therefore, the 3T3 cells were not adversely affected
after being cultured on any of the hydrogels.
The proliferation rate of C2C12 cells was also not affected by these cells having
been cultured on the hydrogels for 5 days. Cell numbers increased after the
cells were harvested from the hydrogels and plated on tissue culture plastic
(Figure 3.7). Cell proliferation was similar for the cells harvested from each
hydrogel and followed that of the control cells that were cultured on tissue
culture plastic for the entire experiment. It is therefore reasonable to conclude
that the hydrogels did not adversely affect the metabolic activity of either cell
type and normal cell proliferation was maintained.
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Figure 3.6: Cell proliferation of 3T3 cells after culture on the hydrogels. The
cells were grown on the hydrogels for 3 days, harvested with trypsin and re-
seeded onto tissue culture plastic for 2 days. The re-seeded cells were as-
sayed everyday, control = cells on tissue culture plastic for entire experiment,
n = 4, error bars show standard deviation, *non-parametric comparison of me-
dians across timepoints.
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Figure 3.7: Cell proliferation of C2C12 cells after culture on the hydrogels. The
cells were grown on the hydrogels for 5 days, harvested with trypsin and re-
seeded onto tissue culture plastic for 2 days. The cells were assayed everyday,
control = cells grown on tissue culture plastic for the entire experiment, n = 4,
error bars show standard deviation. No standard deviation was calculated for
PG8 and PGN8 on day 2 as only 2 results were obtained. *non-parametric
comparison of medians across timepoints.
3.3.1.3 alamarBlue
The alamarBlue assay was tested to determine if direct quantification of the
cell numbers on the hydrogels was possible. The active component in alamar-
Blue is resazurin which is a weakly fluorescent compound that is reduced by
cells to the highly fluorescent resorufin (Figure 3.8). Unfortunately, as seen
in Figure 3.10 the P(HEMA:GMA)-HS discs which had been incubated for 2
h with increasing numbers of C2C12 cells had higher fluorescent signal than
the same number of cells seeded on tissue culture plastic. This indicated that
there was a large background signal from the hydrogels and that a cell num-
ber of 5,000, or below, would not be detected. Nevertheless, an assay was
conducted to assess whether it was possible to use alamarBlue to examine
C2C12 proliferation. The number of cells on all hydrogels increased from day
0 to day 1 and 2 as measured by this assay (Figure 3.9). These results cor-
related well with the AQueous One results (Figure 3.7) except for PHEMA (P2
discs), where the cell number was markedly higher on day 2 than that deter-
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mined previously with AQueous One. The results on day 3 were similar to day
2, but increased cell numbers were obtained when the discs were assessed
on day 6. The plateau in cell proliferation observed from day 2 to 3 was unex-
pected, (a typical growth curve for C2C12 cells can be found here183), however
the overall trend involved increased cell numbers over time.
Figure 3.8: Reduction of resazurin to resorufin. Resazurin is the active com-
ponent in alamarBlue which is reduced to fluorescent resorufin.
Figure 3.9: Proliferation of C2C12 cells on the hydrogels as determined by ala-
marBlue assay. Cells were seeded at a density of 400 cells/disc in proliferation
medium, n = 4, error bars show standard deviation, *non-parametric compar-
ison of medians across timepoints compared to day 0, #compared to day 1,
except PGH10 which is compared to day 3.
An adhesion assay was performed on the hydrogels with alamarBlue. The cells
appeared to have adhered better on PHEMA and P(HEMA:GMA)-HS than the
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other hydrogels, the percentage of cells that adhered to the surfaces compared
to the total number that was seeded was calculated (Table 3.1). The results
showed that almost all of the cells seeded onto P(HEMA:GMA)-HS, 98%, ad-
hered successfully to the surface. A large percentage of cells, 82%, adhered
to PHEMA, while the other surfaces had about 60% adherence.
Table 3.1: Adhesion of C2C12 cells on the hydrogels as determined by ala-
marBlue.
Surface Cells adhered (%)¹
Control 64 ± 3
P2 82 ± 22
PG10 60 ± 22
PGN10 59 ± 23
PGH10 98 ± 44
¹assay was performed 2 h after C2C12 cells were seeded onto the hydrogels in
proliferation medium, control cells were on tissue culture plastic, n = 3, number of
cells seeded was 36,500.
There were very large variations in the alamarBlue data, the standard deviation
was much higher than that observed with the AQueous One assay (Figure 3.6
& Figure 3.9). The highest variability was seen with the cell number on PHEMA
(Figure 3.9). The variability was likely due to the high background measured
with alamarBlue and the hydrogels (with no cells present). This was also ob-
served to be highly variable as 5 randomly selected discs had very different
signals (Figure 3.10), 29-65% deviation. This was likely to have caused the
apparent plateau in the proliferation assay from day 2 to 3 (Figure 3.9). It could
also have affected the variability more at later time points as the background
signal was observed to increase over the length of the experiment. This should
not have occurred since alamarBlue has been reported to be stable in media
(without cells present) for up to 3 days with 2-3% deviation in the fluorescent
signal184. These results indicated that either the alamarBlue was not as stable
as reported, or that there were interactions between the alamarBlue and the
hydrogels that resulted in the reduction of alamarBlue without the presence of
cells.
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Figure 3.10: Assessment of the background fluorescent signal of alamarBlue
with the hydrogels, a) C2C12 cells were assayed 2 h after seeding on PGH8
discs in proliferation medium and incubated for 4 h in alamarBlue, control =
cells on tissue culture plastic, n = 1, b) hydrogels in the absence of cells, n =
5, error bars show the standard deviation.
Results from alamarBlue are known to be affected by the presence of proteins
in the culture media during the incubation time of the assay. Studies have
demonstrated that fetal bovine serum (FBS) and bovine serum albumin (BSA)
can interfere with the reduction kinetics of the alamarBlue. The reduction in the
rate of reduction of the alamarBlue has been shown to decrease the fluores-
cent signal by up to 35%185. Due to the potential interference and inhibition of
the redox reaction of alamarBlue, it has been demonstrated to over-estimate
cell numbers by 21-64%186. For these reasons some literature advises care in
the conduct and verification of assay results while others recommend that the
assay not be used for cell quantification186,187. Others have noted changes
in cell morphology which suggested alamarBlue interference with normal cell
function and possible cytotoxic effects188. Taking these facts into account it
was likely that the high variability in the assays was due to an interaction be-
tween the hydrogels and cells, and alamarBlue. As a consequence of the
variability no further experiments with alamarBlue were performed.
3.3.2 Cell Attachment
The cell adhesion to the hydrogels is shown in Figure 3.11 and Figure 3.12.
The adhesion of both the 3T3 and C2C12 cells was very sparse on PHEMA.
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Poor adhesion was indicated by the spherical, not spread cell morphology. In
addition, the majority of cells were observed to clump together to form large
cell clusters, suggesting the cells preferred to attach to one another rather
than attaching to the PHEMA. This result was expected as PHEMA is well
established as a biologically inert material189 which is not attractive for cell
adhesion96.
Poor cell adhesion to PHEMA has been observed by others. The adhesion of
human lung fibroblasts (IMR-90) to PHEMA gels showed spherical cell mor-
phology with a significantly smaller projected cell area than the control, up to
5 times smaller. The poor cell adhesion diminished the total protein expres-
sion by the cells, specifically the expression of collagen and correlated with
the inhibition of RNA expression and DNA synthesis190. The DNA synthesis
was used as an indication of cell proliferation which was minimal on PHEMA.
Poor or inhibited 3T3 cell adhesion was highlighted in work by Lewandowska66,
where the addition of a soluble RGD peptide to the culture medium resulted in
spherical cell morphology and the 3T3 cells attaching to one another. Poor cell
adhesion of 3T3 and MC3T3E1 (preosteoblasts) cells has also been shown on
printed PHEMA scaffolds, the addition of poly-L-lysine was required for suc-
cessful cell spreading and proliferation of both cell types191.Cell morphology is
closely linked to cell adhesion as the strength and success of cell adhesion is
often determined by the morphology. In general a more spread morphology is
indicative of better cell adhesion, the relationship between spread morphology
and greater strength of 3T3 cell adhesion has been verified192. The morphol-
ogy of 3T3 cells that are well adhered to a surface changes from dendritic to
stellate or bipolar indicating that the cell-matrix interactions have matured193.
The adhesion of the 3T3 cells to P(HEMA:GMA) and P(HEMA:GMA)-NH2 was
similar, with more cells seen on P(HEMA:GMA) (Figure 3.11). The cells re-
mained spherical but did not form clusters, suggesting they had adhered to
the hydrogel. The GMA content of the hydrogels was in the range of 142-157
mmol/g hydrogel. Work by Bayramoglu et al., incorporated 50 wt% GMA, re-
sulting in 3.82 mmol GMA/g polymer138, mesenchymal stem cells grown on
the
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Figure 3.11: 3T3 cell adhesion to the hydrogels. The cells were stained with
CFSE, 2 h after seeding on the hydrogels and imaged with fluorescent mi-
croscopy (Zeiss Axioskop), scale bars show 100 mm. Inserts show cell mor-
phology, scale bars show 50 mm.
copolymer showed similar cell viability as the control cells (on tissue culture
plastic). The incorporation of GMA and other hydrophobic polymers in PHEMA
has shown improvements in cell adhesion and proliferation, as the addition of
polycaprolactone improved cell adhesion and proliferation of fibroblasts190.
The best substrate for 3T3 cell adhesion were the P(HEMA:GMA)-HS hydro-
gels. On this substrate many cells had spread morphology indicating that they
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had attached firmly to the surface. Improved cell adhesion was also implied by
the cell protrusions. The increased cell size and formation of small protrusions
from the cells indicated a rearrangement of the cell cytoskeleton as the cells
formed attachments to the surface194. These results indicated that the mod-
ifications to the PHEMA enhanced 3T3 cell adhesion; copolymerisation and
incorporation of amine assisted the cells to adhere whereas immobilisation of
HS produced the best cell adhesion.
More C2C12 cells adhered to the P(HEMA:GMA) and P(HEMA:GMA)-NH2
hydrogels compared to PHEMA (Figure 3.12). On these hydrogels the cells
adhered to the surface as single cells rather than the cell clusters seen on
PHEMA. On P(HEMA:GMA)-NH2 some cells were larger than those on PHEMA
and had small protrusions indicating a more spread morphology. Therefore by
visual comparison, the increase in cell spreading suggested the cells adhered
better to P(HEMA:GMA) and P(HEMA:GMA)-NH2. These results were sup-
ported by the literature as others have also found the introduction of amine
groups, on PHEMA and other surfaces, assisted with cell adhesion and cell
spreading195,196. It has been reported that the presence of amine groups
increased the density of positive charge, which increased protein adsorption
and adsorbed proteins, such as fibronectin, were orientated in a way that sup-
ported cell adhesion197,198. This improved cell spreading and resulted in cells
that were more strongly attached due to the formation of more mature focal
adhesion complexes and better organised actin stress fibres196.
P(HEMA:GMA)-HS hydrogels were the most favoured for C2C12 cell adhesion.
C2C12 cells on this hydrogel had a spread morphology indicative of stronger
adhesion than on the other hydrogels and the cells had multiple protrusions.
These protrusions were visible after 2 hours (Figure 3.12), and became more
obvious following rhodamine phalloidin staining, which stains polymerised actin
(Figure 3.13). Single protrusions were seen on the C2C12 cells on P(HEMA:GMA)-
NH2, while those on P(HEMA:GMA)-HS had multiple (white arrows). The fil-
amentous actin, stained by rhodamine phalloidin, is linked via a multi-protein
complex to integrin cell adhesion molecules194. Rhodamine phalloidin is there-
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Figure 3.12: C2C12 cell adhesion to the hydrogels. The cells were stained
with CFSE 2 h after seeding on the hydrogels and imaged with fluorescent
microscopy (Zeiss Axioskop), scale bars show 50 mm.
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Figure 3.13: C2C12 cell adhesion to the hydrogels 2. The cells were stained
with rhodamine phalloidin 2 h after seeding on the hydrogels and imaged with
fluorescent microscopy (Zeiss Axioskop). Arrows indicate cell protrusions,
scale bars show 50 mm.
fore often used to investigate cell spreading and the formation of cell adhe-
sions71,72.
Similarly to the 3T3 cells, the C2C12 cells adhered better following modifica-
tion to the PHEMA hydrogel. The copolymer had some improvement in cell
adhesion, the introduction of amine further improved adhesion and the best
cell adhesion was observed on P(HEMA:GMA)-HS, where multiple cell pro-
trusions were seen. These results revealed incremental increases with each
modification in the ability of the hydrogels to support cell adhesion, but the final
modification with the immobilisation of HS markedly improved the adhesion of
both cell types to the hydrogel. The presence of soluble HS has been shown
to increase the number of adhered cells and vinculin staining of astrocytes,
these results indicated that the HS enhanced cell adhesion and increased the
number of focal adhesions formed199. Therefore the presence of immobilised
HS has been demonstrated in this work to act similarly to soluble HS by ac-
tivating the integrin-based focal adhesions, increasing cell adhesion and cell
spreading.
Considerable research has been done on the importance of HS proteoglycans
and their roles in cell behaviour, cell adhesion, proliferation and differentiation.
However HS has rarely been immobilised onto tissue engineering scaffolds,
with most research focussed on the similar bioactivity of heparin. Some work
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has used HS to load scaffolds with growth factors but few have tested the
effects of immobilised HS alone. Of the few that have, they have been focussed
on in vivo results. Therefore there is limited literature that investigates the
potential benefits of immobilised HS with regards to increased cell adhesion.
In the current work the immobilised HS was shown to drastically improve cell
adhesion of both cell types.
3.3.3 Cell Proliferation
The proliferation of 3T3 and C2C12 cells was low to non-existent on the
PHEMA hydrogels (Figure 3.15 and Figure 3.14). Little increase in 3T3 cell
number was observed and compared to the other hydrogels, the lowest cell
number was seen on day 4. The large cell clusters were clearly visible from day
2 on PHEMA, but absent on other hydrogels. Similar cell clusters were formed
by C2C12 cells on PHEMA (Figure 3.15), with little cell proliferation observed
over 6 days. This was probably because adherent cells require stable adhesion
to a surface to be able to proliferate and grow200.
By visual observation the proliferation of both cell types on P(HEMA:GMA)
was similar to that on PHEMA. Some small 3T3 cell clusters were observed on
P(HEMA:GMA) however the number and the size of these clusters was less
than those observed on PHEMA. C2C12 cells were observed to migrate to-
wards one another and form cell clusters on days 4 and 6. These clusters
were also smaller than those observed on PHEMA, but may have attributed to
the low proliferation observed as by day 6, the cell number on P(HEMA:GMA)
had not increased. The cell morphology on P(HEMA:GMA) was more typical
of C2C12 cells grown on tissue culture plastic, being elongated and fusiform
shaped. These results indicated that both cell types had better morphology on
P(HEMA:GMA) than on PHEMA but no observable difference in cell prolifera-
tion.
Few 3T3 cells were observed on P(HEMA:GMA)-NH2 on days 1 and 2, how-
ever more cells were present on days 3 and 4 (Figure 3.14). This indicated
that the cell proliferation was delayed but resulted in higher cell number on day
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Figure 3.14: 3T3 cell proliferation over 4 days on the hydrogels. The cells were
stained with CFSE and imaged with fluorescent microscopy (Zeiss Axioskop),
scale bars are 100 mm.
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Figure 3.15: C2C12 cell proliferation over 6 days on the hydrogels. The cells
were stained with CFSE and imaged with fluorescent microscopy (Zeiss Ax-
ioskop), scale bars are 100 mm.
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4 than on PHEMA or P(HEMA:GMA). This was in contrast to the C2C12 cells
on P(HEMA:GMA)-NH2 which were more highly populated than PHEMA and
P(HEMA:GMA) on days 2-6 (Figure 3.15). After several days, it was clear the
C2C12 cells had proliferated more on P(HEMA:GMA)-NH2 than on PHEMA or
P(HEMA:GMA). As they proliferated they formed larger colonies of cells, how-
ever they maintained their elongated and fusiform morphology. These colonies
were probably formed by proliferation and re-population of the hydrogel sur-
face, than by the migration of cells towards one another, as overall there ap-
peared to be more cells on these surfaces at the later time points. Others have
observed that the introduction of free amines to PHEMA was compatible with
increased fibroblast proliferation195. Similarly, nerve cells on chitin and chi-
tosan scaffolds had improved growth following the introduction and increase of
amines201,202. Here the introduction of free amines has affected and improved
the proliferation of myoblasts more markedly than the fibroblasts.
The highest cell proliferation of both cell types was observed on P(HEMA:GMA)-
HS. The proliferation of 3T3 cells was observed visually after 2 days (Fig-
ure 3.14) and continued to day 4 so that on P(HEMA:GMA)-HS there were
more cells than on any of the other hydrogels. Similarly, by day 6, C2C12 cells
on P(HEMA:GMA)-HS were observed to have increased markedly in number
(Figure 3.15). In some areas the cells were approaching confluency and in
these areas they organised and became aligned. Interestingly HS modified
scaffolds are rarely investigated for their direct effect on cell proliferation, more
commonly they are treated as a delivery device for growth factors. Soluble
HS has been shown to increase cell proliferation of human mesenchymal stem
cells (hMSC) in a dose dependent manner with enhanced results compared
to soluble heparin29. In contrast soluble HS has been shown to enhance the
cell proliferation of neural progenitor cells only when in the presence of a fi-
broblast growth factor (FGF)81. Since the hMSC were cultured with fetal calf
serum (which contains basic FGF, bFGF) it is possible that the increased cell
proliferation was also due to the combined presence of HS and bFGF. In this
work fetal calf serum was also used therefore it is possible that the enhanced
cell proliferation on P(HEMA:GMA)-HS was due to the presence of bFGF that
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had been bound to the hydrogel by the immobilised HS. This possibility is sup-
ported by literature that reported the presence of HS and bFGF was required
for fibroblast proliferation181. Therefore these results demonstrated that the
immobilised HS retained its ability to promote fibroblast proliferation and ex-
tended its influence to also improve myoblast proliferation.
3.3.3.1 Cell Quantification with CellTiter-Glo
The data from the CellTiter-Glo assays is represented with box plots. The box
plots show the interquartile range (IQR) with a coloured box, the box limits are
the 1st and 3rd quartiles. The median is indicated with a horizontal black line
within the coloured boxes and the whiskers extend to the highest and lowest
data points that are within 1.5 times the IQR from the 1st and 3rd quartiles
(tukey definition of whisker extent).
The results with the 3T3 cells showed that there was a statistically signifi-
cant increase in cell number on the hydrogels from day 0 to day 2, except
on PHEMA. On day 2 the number of 3T3 cells was significantly greater on
P(HEMA:GMA)-HS compared to the number on PHEMA and P(HEMA:GMA)-
NH2 (a inFigure 3.16). These results confirmed the visual observations of the
cells on the hydrogels (discussed in 3.3.3).
The results for the cell number on PHEMA on day 2 were quite varied. This was
most likely due to the formation of large cell clusters as seen in Figure 3.14.
These clusters were loosely attached to the PHEMA surface and could there-
fore be easily rinsed off during medium exchange. This would account for some
of the results being quite low and close to the values from day 0 (as the cell
clusters were rinsed off), while the other values were much higher and likely
due to the presence of the cell clusters in the assay. A repeat of the assay
showed the same general trend in the results, with a significant increase in cell
number on P(HEMA:GMA)-HS (b inFigure 3.16). These results indicated that
the 3T3 cells proliferated better and more quickly on P(HEMA:GMA)-NH2 and
P(HEMA:GMA)-HS compared to PHEMA. This demonstrated that the modifi-
cation of PHEMA was successful in improving the bioactivity and enabling 3T3
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Figure 3.16: Proliferation of 3T3 cells on the hydrogels as determined by
CellTiter-Glo, n = 4. Statistics were analysed using a non parametric compari-
son of median values and for an increasing trend with the Jonckheere-Terpstra
test (p<0.05). a) **PGH10 > P2 and PGN10, # day 2 results > day 0, b) *
PGH23 > P2, # day 2 results > day 0.
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Figure 3.17: Proliferation of C2C12 cells on the hydrogels as determined by
CellTiter-Glo, n = 4. Statistics were analysed using a non parametric compari-
son of median values (p<0.05). a) *P2 > PGN23, # all day 2 results > day 0, b)
# day 2 PGN27 > day 0 PGN27.
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Figure 3.18: Proliferation of C2C12 cells on the hydrogels as determined by
CellTiter-Glo 2, n = 3. Statistics were analysed using a non parametric com-
parison of median values (p<0.05). *day 0 PGH33 > P2, *day 6 PGH33 >
PGN33, **day 3 P2 > PGN33 and PGH33, # all day 3 & 6 results > day 0, ##
day 6 PGH33 > day 3 PGH33.
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cells to proliferate better on the hydrogel.
C2C12 cells were observed to increase in cell number from day 0 to 2 on all
of the hydrogels. The increase in C2C12 cell number on day 2 was statistically
significant for each hydrogel (a in Figure 3.17). The increase in cell number
was not as large as that seen for the 3T3 cells, this was likely due to the
slower proliferation rate of C2C12 cells. There was a large variability observed
for the cell number determined on PHEMA (Figure 3.17). This variability was
likely due to the formation of cell clusters on PHEMA, these were observed
in Figure 3.15. When the assay was repeated similar results were obtained.
The results showed a small increase in cell number on P(HEMA:GMA)-NH2 on
day 2 compared to day 0 (b in Figure 3.17). The variability in the cell number
was higher for all hydrogels than in the previous assay. The small difference
observed in cell number was most likely due to the selection of day 2 as a time
point, C2C12 cells are slow proliferators therefore a later time point would be
more appropriate.
The assay time points were adjusted from day 2 to day 3 and an additional time
point at day 6 was added. The results from the assay showed more significant
differences in cell number between time points (Figure 3.18). The number of
C2C12s on PHEMA increased significantly from day 0 to day 3 and on day 6
appeared to be similar to that on day 3 or slightly decreased. In contrast the
cell number on P(HEMA:GMA)-NH2 and P(HEMA:GMA)-HS increased signifi-
cantly from day 0 to day 3 and 6. The results showed that the later time points
were more appropriate to validate the proliferation of the C2C12 cells and that
the C2C12 cells proliferated better and more quickly on P(HEMA:GMA)-NH2
and P(HEMA:GMA)-HS compared to PHEMA. These results supported the vi-
sual observations of the C2C12s as seen in Figure 3.15. These results further
confirmed that the modification of PHEMA was successful in increasing the
bioactivity of the hydrogel resulting in improved proliferation of C2C12 cells.
The literature shows that minimal cell proliferation is observed on neat PHEMA
scaffolds. Generally molecules are added to PHEMA to improve cell prolif-
eration, such as gelatin203, poly-L-lysine191, fibronectin66 and RGD204. The
variability in cell number measured in the current work could be due to a few
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factors. The first possibility was due to the method of polymerisation, in a glass
mould, which resulted in the formation of a skin layer along the surfaces that
were in contact with the glass. The formation of a skin layer has been observed
by others102,205. The variability in the cell number measured could therefore
have been due to the presence of a thin skin which was easily broken, such
areas could have provided a better surface for cell adhesion resulting in the
patchy distribution of cells on PHEMA from day 1 onwards. Another possibility
was the formation of the cell clusters. The large size of the cell clusters meant
that the large cell counts on PHEMA could have been solely due to the cells
within the clusters. This would have indicated that the cells counted by the
assays were present on PHEMA but in a quiescent form.
These results showed the improved bioactivity of PHEMA after modification,
especially after HS immobilisation. HS is a coreceptor for many growth fac-
tors that are involved in cell proliferation173, therefore its immobilisation on the
hydrogel might be expected to assist cell proliferation. Interestingly, the incor-
poration of heparin (a GAG similar to HS, but more sulfated) onto a collagen
scaffold was shown to similarly improve fibroblast proliferation177. HS has been
shown to increase the proliferation of preosteoblast cells in a concentration de-
pendent manner when introduced as a soluble protein in the medium? . Here
it has been shown that HS not only assists in fibroblast proliferation but has a
similar effect on the proliferation of myoblasts.
The CellTiter-Glo assay had the ability to be used directly on the hydrogels
to determine the number of cells. This was a large advantage over the other
assays that were tested and this assay was found to be the most reliable for
cell proliferation data with these hydrogels. The signal produced was lumines-
cent which resulted in markedly lower background than those measured with
the other assays (see method development section). This improved sensitivity
enabled comparison between cells grown on the different hydrogels. As the
hydrogels were 3D there were some diffusion issues which produced some
variability in the data, however this assay was best able to demonstrate dif-
ferences in cell numbers on the hydrogels. The CellTiter-Glo system created




The beginning stages of C2C12 cell differentiation was observed when the
cells were cultured in proliferation media. After 6 days of culture on P(HEMA:GMA),
P(HEMA:GMA)-NH2 and P(HEMA:GMA)-HS the C2C12 cells appeared to be
in the early stages of differentiation as evidenced by their fusiform morphology
(Figure 3.20). This was not observed on PHEMA. The next step in differentia-
tion involves the re-organisation of the cells to align themselves parallel to one
another. Little to no cell organisation was observed on P(HEMA:GMA) and
P(HEMA:GMA)-NH2, but alignment occurred on P(HEMA:GMA)-HS (white ar-
rows) and some cell fusion was evident. As C2C12 cells approach confluency
their morphology changes to bipolar as the cells change into myocytes. The
myocytes align and fuse to form multinucleated myocytes which mature into
myotubes206, as depicted in Figure 3.19.
Figure 3.19: Schematic diagram of the stages of C2C12 differentiation.
The differences in C2C12 cell morphology and behaviour were more pronounced
following rhodamine phalloidin staining. The cells on PHEMA were spherical
with diffuse staining suggesting relatively unorganised filaments (Figure 3.21).
In contrast, the cells on P(HEMA:GMA)-NH2 had fusiform morphology showing
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Figure 3.20: Beginning stages of C2C12 cell differentiation on hydrogels. The
C2C12 cells were cultured in proliferation media and stained with CFSE on day
6. Imaged with fluorescent microscopy (Zeiss Axioskop), scale bars show 100
mm.
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that the filaments were organised, the cells were elongated and by day 6 were
beginning to become aligned. On P(HEMA:GMA)-HS the cells were fusiform
in low cell density areas and in confluent areas had aligned and begun to fuse
(Figure 3.21). Hence, all the modifications of PHEMA assisted in C2C12 cell
differentiation but the inclusion of HS had the greatest effect on differentiation
when the cells were cultured in proliferation media. These results indicated the
requirement of HS immobilisation on the hydrogels to facilitate cell differenti-
ation of the C2C12 cells. HS is involved in strengthening cell-cell adhesions
and as a coreceptor involved in differentiation173, it is required for the binding of
growth factors to coordinate the change from proliferation to differentiation80. It
has been demonstrated that the inhibition of syndecan-3 (a HSPG) expression
in C2C12 cells impeded cell differentiation178. Additionally the requirement of
both HS and bFGF for the differentiation of myoblasts has been reported181.
Therefore its immobilisation on the hydrogel in an active form resulted in suc-
cessful myotube formation.
Figure 3.21: Beginning stages of C2C12 cell differentiation on hydrogels 2.
The C2C12 cells were cultured in proliferation medium and fixed on day 6 with
4% paraformaldehyde and stained with rhodamine phalloidin (red) and DAPI
(blue), scale bars show 50 mm.
3.3.5 Enzyme Linked ImmunoSorbant Assay
The ELISA results showed that more of the basic fibroblast growth factor was
absorbed and eluted from the HS modified scaffold than PHEMA or the other
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hydrogels. The hydrogels with immobilised HS bound 1.7-100 times more
growth factor compared to PHEMA, P(HEMA:GMA) and P(HEMA:GMA)-NH2.
These results were demonstrated in 3 separate assays as seen in Figure 3.22.
These results showed a consistently lower signal from PHEMA, P(HEMA:GMA)
and P(HEMA:GMA)-NH2, which were not markedly different to one another.
The low values were likely due to physically entrapped growth factor in the 3D
hydrogels. The signals from P(HEMA:GMA)-HS were consistently and notably
higher, this confirmed the bioactivity of the immobilised HS. The 2 hydrogels
used, PGH8 and PGH10, had 3.09 ± 0.05 mmol HS/g hydrogel and 0.6 ± 0.2
mmol HS/g hydrogel respectively. The ELISA results were 417 and 497 ng
bFGF for PGH8 and 83 ng bFGF for PGH10, these results had a fold differ-
ence of 5 - 6 times which correlated with the approximate 5 fold difference in
immobilised HS. Therefore the assay was sufficiently sensitive to measure the
fold differences in HS immobilisation which translated to equivalent fold differ-
ences in bFGF binding.
Figure 3.22: Bioactivity of immobilised HS on hydrogels, the amount of bFGF
bound to the hydrogels by immobilised HS as determined by ELISA, n = 1.
Assays with duplicate discs (Figure 3.23) confirmed the trend despite the high
standard deviation observed. A higher signal was obtained from P(HEMA:GMA)-
HS compared to the other hydrogels, but the measured amount of growth factor
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varied substantially. The results were 3.8 times greater for PGH10 than in the
previous assay. Therefore the assay was repeated with more replicate hydro-
gel discs to reduce the experimental variability.
Figure 3.23: Bioactivity of immobilised HS on the hydrogels 2. The amount of
bFGF bound to the immobilised HS on the hydrogels as determined by ELISA.
The assays had duplicate discs and duplicate technical replicates, n = 4, error
bars show the standard deviation.
ELISAs with 4 replicate hydrogel discs attempted to further reduce the exper-
imental variability. As there were no large differences between the other hy-
drogels, only P(HEMA:GMA)-NH2 was used as the control. The HS modified
discs were shown to elute 100 ng bFGF/disc compared to 30 ng bFGF/disc
from P(HEMA:GMA)-NH2(Figure 3.24). The assay showed a 3 fold increase in
signal from P(HEMA:GMA)-HS compared to P(HEMA:GMA)-NH2. The trend
was consistent with the previous assays and the increase in replicate discs
resulted in a decrease in the standard deviation. The overall results demon-
strated that the immobilised HS retained its bioactivity as P(HEMA:GMA)-HS
was able to specifically bind bFGF. These results provided evidence for the
enhanced bioactivity of P(HEMA:GMA)-HS over PHEMA which was shown to
improve cell adhesion and proliferation of both cell types on P(HEMA:GMA)-
HS. These improvements were likely due to the ability of the immobilised HS to
bind and interact with proteins to provide signals that enhanced cell behaviour
on the hydrogels.
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Figure 3.24: Bioactivity of immobilised HS on the hydrogels 3. The amount
of bFGF bound to immobilised HS on the hydrogels as determined by ELISA.
The assays had 4 discs of each hydrogel and duplicate technical replicates, n
= 8, error bars show the standard deviation.
3.3.6 Immunofluorescence of Cell Expressed Fibronectin
Matrix protein expression, specifically the expression of fibronectin is benefi-
cial for cell adhesion as fibronectin acts as an adhesive protein in binding cells
to a surface158. Additionally the complete adhesion of fibroblasts requires the
binding of extracellular fibronectin to cell surface receptors and HS proteogly-
cans207. The expression of fibronectin was examined to explain any observed
differences in cell adhesion to the hydrogels, as fibronectin expression is one
of the prominent cell responses for successful cell adhesion and cell spread-
ing208. Therefore differences in the amount of fibronectin visualised on the
hydrogels should match the trends observed with cell adhesion and cell prolif-
eration.
The cells were cultured on the hydrogels, fixed and stained to visualise the
fibronectin produced by the cells. As a control the hydrogels were also stained
for fibronectin without any cells present. This was to observe whether the pro-
tein was specifically absorbed by the hydrogels after incubation in serum. No
specific staining was observed and no staining was seen when the hydrogels
were incubated in a concentrated solution of fibronectin (data not shown). Con-
trols were also performed by growing the cells on the hydrogels and replacing
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Figure 3.25: Examination of fibronectin expression of 3T3 cells grown on the
hydrogels. The cells were grown for 3 days, fixed with 4% paraformaldehyde
and stained with fibronectin antibody (ab2413) followed by secondary antibody
(Alexa Fluor® 488 F(ab’)2 goat anti-rabbit IgG, green), scale bars are 100 mm.
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Figure 3.26: Examination of Fibronectin expressed by C2C12 cells grown on
the hydrogels. The cells were grown for 2 days, fixed with 4% paraformalde-
hyde, stained with fibronectin antibody (ab2413) followed by secondary anti-
body (Alexa Fluor® 488 F(ab’)2 goat anti-rabbit IgG, green) and DAPI for the
nucleus (blue), scale bars are 50 mm.
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the incubation of the primary antibody to fibronectin with a buffer incubation.
This tested for any unspecific absorption of the secondary fluorescent antibody
by the cells or the hydrogels and was negligible (Figure A.3).
The fibronectin staining for the 3T3 and C2C12 cells grown on the hydrogels is
shown in Figure 3.25 and Figure 3.26 respectively. The lowest fibronectin ex-
pression was seen for both of the cell types grown on PHEMA. The fibronectin
was only observed close to the centre of the cells, which correlated with the
cell morphology, small and spherical. The size of a fibronectin coated area has
been shown to influence cell behaviour such as morphology and cell spread-
ing209. Therefore as the cells on PHEMA were not expressing large amounts of
fibronectin, they were unable to create a large enough fibronectin coated area
to spread onto. This in turn affected their adhesion, the poor cell adhesion then
further inhibited cell proliferation.
Similar fibronectin expression was observed by the 3T3 cells grown on the
other hydrogels (Figure 3.25). The expressed fibronectin was seen to be fibril-
lar and occasionally spanned between cells. This indicated that the fibronectin
had been organised by the cells, this happened during cell spreading as the
secretion of their own fibronectin assisted in their adhesion210. It has been
demonstrated that cells have the ability to sense the macromolecular compo-
sition of the surface and adjust their biosynthetic activity211. Therefore as the
3T3 cells produced similar amounts of fibronectin with similar organisation, it
could be said that the different hydrogels were equally suitable for fibroblast
adhesion and all hydrogels were more suitable than PHEMA.
The fibronectin staining of the hydrogels after C2C12 culture showed extensive
fibronectin production by the cells (Figure 3.26). As with the 3T3 cells, the
C2C12 cells had the lowest fibronectin expression when grown on PHEMA.
The other hydrogels showed similar fibronectin expression to each other and
all were markedly greater than that seen on PHEMA. The fibronectin staining
was observed as long fibres stretched between the C2C12 cells. This fibrillar
structure of fibronectin indicated that the cells had organised the protein to
optimise cell processes such as adhesion and spreading.
HS has a known affinity for fibronectin, the HS-fibronectin binding is impor-
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tant for integrin associated cell adhesion which has a role in focal adhesion
formation212. Therefore HS was expected to assist in greater fibronectin de-
position by both cell types, there was no observable increase for the 3T3 cells
and the C2C12 cells had a moderate increase. There were a few possibilities
to explain why an increase was not observed for the 3T3 cells and why the
increase was only moderate for the C2C12 cells. Firstly HS-fibronectin binding
is relatively weak (100-1000 fold weaker than HS-bFGF binding) and therefore
consists of multiple reversible interactions212. Secondly the synthesis of fi-
bronectin is known to change during myogenesis211 therefore if the myoblasts
were approaching confluency and preparing to differentiate they would rely
less on having a fibronectin matrix around themselves34. Despite this, there
was a clear improvement in fibronectin organisation by the C2C12 cells on
P(HEMA:GMA)-HS. Many fibronectin fibres were stretched between the cells
to form a substantial protein network. In conclusion all of the modified hy-
drogels showed enhanced cell expression and organisation of fibronectin in
comparison to PHEMA, therefore all of the modifications were successful in
improving cell behaviour.
3.4 Conclusions
Cell adhesion of 3T3 and C2C12 cells was observed to be better on the modi-
fied PHEMA hydrogels. This was seen visually with the fluorescent staining of
the cells and was also confirmed by assay. The imaged cells were observed to
be more spread and show protrusions coming from the cells when cultured on
P(HEMA:GMA)-NH2 and P(HEMA:GMA)-HS. The increased cell attachment
on P(HEMA:GMA)-HS was shown with ImageJ analysis of cell images and
confirmed with the assay results.
The proliferation of 3T3 and C2C12 cells was observed to be faster and su-
perior on the modified PHEMA hydrogels. This was observed visually with the
fluorescent staining of the cells and was quantified by assay. The AQueous
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One system proved that there were no adverse effects on either cell type after
their culture on all of the hydrogels. Both cell lines proliferated similarly to con-
trol cells grown on tissue culture plastic. Direct quantification of cell number on
the hydrogel scaffolds was successful with the CellTiter-Glo assay.
The proliferation of both cell lines on PHEMA was observed to be very variable,
but with a general increasing trend. The cell proliferation on P(HEMA:GMA)-
NH2 and P(HEMA:GMA)-HS was better with the best cell proliferation observed
on P(HEMA:GMA)-HS. These results indicated that the presence of the HS
had a significant effect on cell behaviour. The differentiation of C2C12 cells was
only observed on P(HEMA:GMA)-HS. This result indicated that the presence of
HS was required for the initiation of differentiation and the successful formation
of myotubes.
The ELISA results confirmed the bioactivity of the HS after immobilisation on
the hydrogels. The signal from P(HEMA:GMA)-HS was significantly above the
other hydrogels indicating that the growth factor was specifically bound to the
HS. The ELISA results correlated well with the improvement in cell behaviour
that was seen on P(HEMA:GMA)-HS compared to the other hydrogels. Cell
expression of fibronectin was greater and more organised on the modified hy-
drogels in comparison to PHEMA. These results indicated that all of the modi-
fications of PHEMA improved the bioactivity of the hydrogel. The improvement
in bioactivity resulted in the enhancement of cell behaviour including; cell ad-
hesion, proliferation and differentiation. The best cell behaviour was observed






P(HEMA:GMA)-HS and RGD and
Intermediates
4.1 Introduction
This chapter focuses on the characterisation of the bioactivity of P(HEMA:GMA)-
RGD and P(HEMA:GMA)-HS&RGD. While the peptide from fibronectin and
other extracellular matrix proteins that facilitate cell adhesion, have been im-
mobilised on a variety of materials, to my knowledge there is only one previous
report of RGD immobilisation on sponge PHEMA144. These researchers found
immobilised RGD improved cell invasion of the hydrogel. In contrast, the incor-
poration of RGD with other forms of PHEMA have been investigated by a num-
ber of groups. For example, GRGD immobilised on a PHEMA film was found
to increase 3T3 fibroblast spreading when the cells were grown in serum-free
medium72. A PHEMA brush has similarly been functionalised with an RGD
containing peptide and this improved the adhesion and spreading of human
umbilical vascular endothelial cells204. Another PHEMA brush was modified
with RGD and PHSRN (which is a synergistic site from fibronectin), the co-
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presentation of the peptides resulted in synergistic effects that enhanced cell
adhesion130.
Figure 4.1: The different forms that PHEMA has been synthesised as. a)
macroscale schematic of the different forms of PHEMA, gel and brush surfaces
are smooth and continuous, sponge PHEMA has large pores, b) microscale
schematic showing the difference in the arrangement of the polymer.
The immobilisation of both HS and RGD on the same scaffold has not been
reported for PHEMA scaffolds or scaffolds of any other material. The immo-
bilisation or incorporation of multiple biomolecules in scaffolds has generally
been confined to a protein or GAG with a growth factor, multiple growth factors
or multiple peptides. For example, a peptide that binds heparin has been cova-
lently attached to a fibrin scaffold, and the heparin in turn bound and presented
bFGF176. The incorporation of all 3 components (peptide, heparin and bFGF)
was shown to be required for enhanced neurite extension, with an 100% in-
crease compared to the fibrin scaffold alone176. Heparin has been attached to
a number of different scaffolds to improve their bioactivity; such as a collagen
scaffold, which improved fibroblast adhesion and proliferation177. The possi-
bility that heparin may act synergistically with lactose to promote chondrocyte
adhesion, proliferation and viability has been explored using a chitosan scaf-
fold213. Additionally heparin was crosslinked within a hyaluronan scaffold in
the hope of sequestering vascular endothelial growth factor and angiopoietin-
1. The scaffold with heparin produced intact microvessel beds with mature
vessels walls in vivo24.
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Co-presentation of various peptides known to be involved in cell adhesion have
been found to improve cell adhesion and cell proliferation when immobilised on
scaffolds. For example CDRGDS and CWQPPRARI enhanced the endothelial
cell proliferation on a polytetrafluoroethylene surface214 A mixture of GRGDSS
with KKKTTK was used to create a self-assembled monolayer which demon-
strated increased cell adhesion and spreading of 3T3 cells215. The immobili-
sation of PDSGR and YIGSR on a PEG scaffold promoted greater cell survival
of pancreatic b-cells and glucose stimulated greater insulin release compared
to that seen when the b-cells were cultured on the scaffolds with each peptide
individually216. Importantly RGD has been co-immobilised on alginate with a
heparin binding peptide, GGGGSPPRRARVTY, allowing RGD and heparin to
be present on the same scaffold. These scaffolds provided the best support for
cardiac tissue development in comparison to the scaffolds functionalised with
only one of the molecules217. These results suggest there is great potential
for co-immobilised biomolecules to act synergistically to improve cell functions
and hence improve their application as tissue engineering scaffolds.
This current work investigated the effect of the co-immobilisation of HS and
RGD on sponge PHEMA, and provided comparison of each end modifica-
tion, that is: P(HEMA:GMA)-HS, P(HEMA:GMA)-RGD and P(HEMA:GMA)-
HS&RGD (from here referred to collectively as end modification hydrogels).
The end modification hydrogels were additionally compared with the interme-
diate hydrogels (P(HEMA:GMA) and P(HEMA:GMA)-NH2) to demonstrate any
improvement in cell behaviour that was attributed to the immobilisation of RGD
or HS and RGD. The comparisons allowed for the investigation of any syner-
gistic effects of having both HS and RGD immobilised on the same hydrogel.
The bioactivity of the hydrogels was assessed with the culture of 2 cell types




Kwikdiff was purchased from Thermo electron corporation. Other reagents, the
cell culture procedure and the immunofluorescent staining of fibronectin were
the same as those used in Chapter 3.
Cell Staining For Kwikdiff staining the cells were first fixed by incubating
them in 0.5 mL of warm 4% formaldehyde at room temperature for 30 min in
the dark. The discs were rinsed twice with 1 mL PBS and the cells were then
permeabilised with 0.5 mL cold 0.1% (v/v) TX-100 and incubated at 4◦C for 4
min. The discs were rinsed twice with 1 mL PBS and then 50 mL of Kwikdiff
solution 3 was added. The discs were rinsed 4 times in 1 mL ultra-pure water
and then incubated in ultra-pure water for 16 h at room temperature.
Cell Proliferation with CellTiter-Glo Assay The same procedure outlined in
chapter 3 was used except for the introduction of rinses for the hydrogel discs
immediately before the addition of the CellTiter-Glo reagent.
Enzyme Linked ImmunoSorbant Assay The ELISA protocol was identical
to that described in chapter 3 except for the increase in elution time, from 10
to 30 min, and the dilution factors used for the samples was 20 times.
4.3 Results and Discussion
4.3.1 Cell Adhesion
The cell adhesion was investigated 2 hours after cell seeding on the hydro-
gels. Both cell types had poor adhesion on PHEMA as discussed in chapter
3. The 3T3 cell adhesion on P(HEMA:GMA)-RGD was observed to be sim-
ilar to that on P(HEMA:GMA)-NH2 and P(HEMA:GMA) (Figure 4.2). There
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Figure 4.2: Adhesion of 3T3 cells on the hydrogels. The cells were stained with
CFSE 2 h after cell seeding and the experiment was performed in duplicate,
scale bars show 50 mm.
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Figure 4.3: Adhesion of 3T3 cells on the end modification hydrogels. The cells
were stained with CFSE 2 h after cell seeding, the scale bars show 50 mm.
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Figure 4.4: Adhesion of C2C12 cells on the end modification hydrogels. Cells
were stained with CFSE 2 h after cell seeding, the experiment was performed
in duplicate, scale bars show 50 mm.
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Figure 4.5: Adhesion of C2C12 cells on the end modification hydrogels 2.
The cells were fixed with 4% paraformaldehyde and stained with rhodamine
phalloidin 2 h after cell seeding. White arrows indicate cell protrusions, scale
bars show 50 mm.
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were some spread cells on P(HEMA:GMA)-RGD which were larger than those
on the other hydrogels and some cells had protrusions extending from them
which indicated better cell adhesion (Figure 4.3). Overall the 3T3 cells on
P(HEMA:GMA)-RGD varied their morphology, it appeared that the RGD did
not consistently improve the adhesiveness of the hydrogel towards fibroblasts.
PGR28 had 1.7 times the amount of RGD as that on PGR22, the cells had
protrusions on PGR22 but more cell adhesion occurred on PGR28. The best
3T3 cell adhesion was observed on P(HEMA:GMA)-HS&RGD. More cells had
protrusions extending from them which showed stronger cell adhesion than on
the other hydrogels. The improved cell adhesion could have been due to the
synergistic effect of having HS and RGD present on the same hydrogel.
Similar to the 3T3 cells, the C2C12s were more spread on P(HEMA:GMA)-
RGD than on PHEMA, as seen in Figure 4.4 and Figure 4.5. Cell protrusions
extended from the cells grown on P(HEMA:GMA)-RGD, indicating better adhe-
sion. However the best cell adhesion was seen on P(HEMA:GMA)-HS&RGD,
where the C2C12 cells were consistently spread and visibly larger with multiple
protrusions. The improvement could have been due to synergistic effects as
the presence of both biomolecules could have enabled the cells to form more
focal adhesions to the hydrogel which would explain the presence of multi-
ple cell protrusions. Such enhanced cell adhesion and spreading has been
demonstrated with the co-immobilisation of different peptides130,215.
The lack of an increase in cell adhesion after RGD immobilisation was ob-
served. The critical RGD surface concentration is considered to be between 1-
10 pmol/cm2 167,218? . By making the assumption that most of the immobilised
RGD was on the surface of the hydrogels their concentrations were estimated
to be between 0.3-0.5 mmol/cm2, this was significantly higher than the critical
concentration. The difference is likely due to the different forms of the mate-
rials, brush and gel polymers are markedly more dense than sponge PHEMA
creating the large difference in RGD concentration, such as the estimated 23
pmol/cm2 on a PHEMA brush surface130. Therefore it was unlikely that the
concentration of the immobilised RGD on the hydrogels, created in this work,
was too low to support and enhance cell adhesion.
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The lack of consistent cell adhesion was observed with lower cell adhesion in
Figure 4.4 compared to Figure 4.5. Both experiments used the same hydrogel
therefore the variability could have been due to the method of RGD immobil-
isation or the spacing of the immobilised RGD. A copolymer of PHEMA and
GMA has been used to immobilise various densities of a peptide to the scaf-
fold167. The lowest peptide density tested was 22 pmol peptide/mg polymer,
alternatively represented as 0.14 peptide chains/nm3. The RGD density on the
hydrogels synthesised in this project was 33 and 52 nmol RGD/mg hydrogel
(PGR29 and PGR28 respectively) which equated to approximately 0.004 and
0.006 peptide chains/nm3. Therefore while the RGD concentration was suf-
ficient, the RGD density may have been too small. This may have been the
reason for the lack of a significant increase in cell adhesion as the immobilised
RGD sites were spread too far apart to optimise cell adhesion. It has been
demonstrated that additional to the positive relationship between RGD con-
centration and cell adhesion, the distance between adjacent RGD molecules
is also important. Clusters of immobilised RGD, where the molecules were
on average closer together, are better at enhancing cell proliferation than the
same concentration of RGD with the molecules more spread apart73. This is
due to the link between integrin clustering during focal adhesion maturation
and myosin-actin interactions73.
RGD might not have improved cell adhesion as much as anticipated due to its
presentation, this may have been due to the method of immobilisation. While
may other researchers use NHS to form a peptide bond between RGD and the
scaffold, most utilise one of the amine groups on the RGD for the immobilisa-
tion219. In this work the amine was present on the scaffold and the carboxylic
acid group on the RGD was used. The difference in the site through which the
RGD was attached may have affected the ability of the RGD to interact with
cells. For example, it has been shown that cyclic RGD has a 10-fold greater
ability than the linear version to bind aVb3, aVb5 and a5b1 integrins. It has
also been shown that a kinked conformation of RGD enhances binding to a5b3
while the linear conformation prefers aIIbb3. One of the prodominant integrins
used in C2C12 adhesion are the aVb3, therefore the immobilisation of the RGD
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in this work may have presented the RGD in a more linear conformation than
that used by others. In addition, the activity of RGD is lower than fibronectin
and recombinant fragments (that mimic the monomer of the dimer structure of
fibronectin), which mediate stronger cell adhesion220. These results suggest
that RGD alone may not be sufficient, and longer peptides are necessary for
superior cell adherence221.
4.3.2 Cell Proliferation
The proliferation of 3T3 cells was low on PHEMA and P(HEMA:GMA). Vi-
sually the cell number was not seen to increase greatly, however there was a
small increase on PHEMA from day 1 to 2 and a small increase on P(HEMA:GMA)
from day 3 to 4. These observations indicated little to no cell proliferation on
PHEMA and P(HEMA:GMA) (Figure 4.6). Some cell proliferation was seen on
P(HEMA:GMA)-NH2, as an increase in cell number was observed from day 2
to 4. These results were consistent with those observed in chapter 3. Better
cell proliferation was seen on P(HEMA:GMA)-RGD, the cell number increased
daily up to day 4. These results demonstrated that the immobilisation of RGD
introduced bioactivity to the hydrogel which improved and increased 3T3 cell
proliferation. The proliferation of 3T3 cells was greatest on P(HEMA:GMA)-
HS&RGD and similar to the proliferation observed on P(HEMA:GMA)-HS (Fig-
ure 4.7).
The proliferation of C2C12 cells was similar on PHEMA and P(HEMA:GMA).
Little to no cell proliferation was observed on either hydrogel (Figure 4.8).
More cell proliferation was seen on P(HEMA:GMA)-NH2. The C2C12 cells
were spread on P(HEMA:GMA)-NH2 on day 1, protrusions from the cells in-
dicated better cell adhesion which lead to increased cell proliferation. The
same occurred on P(HEMA:GMA)-RGD, the spread morphology of the cells
on day 1 resulted in higher cell proliferation by day 6. The cell proliferation
was greater on P(HEMA:GMA)-RGD than P(HEMA:GMA)-NH2. Additionally
the orientation of the cells was different on the hydrogels on day 6. The C2C12
cells were sparsely populated on PHEMA and P(HEMA:GMA) with no partic-
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Figure 4.6: 3T3 cell proliferation on the hydrogels. The cells were stained with
CFSE and the experiment was performed in duplicate, the scale bars show
100 mm.
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Figure 4.7: Proliferation of 3T3 cells on the end modification hydrogels. The
cells were stained with CFSE and the experiment was performed in duplicate,
scale bars show 100 mm.
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Figure 4.8: Proliferation of C2C12 cells on the hydrogels. Cells were fixed with
4% paraformaldehyde before Kwikdiff staining. PHEMA irreversibly absorbed
Kwikdiff resulting in the blue background, experiment was performed in tripli-
cate, scale bars show 100 mm.
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Figure 4.9: Proliferation of C2C12 cells on the end modification hydrogels.
The cells were fixed with 4% paraformaldhyde and stained with rhodamine
phalloidin. The experiment was performed in duplicate, scale bars show 100
mm.
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ular orientation. In contrast the cells on P(HEMA:GMA)-NH2 had aggregated
into large cell colonies creating a sunburst shape. The cells in these aggre-
gates still maintained a spread morphology that was significantly different to
the round cell clusters on PHEMA and P(HEMA:GMA). The aggregated cells
on P(HEMA:GMA)-RGD were aligned along one another. The alignment of
C2C12 cells is one of the first steps towards cell differentiation. Therefore the
RGD on the hydrogel had assisted the C2C12 cells in their organisation and
they had begun cell differentiation. These results indicated that the RGD im-
mobilised on the hydrogel had improved the bioactivity of the hydrogel resulting
in enhanced cell behaviour with respect to cell proliferation and organisation.
The proliferation of 3T3 and C2C12 cells was compared on all end modi-
fication hydrogels (Figure 4.7 and Figure 4.9). On P(HEMA:GMA)-HS and
P(HEMA:GMA)-HS&RGD the cell number increase from day 0 to 2 was more
obvious and was followed by a larger increase from day 2 to 4. The highest 3T3
cell proliferation was observed on the hydrogels with HS immobilised, followed
by P(HEMA:GMA)-RGD. The C2C12 cells proliferated on all end modification
hydrogels from day 0 to day 6 (Figure 4.9), and the highest cell number was
on P(HEMA:GMA)-HS&RGD on day 6. From day 6 to 10 the cells organised
and aligned on the hydrogels with immobilised HS, but on P(HEMA:GMA)-
RGD the cell number decreased. These results showed that C2C12 cell pro-
liferation was enhanced on all end modification hydrogels up to day 6 but HS
was required on the hydrogel to support the cells past this timepoint. All end
modification hydrogels had higher cell proliferation than PHEMA, therefore all
modifications were successful in improving cell proliferation of both cell types.
4.3.3 Cell Quantification with CellTiter-Glo
The number of 3T3 cells on the hydrogels was quantified with the CellTiter-
Glo assay on day 0 and 2 of culture. P(HEMA:GMA)-NH2 was included in the
assays as a control to determine whether any improvement in cell behaviour
was due to the immobilisation of RGD or due to the preceding modification
steps. The lowest luminescent signal and therefore lowest cell number was
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Figure 4.10: Proliferation of 3T3 cells on RGD hydrogels. Figures left to right
show 3 independent experiments, n = 4. Statistics were analysed using a non
parametric model to compare the median values (p<0.05), * PGR22 > P2, **
PGR22 > PGN22, $ PGN22 > P2, # all day 2 results > day 0.
Figure 4.11: Proliferation of 3T3 cells on HS&RGD hydrogels, n = 4. Statistics
were analysed using a non parametric model to compare the median values
(p<0.05), * PGN21 > P2, ** PGHR21 > PGN21 & P2, # day 2 results > day 0.
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Figure 4.12: Proliferation of 3T3 cells on end modification hydrogels, n = 3.
Statistics were analysed using a non parametric model to compare the median
values (* and #, p<0.05), on day 6, * PGR22 > P2, ** PGH23 and PGHR21 >
P2 & PGR22, # all day 2 results > day 0, ## all day 4 results > day 2 except
PHEMA which was < day 2 results.
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Figure 4.13: Proliferation of C2C12 cells on RGD hydrogels, n = 3. Statistics
were analysed using a non parametric model to compare the median values
(p<0.05), *day 0: PG28 & PGN28 > P2, *days 3 & 6: PG28, PGN28 & PGR28
> P2, # day 3 & 6 results > day 0.
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Figure 4.14: Proliferation of C2C12 cells on HS&RGD hydrogels, n = 3. Statis-
tics were analysed using a non parametric model to compare the median val-
ues (p<0.05), *PGHR30 > PGN30, # day 3 & 6: PG30 & PGHR30 > day 0, ##
day 6: PGHR30 > day 3.
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Figure 4.15: Proliferation of C2C12 cells on end modification hydrogels, n = 3.
Statistics were analysed using a non parametric model to test for an increasing
trend with the Jonckheere-Terpstra test (a, p<0.05), aall day 3 results > day
0,aday 6: PGH33, PGR29 & PGHR21 > day 0. b) same data as a) presented
without PHEMA results, *day 0 PGH33 > PGR29, *day 3 PGH33 & PGHR21 >
PGR29,aall day 3 results > day 0,aall day 6 results > day 0.
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Figure 4.16: Proliferation of C2C12 cells on end modification hydrogels 2, n =
3. Statistics were analysed using a non parametric model to test to compare
the median values (* and #) and for an increasing trend with the Jonckheere-
Terpstra test (white arrows, p<0.05), * day 0 PGH33 > PGR29, ** day 0
PGHR30 > all other hydrogels, * day 3: PGHR30 > PGN30, ** PGHR30 >
all other hydrogels, # day 3 & 6 > day 0, ## day 6 > days 0 & 3.
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on PHEMA on day 0 (Figure 4.10). This indicated that the cell adhesion on
PHEMA was lower than the other hydrogels. There was an increase in cell
number on all hydrogels on day 2, compared to day 0, demonstrating prolifer-
ation on all hydrogels. There were no statistical differences between the cell
number on the different hydrogels on day 2. These results were consistent
with the observations of the fluorescently stained cells on the hydrogels, which
showed an increase in cell number from day 0 to day 2 but no significant differ-
ence in cell number between the hydrogels (Figure 4.2).
To observe the 3T3 cell proliferation due to the immobilisation of both HS
and RGD the hydrogel was first compared with the controls, PHEMA and
P(HEMA:GMA)-NH2. There was no difference in the cell number between
the hydrogels on day 0, however there were differences between all hydro-
gels on day 2 (Figure 4.11). The cell number on PHEMA was the lowest and
the cell number had not increased from day 0, the cells had not proliferated on
PHEMA. The cell number on P(HEMA:GMA)-NH2 had increased from day 0
and was significantly higher than PHEMA. The highest increase in cell number
was seen on P(HEMA:GMA)-HS&RGD. These results were similar to those
obtained for the P(HEMA:GMA)-HS hydrogels (Figure 3.16). Similar amounts
of HS was immobilised, 0.6 and 1.8 mmol/g for the P(HEMA:GMA)-HS hydro-
gels and 1.4 mmol/g for P(HEMA:GMA)-HS&RGD, therefore the improvement
in cell proliferation may have been due to the higher concentration of HS.
The 3T3 cell proliferation on the end modification hydrogels was directly com-
pared. The cell number increased on PHEMA from day 0 to day 2 but then
decreased to day 4 (Figure 4.12). As the lowest cell number was seen on
PHEMA on day 4, PHEMA demonstrated the worst cell proliferation. The cell
number on P(HEMA:GMA)-RGD increased from day 0 to 2 and again to day
4, therefore the day 4 timepoint was able to differentiate the cell proliferation
and show that it was significantly better than on PHEMA. The highest increase
in cell number was on P(HEMA:GMA)-HS and P(HEMA:GMA)-HS&RGD, the
cell number increased continually from day 0 to 4. The highest cell proliferation
occurred on these hydrogels and these results correlated well with the obser-
vations by fluorescent staining (Figure 4.6). The immobilisation of RGD was
127
seen to improve 3T3 cell proliferation, the immobilisation of both biomolecules
resulted in similar proliferation to that observed on P(HEMA:GMA)-HS.
The C2C12 cell number on day 0 on P(HEMA:GMA) and P(HEMA:GMA)-NH2
was greater than that on PHEMA (Figure 4.13). On days 3 and 6 the cell num-
ber on P(HEMA:GMA), P(HEMA:GMA)-NH2 and P(HEMA:GMA)-RGD were
higher than that on PHEMA. These results indicated that the copolymer pro-
vided a better substrate for C2C12 cell proliferation than PHEMA. The cell
number on these hydrogels was also significantly above the number on day 0,
this showed that the cells had proliferated over 6 days. However there were
no significant differences in cell number between these hydrogels, indicating
that the immobilised RGD had limited impact on cell proliferation. This was
interesting since the images of the cells (Figure 4.8) showed less cell cover-
age on P(HEMA:GMA) on day 6 compared to the other hydrogels. These re-
sults highlight the limitations of visual inspection and the importance of reliable
quantitative cell assays.
The cells proliferated on all of the hydrogels with the highest cell proliferation
on P(HEMA:GMA)-HS&RGD (Figure 4.14). As with the previous results,Fig-
ure 4.13, no significant difference was seen in cell number between P(HEMA:G-
MA) and P(HEMA:GMA)-NH2. These results indicated that the improvement in
cell proliferation was likely due to the copolymerisation of HEMA with GMA with
no further improvement after the addition of a free amine. Co-immobilisation
of HS and RGD significantly increased cell proliferation, with the highest cell
number observed on P(HEMA:GMA)-HS&RGD on day 6. These results were
similar to the results obtained for P(HEMA:GMA)-HS, which also showed a
continuous increase in cell number from day 0 to 6 (Figure 3.18).
The C2C12 cell number was directly compared on each end modification hy-
drogel and to PHEMA. There were no statistical differences between the me-
dian values on the different hydrogels or across the time points (Figure 4.15).
These results implied that the variability seen in the cell number on PHEMA
could have obscured any significant difference between the other hydrogels.
Indeed when the statistics were applied without the PHEMA data, the cell num-
bers on P(HEMA:GMA)-HS and P(HEMA:GMA)-HS&RGD were significantly
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higher than on P(HEMA:GMA)-RGD on day 3. There was an increasing trend
in the median values of all hydrogels from day 0 to day 3 and an increas-
ing trend for all end modifications from day 0 to day 6. These results con-
trasted with the cell proliferation seen in previous assays (Figure 3.18 and Fig-
ure 4.14) which showed statistically significant increases in C2C12 cell number
on P(HEMA:GMA)-HS and P(HEMA:GMA)-HS&RGD at all time points.
The C2C12 cell number was then directly compared between P(HEMA:GMA)-
NH2 and the end modification hydrogels. On day 0 the cell number was higher
on P(HEMA:GMA)-HS&RGD than the other hydrogels (Figure 4.16). This indi-
cated better cell adhesion on P(HEMA:GMA)-HS&RGD than the other hydro-
gels which confirmed the results from the fluorescent staining of the cells on
the hydrogels (Figure 4.5). On day 3 the cell number was significantly higher
on P(HEMA:GMA)-HS&RGD than P(HEMA:GMA)-NH2 and there was an in-
creasing trend in cell number from P(HEMA:GMA)-NH2 to P(HEMA:GMA)-HS
and to P(HEMA:GMA)-HS&RGD. All end modification hydrogels had higher
cell numbers on days 3 and 6 compared to day 0 but only on P(HEMA:GMA)-
HS did the cell number increase sequentially from day 0 to 6. These results
suggested that the variability on PHEMA did obscure some of the differences
in cell number across the hydrogels and timepoints. Nonetheless cell prolif-
eration was observed on all end modification hydrogels from day 0 to 3 with
further proliferation to day 6 on P(HEMA:GMA)-HS. There were no significant
differences in C2C12 cell proliferation on day 6 which was likely due to the cells
decreasing their proliferation rate as they initiated differentiation.
While the overall C2C12 cell number may have been similar on the hydrogels,
the cell morphology was clearly different. The cells on P(HEMA:GMA)-NH2
and P(HEMA:GMA)-RGD had the typical fusiform morphology and were well
spread, in stark contrast to the cells on P(HEMA:GMA) which were spherical
and not spread (Figure A.5). These results highlight the importance of multiple
observations of the cell proliferation as the cell assays alone would indicate
similar applicability of the hydrogels, while the cell images show differences in
cell morphology which affect cell behaviour.
In conclusion the results from the CellTiter-Glo assays showed that both cell
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types proliferated on all of the hydrogels. Cell proliferation on PHEMA was
very variable, some assays showed an increase in cell number where oth-
ers showed no change or even a decrease. No significant difference was ob-
served between cell proliferation on P(HEMA:GMA) and P(HEMA:GMA)-NH2
hydrogels, however some assays indicated that the cell proliferation was im-
proved in comparison to PHEMA. Most assays showed no significant increase
in cell proliferation after the addition of RGD when compared to P(HEMA:GMA)
and P(HEMA:GMA)-NH2. Most assays showed the highest cell proliferation on
P(HEMA:GMA)-HS&RGD which was sometimes greater than the proliferation
on P(HEMA:GMA)-NH2. Importantly the improvement in cell proliferation of
both cell types on P(HEMA:GMA)-HS&RGD was seen to follow the cell pro-
liferation observed on P(HEMA:GMA)-HS. Therefore these results indicated
a more significant effect on cell proliferation by HS than RGD immobilisation.
Work by others has also observed no significant increase in 3T3 cell prolifera-
tion after the incorporation of RGD into the scaffold, in fact a decrease in cell
proliferation was found222.
4.3.4 Cell Differentiation
The C2C12 cells were observed to orientate themselves along one another
and approach confluency on the hydrogels. This cell behaviour was seen from
day 6 of culture on all of the end modification hydrogels (Figure 4.17). The
C2C12 cells were cultured for 10 days to investigate whether they would differ-
entiate on the hydrogels, the differentiation was assisted by changing the me-
dia from proliferation to differentiation media on day 6. The C2C12 cells were
struggling to survive on PHEMA, most likely due to their poor adhesion and pro-
liferation on PHEMA. The cells on P(HEMA:GMA)-NH2 and P(HEMA:GMA)-
RGD were networked, some cells were aligned on P(HEMA:GMA)-RGD but
no myotubes were formed. The lack of cell differentiation on P(HEMA:GMA)-
RGD could have been due to a couple of reasons. Firstly there was a difference
in the organisation of the cells on day 6, the cells were arranged in a sunburst
shape (Figure 4.17). This was in contrast with the cells on the HS immobilised
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Figure 4.17: Stages of C2C12 cell differentiation on the hydrogels. The cells
were fixed with 4% paraformaldhyde and stained with rhodamine phalloidin on
day 6, day 10 the cells were additionally counter-stained with DAPI (blue). The
experiment was performed in duplicate, scale bars show 50 mm.
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hydrogels which were aligned along one another. The re-orientation of the cells
is important for cell fusion which leads to myotube formation. The other poten-
tial reason is that the cells reached their peak on day 6 (or earlier) and were
declining so that by day 10 there were insufficient cells present for successful
differentiation.
As the distance between the immobilised RGD molecules was likely unopti-
mised for cell adhesion it was also likely to have affected the development of
actin fibres. This is turn could have affected the ability of the C2C12 cells to-
wards differentiation. Optimisation of the distance between immobilised RGD
molecules has been demonstrated to enhance actin fibre and focal adhesion
formation and maturation73. These events are vital to initiate cell signals which
control other cell behaviours such as proliferation and differentiation.
The cells on P(HEMA:GMA)-HS&RGD were confluent, had aligned themselves
and the cells were fused together forming myotubes. Differentiation of the
C2C12s was abundant on P(HEMA:GMA)-HS&RGD but absent on all other hy-
drogels except P(HEMA:GMA)-HS. Single mytubes were formed on P(HEMA:G-
MA)-HS while bundles of aligned myotubes were seen on P(HEMA:GMA)-
HS&RGD. The differentiation of the C2C12 cells was compared on all of the
end modification hydrogels. The C2C12 cells only formed multinucleated my-
otubes on hydrogels with immobilised HS. Myotubes formed on P(HEMA:GMA)-
HS were surrounded by cells in varying states of alignment and fusion, whereas
areas of multiple myotubes were seen on P(HEMA:GMA)-HS&RGD. These
bundles of aligned myotubes mimicked the myofibril structure of myofibres.
These results showed that the presence of HS was required by the cells for
successful differentiation. Additionally the presence of both HS and RGD re-
sulted in multiple myotube formation which created areas of aligned myotubes
that mimicked muscle fibre structure. Therefore the presence of both HS and
RGD were required to enhance cell adhesion and cell proliferation so that the
cells could approach confluency and successfully differentiate.
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4.3.5 Enzyme Linked ImmunoSorbant Assay
The activity of HS immobilised on P(HEMA:GMA)-HS&RGD was confirmed
with the bFGF ELISA. The calculated amount of bFGF eluted from P(HEMA:GM-
A)-HS&RGD was 9 fold larger than the amount from P(HEMA:GMA)-NH2, which
was used as the control (Figure 4.18). The results showed that the HS immo-
bilised on P(HEMA:GMA)-HS&RGD bound bFGF while the signal from P(HEM-
A:GMA)-NH2 was due to physical entrapment of the growth factor in the hydro-
gel. This trend was consistent with the values obtained when the hydrogels
with only HS immobilised were assayed (discussed in chapter 3). There was
a small difference in the amount of HS immobilised when it was immobilised
alone and when together with RGD, PGH12 and PGHR21 had 1.0 ± 0.4 and
1.4 ± 0.3 mmol HS/g hydrogel respectively. The 2 hydrogels were compared
and the results showed that PGH12 and PGHR21 bound and eluted 337 ±
119 and 378 ± 138 ng bFGF. The hydrogels bound a similar amount of bFGF,
therefore the HS bioactivity was maintained on P(HEMA:GMA)-HS&RGD with
similar bioactivity to P(HEMA:GMA)-HS.
Figure 4.18: Bioactivity of immobilised HS on P(HEMA:GMA)-HS&RGD. Cal-
culated bFGF bound to hydrogels as determined by ELISA, the assays had
3 discs of each hydrogel and duplicate technical replicates, n = 6, error bars
show the standard deviation.
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4.3.6 Immunofluorescence of Cell Expressed Fibronectin
The expression of fibronectin by 3T3 and C2C12 cells on the end modifica-
tion hydrogels was visualised with immunofluorescence. The lowest fibronectin
production was by the 3T3 cells that were cultured on PHEMA, as discussed
in Chapter 3. Fibronectin expressed by the 3T3 cells on P(HEMA:GMA)-HS
was more abundant and observed to stretch between cells with the highest
fibronectin production on P(HEMA:GMA)-HS&RGD (Figure 4.19). Organisa-
tion of cell expressed fibronectin occurred on both HS immobilised hydrogels,
however the maturation of the fibronectin network was markedly better on
P(HEMA:GMA)-HS&RGD. As the amount of HS immobilised on P(HEMA:GMA)-
HS was 2.4 ± 0.2 mmol/g hydrogel and 1.4 ± 0.3 mmol/g hydrogel on P(HEMA:GMA)-
HS&RGD, these differences in fibronectin expression were likely due to a syn-
ergistic effect. Therefore the immobilisation of both HS and RGD enhanced
cell expression of fibronectin and enabled better maturation of cell expressed
ECM proteins. These results demonstrated that the co-immobilisation of HS
and RGD provided a surface that was able to interact with the 3T3 cells to
provide signals which enhanced cell behaviour.
Figure 4.19: Immunofluorescence of fibronectin produced by 3T3 cells on the
hydrogels. The cells were stained for fibronectin after 3 days of culture on
the hydrogels, fibronectin antibody (ab2413) followed by secondary antibody
(Alexa Fluor® 488 F(ab’)2 goat anti-rabbit IgG, green). Images taken with a
Nikon confocal microscope, scale bars are 100 mm.
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Figure 4.20: Immunofluorescence of fibronectin produced by C2C12 cells on
the end modification hydrogels. The cells were stained for fibronectin after
3 days of culture on the hydrogels, fibronectin antibody (ab2413) followed by
secondary antibody (Alexa Fluor® 488 F(ab’)2 goat anti-rabbit IgG, green) and
the nuclei were stained blue (DAPI). Images taken with a Nikon confocal mi-
croscope, scale bars show 50 mm.
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The C2C12 cells expressed fibronectin on all hydrogels, with the lowest ex-
pression on PHEMA as shown in Chapter 3. In contrast the fibronectin ex-
pressed by the C2C12 cells on the other hydrogels was more abundant and
stretched between cells (Figure 4.20). The organisation of the fibronectin cre-
ated a fibrillar network between the cells, this resulted in better cell adhesion
and spreading as was demonstrated by the fluorescent staining of the cells on
the hydrogels. The amount and structure of the fibronectin was very similar on
P(HEMA:GMA)-HS and P(HEMA:GMA)-RGD but there was less fibronectin on
P(HEMA:GMA)-HS&RGD. The reduction in fibronectin could have been due
to the beginning stages of cell differentiation, as the synthesis of fibronectin
is known to change during myogenesis211. Therefore if the myoblasts were
approaching confluency and preparing to differentiate they would rely less on
having a fibronectin matrix around themselves34. These results have shown
that all of the end modifications on PHEMA created hydrogels that enhanced
the matrix protein expression of both cell types.
In summary the combination of techniques used have shown that all modifica-
tions on PHEMA have improved the bioactivity of the hydrogel. The best cell re-
sults were on the end modification hydrogels, especially those with immobilised
HS. All end modification hydrogels showed enhanced cell adhesion, prolifera-
tion and differentiation. The presence of both HS and RGD have shown some
synergistic effect with respect to the differentiation of the C2C12 cells. It is likely
that the combination of the two biomolecules provided an environment for the
cells that enhanced cell adhesion which in turn increased cell proliferation and
differentiation. The ELISA and immunofluorescence results demonstrated the
bioactivity of the immobilised HS, this proved that the HS was able to bind pro-
teins similar to in vivo processes. A potential mechanism for the synergistic
effect of HS and RGD is presented. It has been shown that a5 expression
increases during the myogenesis of C2C12 cells, which can link actin to form
actin-membrane interactions which reinforce cell-cell interactions223. The bind-
ing of a5 to nescharin begins the pathway to cell migration and the upregulation
of heparanase leads to cell fusion223. Therefore the presence of HS and RGD
on the hydrogels increased the integrin binding and presented bioactive HS
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which in combination enhanced cell migration and cell fusion resulting in the
promotion of cell differentiation.
To further examine the how the immobilised HS and RGD improved the cell
behaviour, a few additional experiments could be performed. These would in-
clude serum free conditions to observe whether the cells maintain their cell
behaviour. This would indicate whether the bioactivity of the hydrogels is suffi-
cient to promote the cell behaviour observed in this work or whether additional
factors from the serum were involved (i.e. to test whether the improvements
with HS were partially due to the binding of bFGF to the hydrogel). Specifically
serum free conditions for the cell deposition of fibronectin would be useful to
observe and correlate with any changes in cell behaviour. With serum free
conditions it would also be interesting to test for any changes in cell adhesion
when soluble HS or RGD are present in the medium. Decreased cell adhesion
would indicate that the HS and RGD were being directly used to assist with the
adhesion of the cells to the hydrogels.
4.4 Conclusions
The modification of PHEMA with RGD resulted in a small improvement in
cell adhesion of both 3T3 and C2C12 cells. The cells had a more spread
morphology than the controls, PHEMA, P(HEMA:GMA) and P(HEMA:GMA)-
NH2. The cells were observed to form small protrusions which were the be-
ginning stages of better cell adhesion and potential focal adhesion matura-
tion. The improvement in cell adhesion on P(HEMA:GMA)-RGD also improved
cell proliferation of both cell types. Significantly more cells were seen on
P(HEMA:GMA)-RGD at later time points than the controls. These visual obser-
vations were confirmed with the assay results. The modification of PHEMA with
both HS and RGD resulted in the most drastic improvements in cell behaviour.
P(HEMA:GMA)-HS&RGD demonstrated the best cell adhesion, proliferation
and also assisted in the best C2C12 differentiation.
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The activity of immobilised HS on P(HEMA:GMA)-HS&RGD was tested and
compared to P(HEMA:GMA)-HS. The results showed that both hydrogels, that
contained similar amounts of HS, were able to bind a similar amount of bFGF.
This indicated that the co-immobilisation of HS and RGD on the same hydrogel
did not adversely affect the activity of the HS. The expression of fibronectin
by the 3T3 cells was higher on the end modification hydrogels than PHEMA.
This indicated that the cells were better adhered and spread on the modified
hydrogels which lead to better cell proliferation.
Myotube formation only occurred on P(HEMA:GMA)-HS and P(HEMA:GMA)-
HS&RGD. The ELISA results indicated that both of the hydrogels with HS
bound similar amounts of bFGF therefore the HS bioactivity was similar. The
myotube formation on P(HEMA:GMA)-HS&RGD was more abundant and the
formed myotubes were aligned, characteristic of muscle fibre alignment in
vivo. These results suggested that there was a synergistic effect from the co-
immobilisation of HS and RGD on the same hydrogel. This synergistic effect
was observed to have minimal effects on the adhesion and proliferation of the
cells, however they resulted in the best C2C12 differentiation creating aligned
bundles of myotubes that mimicked muscle fibre formation.
In conclusion each end modification hydrogel demonstrated improved cell ad-
hesion and proliferation of fibroblasts and myoblasts over PHEMA. The cell
adhesion and proliferation of both cell types was similar on each end modifi-
cation hydrogel. The important difference between the hydrogels was that the
presence of HS was required by the myoblasts for successful cell differentia-
tion. Additionally the myotube formation was best on P(HEMA:GMA)-HS&RGD
suggesting a synergistic effect of the co-immobilisation on the cells. These re-
sults show 3 successful modifications on PHEMA that improved the bioactivity





This project focused on the modification of PHEMA, a widely used and FDA ap-
proved bio-inert hydrogel, with HS and RGD to improve its bioactivity for possi-
ble uses as a tissue engineering scaffold. This included the design, synthesis,
physical and chemical characterisation, and cellular evaluation of six different
hydrogels; PHEMA, P(HEMA:GMA), P(HEMA:GMA)-NH2 , P(HEMA:GMA)-
HS, P(HEMA:GMA)-RGD and P(HEMA:GMA)-HS&RGD, where P(HEMA:GMA)
and P(HEMA:GMA)-NH2 acted as intermediates for the immobilisation of HS
and RGD. The work firstly revealed , that the covalent immobilisation of HS or
RGD to the hydrogel did not markedly alter the physical properties of the hydro-
gel, and secondly, that the biological activities of the immobilised entities were
conserved. The overall outcomes were hydrogels with enhanced cell attach-
ment properties and, in the case of hydrogels containing the HS structures,
support for cell differentiation. Collectively the modified hydrogels demon-
strated superior functionality compared to that of the unmodified PHEMA, with
functions that are appropriate for a tissue engineering scaffold.
In summary, the hydrogel maintained high water content, high surface area,
interconnected pore structure and elastic properties, which are important for
a tissue scaffold. Increased thermal stability of the modified PHEMA hydro-
gels was observed and likely due to the increased crosslinking with the co-
monomer. The viscoelastic properties of all of the hydrogels were within the
ranges for soft to intermediate tissues. The elastic recovery of the hydrogels
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was high and their performance under repeated stress demonstrated their po-
tential for long term implant applications.
Clear improvements in cell adhesion, proliferation and differentiation were shown
on the modified hydrogels. Copolymerisation increased cell adhesion of fibrob-
lasts and myoblasts and the immobilisation of the biomolecules increased cell
proliferation and differentiation. Specifically, the behaviour of 3T3 and C2C12
cells was indicative of healthier cells on all the modified hydrogels compared
to those on PHEMA. The cells were observed to attach, proliferate and differ-
entiate best on the end modification hydrogels. The best cell results occurred
on P(HEMA:GMA)-HS and P(HEMA:GMA)-HS&RGD. C2C12 cell differentia-
tion was only observed on the hydrogels modified with HS. This indicated that
the HS hydrogels were able to promote cell organisation and orientation which
led to successful cell differentiation. The most interesting finding was the for-
mation of aligned myotubes on P(HEMA:GMA)-HS&RGD. Their orientation in
bundles mimicked the in vivo structure of muscle fibres. The results from im-
munofluorescent staining showed that the cells expressed more fibronectin on
the end modification hydrogels which correlated to the improved cell behaviour
observed on those hydrogels. Image analysis showed that the fibronectin was
better organised on the HS immobilised hydrogels which indicated the first
stages of a mature ECM microenvironment around the cells.
Results showed that HS can be easily attached in a bioactive form, with evi-
dence showing that the immobilised HS bound and sequestered bFGF in the
same way as is observed in vivo. Thus, the created scaffold provided a method
to mimic ECM signalling that promoted fibroblast proliferation and myoblast
differentiation. Application of this hydrogel in vivo may support wound heal-
ing by enhancing the fibroblast population to create ECM while simultaneously
supporting the differentiation of myoblasts to create muscle tissue. The exact
structure and biological interactions of muscle ECM and muscle cells has not
been determined224. The hydrogels created here could be used as a model to
gain insights into how cell-ECM interactions change during muscle injury and
repair. The methodology developed can be applied to immobilise other GAGs
enabling the investigation of each GAG type individually or in various combina-
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tions. In this way the complex roles of the GAG component of the ECM would
be better revealed than has been previously possible. A better understand-
ing of these interactions will assist in designing scaffolds to facilitate muscle
regeneration.
Technically the quantification of cells on the porous, opaque, 3D hydrogels
was a major challenge. Several methods were trialled, but the CellTitre-Glo
assay was proven the most effective and reproducible. The luminescent sig-
nal, produced as a result of cell metabolism and monitored in the assay, is ad-
vantageous for scaffolds where absorbance or fluorescent techniques create
significant background. Success with this assay allowed a rigorous, unbiased
assessment of the effects of the immobilised entities on cell behaviour. In con-
trast to the visual assessments commonly used in this field which are subject
to bias, as cells rarely attach evenly across the scaffolds.
The elasticity of the hydrogel was between the range that has been mea-
sured for whole skin, 0.36-0.45 kPa172, and individual fibroblasts, 3-12 kPa169,
hence, it was expected to provide a suitable mechanical environment for fibrob-
lasts. Interestingly the same hydrogel was also able to support and enhance
the differentiation of myoblasts despite having lower elasticity than muscle tis-
sue, 31-450 kPa225. This work has shown that a single hydrogel can support
and enhance the cell behaviours of different cell types. This would be useful
for the regeneration of deep wounds as the hydrogel would be able to inte-
grate with both muscle and skin tissue. As all current commercial products for
wound healing are only applicable to skin depth wounds, this hydrogel has the
potential to fill this deficiency.
Overall, this project provided a facile method for the functionalisation and the
chemical immobilisation of the well-known and relatively inert PHEMA hydro-
gels with biomolecules to create a scaffold more appropriate for tissue engi-
neering applications. The project also developed a reliable method to quantify
cells on the porous and opaque 3D hydrogels. The produced 3D bioactive
hydrogel scaffolds demonstrated promise for deep tissue wound healing and
muscle regeneration treatments. The work has shown that using the synthetic
pathway designed, it is possible to immobilise HS and maintain its bioactivity.
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This bioactivity was proven to mirror the effect of soluble HS on cell behaviour,
mimicking in vivo signalling. The results from this work will enhance the cur-
rent knowledge on cell-scaffold interactions enabling better scaffold design in
the future.
Future Directions
While further investigations are required to understand how the immobilised
biomolecules have interacted with the investigated cell lines, and to prove the
concept in vivo, the developed scaffold could also be used as a model for
the investigation and advanced understanding of the cell interaction with the
biomolecules immobilised on the surface of the hydrogels. One particular inter-
est in this direction is to use the scaffold, which has demonstrated high elastic
recovery under repeated stress, to investigate the responses of different cells
to the tension and stress in the biological environment to evaluate the potential
of scaffolds as long-term implants.
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Radiation Physics and Chemistry 2010, 79, 643–649.
[120] Belkas, J. S.; Munro, C. a.; Shoichet, M. S.; Johnston, M.; Midha, R.
Biomaterials 2005, 26, 1741–9.
[121] Katayama, Y.; Montenegro, R.; Freier, T.; Midha, R.; Belkas, J. S.;
Shoichet, M. S. Biomaterials 2006, 27, 505–518.
[122] Reynolds, L. F.; Bren, M. C.; Wilson, B. C.; Gibson, G. D.;
Shoichet, M. S.; Murphy, R. J. L. Spinal cord : the official journal of
the International Medical Society of Paraplegia 2008, 46, 58–64.
[123] Plant, G. W.; Woerly, S.; Harvey, a. R. Experimental neurology 1997,
143, 287–99.
[124] Woerly, S.; Laroche, G.; Marchand, R.; Pato, J.; Subr, V.; Ulbrich, K.
Journal of neural transplantation & plasticity 1995, 5, 245–55.
[125] Woerly, S.; Pinet, E.; de Robertis, L.; Van Diep, D.; Bousmina, M. Bio-
materials 2001, 22, 1095–111.
[126] Long, T. J.; Sprenger, C. C.; Plymate, S. R.; Ratner, B. D. Biomaterials
2014, 35, 8164–8174.
[127] Hradil, J.; Horák, D. Reactive and Functional Polymers 2005, 62, 1–9.
[128] Xu, F.; Neoh, K.; Kang, E. Progress in Polymer Science 2009, 34, 719–
761.
[129] Rezaei, S. M.; Mohd Ishak, Z. a. Express Polymer Letters 2014, 8, 39–
49.
[130] Desseaux, S.; Klok, H.-A. Biomaterials 2015, 44, 24–35.
[131] Sun, L.; Li, D.; Hemraz, U. D.; Fenniri, H.; Webster, T. J. Journal of
Biomedical Materials Research - Part A 2013, 3446–3451.
[132] Ren, T.; Yu, S.; Mao, Z.; Moya, S. E.; Han, L.; Gao, C. Biomacro-
molecules 2014, 15, 2256–2264.
152
[133] Wu, J.; Mao, Z.; Han, L.; Xi, J.; Zhao, Y.; Gao, C. Journal of Bioactive
and Compatible Polymers 2013, 28, 605–620.
[134] Horak, D, Dvorak, P, Hampl, A & Slouf, M. Journal of Applied Polymer
Science 2003, 87, 425–432.
[135] Horák, D.; Kroupová, J.; Slouf, M.; Dvorák, P. Biomaterials 2004, 25,
5249–60.
[136] Kroupova, J.; Horak, D.; Pachernik, J.; Dvorak, P.; Slouf, M. Journal of
Biomedical Materials Research - Part B Applied Biomaterials 2006, 76,
315–325.
[137] Kubinova, S.; Horak, D.; Sykova, E. Biomaterials 2009, 30, 4601–9.
[138] Bayramoglu, G.; Bitirim, V.; Tunali, Y.; Arica, M. Y.; Akcali, K. C. Materials
Science and Engineering C 2013, 33, 801–810.
[139] Brynda, E.; Houska, M.; Kysilka, J.; Pradny, M.; Lesny, P.; Jendelova, P.;
Michalek, J.; Sykova, E. Journal of Materials Science: Materials in
Medicine 2009, 20, 909–915.
[140] Arslantunali, D.; Budak, G.; Hasirci, V. Journal of Biomedical Materials
Research - Part A 2014, 102, 828–841.
[141] Plant, G. W.; Harvey, a. R.; Chirila, T. V. Brain Research 1995, 671, 119–
130.
[142] Pertici, V.; Trimaille, T.; Laurin, J.; Felix, M. S.; Marqueste, T.;
Pettmann, B.; Chauvin, J. P.; Gigmes, D.; Decherchi, P. Biomaterials
2014, 35, 6248–6258.
[143] Dalton, P. D.; Shoichet, M. S. Biomaterials 2001, 22, 2661–9.
[144] Paterson, S. M.; Shadforth, A. M. a.; Shaw, J. a.; Brown, D. H.; Chir-
ila, T. V.; Baker, M. V. Materials science & engineering. C, Materials for
biological applications 2013, 33, 4917–22.
153
[145] Kumar, D.; Gerges, I.; Tamplenizza, M.; Lenardi, C.; Forsyth, N. R.;
Liu, Y. Acta Biomaterialia 2014, 10, 3463–3474.
[146] Higa, O. Z.; Faria, H. A. M.; a.a. de Queiroz, A. Radiation Physics and
Chemistry 2014, 98, 118–123.
[147] Volkmer, T.; Magalhães, J.; Sousa, V.; Santos, L.; Burguera, E.;
Blanco, F.; Román, J.; Rodríguez-Lorenzo, L. Polymers 2014, 6, 2510–
2525.
[148] Cetin, D.; Kahraman, a. S.; Gumusderelioglu, M. Journal of biomaterials
science Polymer edition 2011, 22, 1157–1178.
[149] Huang, J.; Ten, E.; Liu, G.; Finzen, M.; Yu, W.; Lee, J. S.; Saiz, E.;
Tomsia, A. P. Polymer 2013, 54, 1197–1207.
[150] Zainuddin,; Chirila, T. V.; Brnard, Z.; Watson, G. S.; Toh, C.; Blakey, I.;
Whittaker, A. K.; Hill, D. J. T. Radiation Physics and Chemistry 2011, 80,
219–229.
[151] Lou, X.; Munro, S.; Wang, S. Biomaterials 2004, 25, 5071–80.
[152] Lou, X.; Vijayasekaran, S.; Chirila, T. V.; Maley, M. a.; Hicks, C. R.; Con-
stable, I. J. Journal of biomedical materials research 1999, 47, 404–11.
[153] Pieper, J. S.; Hafmans, T.; van Wachem, P. B.; van Luyn, M. J. A.;
Brouwer, L. A.; Veerkamp, J. H.; van Kuppevelt, T. H. Journal of Biomed-
ical Materials Research 2002, 62, 185 – 194.
[154] Meade, K. a.; White, K. J.; Pickford, C. E.; Holley, R. J.; Marson, A.;
Tillotson, D.; van Kuppevelt, T. H.; Whittle, J. D.; Day, A. J.; Merry, C.
L. R. The Journal of biological chemistry 2013, 288, 5530–8.
[155] Cushing, M. C.; Liao, J.-T.; Jaeggli, M. P.; Anseth, K. S. Biomaterials
2007, 28, 3378–87.
[156] Farndale, R. W.; Buttle, D. J.; Barrett, a. J. Biochimica et biophysica acta
1986, 883, 173–7.
154
[157] Farndale, R. W.; Sayers, C. a.; Barrett, a. J. Connective tissue research
1982, 9, 247–8.
[158] Rimmer, S.; Johnson, C.; Zhao, B.; Collier, J.; Gilmore, L.; Sabnis, S.;
Wyman, P.; Sammon, C.; Fullwood, N. J.; MacNeil, S. Biomaterials 2007,
28, 5319–31.
[159] Teixeira, S.; Yang, L.; Dijkstra, P. J.; Ferraz, M. P.; Monteiro, F. J. Journal
of materials science. Materials in medicine 2010, 21, 2385–92.
[160] Arica, M. Y.; Bayramoglu, G. Journal of Molecular Catalysis B: Enzymatic
2004, 27, 255–265.
[161] Geurts, J. M.; Jacobs, P. E.; Muijs, J. G.; Steven Van Es, J. J. G.; Ger-
man, A. L. Journal of Applied Polymer Science 1996, 61, 9–19.
[162] Morita, S. Frontiers in chemistry 2014, 2, 10.
[163] Zhang, L.; Zheng, G.-J.; Guo, Y.-T.; Zhou, L.; Du, J.; He, H. Asian Pacific
journal of tropical medicine 2014, 7, 136–40.
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Appendix
Table A.1: Equilibrium water content of hydrogels in phosphate buffered saline
Hydrogel EWC% ¹
PG26 78.1 ± 0.4
PGN26 78.8 ± 0.5
PGR26 79.1 ± 0.7
¹values were the average of 5 samples ± standard deviation
Figure A.1: Bioactivity of immobilised HS on the hydrogels 4. The amount of
bFGF bound to immobilised HS on the hydrogels as determined by ELISA,
n=8, error bars show standard deviation.
161
Figure A.2: C2C12 cell adhesion on the hydrogels 2. The cells were stained
with CFSE 2 h after seeding on the hydrogels and imaged with fluorescent
microscopy, scale bars show 100 mm.
162
Figure A.3: Control images for Fibronectin staining on hydrogels. The cells
were grown on the hydrogels, top row, 3T3 cells, bottom row C2C12 cells. The
cells were fixed with 4% paraformaldehyde, incubated in buffer followed by the
secondary fluorescent antibody (Alexa Fluor® 488 F(ab’)2 goat anti-rabbit IgG,
green) and DAPI for the nucleus (blue), the scale bars are 100 mm.
163
Figure A.4: Morphology of 3T3 cells on end modification hydrogels. The cells
were stained with CFSE and imaged with fluorescent microscopy, scale bars
show 50 mm.
164
Figure A.5: Morphology of C2C12 cells on end modification hydrogels.
165
Every reasonable effort has been made to acknowledge the owners of copy-
right material. I would be pleased to hear from any copyright owner who has
been omitted or incorrectly acknowledged.
166
